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SUMMARY 
A number of studies have shown exercise to stimulate human growth hormone (hGH) 
secretion, although most of these have considered prolonged submaximal or 
resistance exercise. Only a few have studied maximal sprint exercise, and these 
studies have demonstrated considerably elevated circulating hGH concentrations 
during recovery. However, there is little agreement in the literature regarding the 
regulation of hGH secretion during and after exercise. This thesis describes a series 
of experiments considering the hGH response to sprint exercise, with the intention of 
gaining a better understanding of some of the mechanisms involved in regulating the 
exercise-induced hGH release. 
The time-courses of the hGH response to maximal cycle ergometer sprints of 6 sand 
30 s duration are described in the first experimental chapter (Chapter 4). Highest 
measured mean serum hGH concentrations were more than four and a half times 
greater following the 30 s sprint than they were following the 6 s sprint (37.0±6.2 vs. 
8.0±2.9 mU.r1, P<O.OS), and remained elevated above pre-exercise levels for longer 
during recovery, demonstrating that the duration of a sprint has a marked effect on the 
exercise-induced hGH response. In addition, this chapter highlights the large inter-
individual variation in the hGH response to sprinting. 
Sprinting at different pedal speeds made it possible to study the effect of the number 
of muscle actions during a sprint on the hGH response to sprint exercise (Chapter 5). 
In addition, the effect of performing a second 30 s sprint whilst hGH was still 
elevated, as a result of the first bout, was considered. There was a trend for serum 
hGH concentrations to be greater following sprints at faster pedal speeds (mean 2 h 
integrated hGH concentrations 1381±231 vs. 663±162 mU.r\ P=0.06), suggesting a 
possible role for proprioceptive feedback in the regulation of hGH secretion. It was 
also observed that there was a marked hGH response to the first sprint in each trial 
(highest measured mean concentration 40.8±8.2 and 20.8±6.1 mU.r1 for the FAST 
and SLOW trials, respectively), but that the second sprint in each trial did not elicit a 
hGH response (P<O.OS), despite a similar pH and lactate response to the two sprints. 
Since circulating hGH concentrations were still elevated prior to the second sprint this 
was likely to be a result of hGH autbinhibition. The plasma ammonia response to the 
second sprint was also attenuated in these trials. 
)" ... 
The effect of sprint training on the ·hGH response to repeated maximal cycle 
ergometer sprinting is described in the third experimental chapter (Chapter 6). Six 
weeks of combined speed and speea.:endilrailce training was found to result in an 
improvement in sprint performance, but the hGH response to exercise was reduced in 
all subjects in the training group, result1n:g in a- decrease in highest measured mean 
hGH concentrations of over 40 % (20.5±6.2 vs. 11.(>±5.0 mU.r\ group-training 
interaction effect, P<O.OS). Trainirrg-was··also·fourr&t(yresult in a reduced ammonia 
response to sprinting. However, sprint training did not alter the attenuation of the 
hGH response to repeated sprints. 
The fourth experimental chapter (Chapter 7) describes the effect of a longer recovery 
period between repeated bouts of sprint cycling on the hGH response to the second of 
two sprint bouts. After 4 h recovery from a single 30 s sprint, when hGH had 
returned to pre-exercise concentrations, the hGH response to a second 30 s sprint still 
showed a tendency to be attenuated ( mean highest measured hGH concentrations 
34.1±24.8 vs. 16.8±5.0 mU.r1, P=0.09). Serum IGF-1 was found to be acutely 
elevated 5 min after a single sprint, but was not elevated prior to a second sprint 
completed 4 h later. Therefore, since neither hGH nor IGF-1 were elevated prior to 
the second sprint, an alternative mechanism of feedback, possibly mediated by 
elevated circulating free fatty acids (FFAs), was probably in operation. In addition, 
resting IGF-1 concentrations were found to be lower the day after exercise, possibly 
reflecting a change in the pattern of nocturnal hGH secretion. 
The studies presented in this thesis have provided evidence of an attenuation of the 
hGH response to repeated exercise, and also following short-term sprint-training. The 
mechanism for attenuation with repeated sprinting appears to be negative feedback, 
probably mediated by circulating hGH in the 2 h after exercise (when hGH is still 
elevated), but thereafter by another mechanism, possibly elevated circulating FFAs. 
In addition, the studies in this thesis have provided information regarding the 
mechanism regulating hGH secretion. It appears that blood pH and lactate do not 
have an important role in this regulation of hGH release, whilst blood-borne ammonia 
might have more of an influence. In addition, it is possible that proprioceptive 
feedback might also modulate the hGH response to exercise. 
Some of the experiments described in this thesis have been published as follows: 
Stokes KA, Nevill ME, Hall GM, Lakomy HKA, Cherry PW (1999) Growth hormone 
responses to repeated maximal cycle ergometer exercise at different pedal speeds. J 
Physiol515:75P 
Stokes KA, Nevill ME, Cherry PW, Hall GM, Lakomy HKA (2000) The effect of 6 
weeks of sprint training on the growth hormone response to repeated maximal cycle 
ergometer exercise. J Physiol 528:51P 
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CHAPTER! 
GENERAL INTRODUCTION 
In the past twenty years there has been a rapid growth of interest in the metabolic 
responses to sprint exercise, which can be defined as an activity in which exercise is 
performed at a maximal rate from the onset of exercise (Nevill et al., 1996a). The 
term 'maximal exercise' is often thought of as exercise at an intensity that elicits 
maximum oxygen uptake (VOzmax), however, during sprinting of 20-30 s duration, 
the average power output is approximately 2-3 times higher than that required to elicit 
V02max (Wooton, 1984). 
The development of the 30 s maximal cycle ergometer sprint 'Wingate' test by Bar-
Or et al. (1978), which was later modified by Lakomy (1986), in order to take into 
account the effect of acceleration, allowed high resolution measurement of power 
output, speed and acceleration during cycle ergometer sprint exercise in the 
laboratory. The use of sprinting on a friction-loaded cycle ergometer is a very 
attractive method of exercise testing, since it better represents 'real-life' exercise 
when compared with isometric contractions, electrical stimulation models and 
isokinetic cycling, and both the force and velocity components of power output can be 
considered. The combination of high resolution power. output and both blood and 
muscle biopsy sampling has allowed the study of the relationship between exercise 
performance and biochemical changes in the body, with a particular view to 
furthering the understanding of mechanisms involved in fatigue. However, there is 
very little information available regarding the human growth hormone (hGH) 
response to exercise, and particularly the hGH response to sprinting. 
Human growth hormone is released from the anterior pituitary gland, largely 
regulated by the balance between two hypothalamic hormones; growth hormone 
releasing hormone (GHRH) and somatostatin. There are a number of stimuli to hGH 
secretion, including stress, sleep, hypoglycaemia and exercise, and whilst prolonged 
exercise has been shown to be a potent stimulus for hGH secretion, very little research 
has focussed on the hGH response to sprinting. However, Nevill et al (1996b) 
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reported that a single 30 s treadmill sprint resulted in a 'near maximal' hGH response, 
when compared with pharmacological intervention studies. Sprint exercise, therefore, 
provides a very potent stimulus to hGH secretion without the need for extended 
exercise time and can be used to provide information about the hGH response to 
exercise, specifically with regard to the mechanisms responsible for the regulation of 
hGH secretion. 
The mechanisms responsible for exercise-induced hGH secretion are not fully 
understood, despite the attention of a number of studies. The roles of intensity and 
duration of exercise, blood lactate, blood pH, circulating catecholamines and oxygen 
demand and availability in the regulation of the magnitude of the hGH response to 
exercise have all been considered. It is likely that more than one of these factors work 
together, possibly with a contribution from motor centres in the brain, to regulate 
hGH secretion, but there is little agreement regarding the relative importance of the 
different mechanisms. Furthermore, the evidence regarding the hGH response to 
repeated bouts of exercise remains equivocal, since repeated bouts of exercise have 
been shown to both augment and inhibit hGH secretion. 
Although the actions of hGH, particularly in adulthood, are not fully understood, it is 
widely accepted that there is a role for hGH in the regulation of lipolysis as well as 
direct and indirect regulation of protein synthesis. Growth hormone replacement with 
recombinant (r)hGH is employed in the treatment of a number of disorders where 
hGH is lacking both as a cause and as a result of the illness. In addition, exogenous 
GH is used as an illegal performance enhancing agent in athletic competition, a 
practice which has reportedly increased in popularity following the development of 
the recombinant form. The study of natural hGH responses to an exercise stimulus 
and, in particular, repeated exercise might prove useful in the understanding of 
feedback regulation of hGH secretion, with implications for the therapeutic use of 
both exercise and rhGH. 
The main aim of this thesis is to study the hGH response to sprint exercise on a 
friction-loaded cycle ergometer with a view to contributing to the understanding of 
the mechanisms regulating exercise-induced hGH secretion. This thesis is presented 
in a further seven chapters: 
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• The review of literature (Chapter 2) provides on overview of fatigue during cycle 
ergometer sprinting, describing the effects of recovery during repeated sprints, 
pedalling rate and training on the metabolic responses to sprint exercise. The 
control of the secretion of hGH is also reviewed, with specific reference to the 
hGH response to exercise, as well as the importance of feedback in the hGH 
regulation. 
• The general methods (Chapter 3) describe the equipment, methods of analysis 
and procedures common to the experimental chapters are described. 
• The aim of the first experimental chapter (Chapter 4) is to describe the time-
course of the hGH response to maximal sprints of different duration. 
• The second experimental chapter (Chapter 5) investigates the effect of repeated 
bouts of maximal sprint exercise on the hGH response, whilst studying the effect 
of sprint cycling at different pedalling rates on hGH secretion. 
• The purpose of the third experimental chapter (Chapter 6) is to examine the effect 
of 6 wk of sprint training on the performance of, and hGH response to, repeated 
cycle ergometer sprinting. 
• The aim of the fourth experimental chapter (Chapter 7) is to study the effect of 
the duration of the recovery period between repeated sprints on hGH secretion, 
and consider the involvement of insulin-like growth factor I (IGF-1) in the 
regulation of the hGH response to exercise. 
• Chapter 8 is a general discussion which draws together the findings of the 
experimental chapters, explaining some of the possible the mechanisms involved 
in the regulation of hGH secretion following sprint exercise. 
2.1. Introduction 
CHAPTER2 
REVIEW OF LITERATURE 
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This Chapter is divided into two main sections. The first section provides an 
overview of the regulation of energy metabolism during maximal, or sprint, exercise, 
and also highlights relevant literature regarding the causes of fatigue during sprint 
exercise, the recovery of power output and the effect of training the performance of, 
and metabolic responses to, sprint exercise. The second main section provides a 
background to hGH, with particular reference to the regulation of hGH release, and 
the actions of hGH. In addition, specific reference is made to the regulation of 
exercise-induced hGH secretion. 
2.2. Sprint exercise 
2.2.1. Metabolic changes as a result of sprinting 
Sprint exercise results in power production many times that required to elicit maximal 
oxygen uptake (Spriet, 1995), and this requires very high levels of ATP hydrolysis, 
catalysed by the activity of three ATPases: 
• Actomyosin ATPase, for the dissociation of cross-bridges (Jones and Round, 
1990) 
• Calcium (Ca2+) transport ATPase, for Ca2+ reuptake by the sarcoplasmic reticulum 
(Carafoli, 1991) 
• N a+-K+ ATPase, for restoring membrane ionic balance after each action potential 
(Horisberger et al., 1991) 
ATPases 
Resting muscle concentrations of ATP are reported to be between -21 (Jacobs et al., 
1982) and -28 (Cheetham et al., 1986) mmol.kg dry muscle-1 which represents a 
relatively small reserve, and, therefore, during sprint exercise ATP must be 
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resynthesised at a very fast rate, relying largely on anaerobic metabolism. There are a 
number of pathways by which ATP can be resynthesised anaerobically: 
CPK 
PCr +ADP+ H+ ----- ATP + Cr 
Glycogen+ 3 ADP+ 3Pi--~ 3ATP + 2Lactate- + 2H+ 
adenylate kinase 
2ADP --------+ ATP +AMP 
1 AMP deaminase 
AMP+ H+ --------IMP+ NH4+ 
During a 6 s sprint, the total ATP turnover rate from anaerobic sources was reported 
to be 10.4 mmol.kg dry muscle-1.s-1 (Boobis, 1987) although Gaitanos et al. (1983) 
observed ATP production from anaerobic sources to be -15 mmol.kg dry muscle-1.s-1 
during similar exercise. 
ATP resynthesis from phosphocreatine degradation 
Of all the processes in the cell used in the resynthesis of ATP, the creatine kinase 
reaction is the most powerful (Sahlin, 1986a), and the muscle content of 
phosphocreatine (PCr) is 3-4 times higher than that of ATP (Table 2.1). Since the 
activity of creatine kinase is higher than the activity of ATPase, significant decreases 
in muscle ATP concentrations only occur when PCr is broken down to 60 % of the 
resting value (Hultman et al., 1987). At the end of a single 30 s cycle ergometer 
sprint, PCr was observed to be reduced to as little as -17 % of resting concentrations 
(Bogdanis et al., 1996). 
The creatine kinase reaction also has a buffering effect due to the involvement of 
hydrogen ions (H+). Breakdown of PCr absorbs H+, which has the effect of increasing 
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pH during the first few seconds of maximal contraction. Since the activity of 
phosphofructokinase (PFK) is pH dependent, alkalisation as a result of PCr 
breakdown will facilitate the activation of PFK and accelerate glycolysis. 
ATP resynthesis from glycolysis 
Limited muscle PCr content means that the creatine kinase reaction can only supply 
energy at a high rate for the first few seconds of intense exercise. Therefore, the 
glycolytic pathway is activated almost immediately after the start of intense 
contractions (Jacobs et al., 1983), and the findings of Greenhaff et al. (1996) suggest 
that it takes approximately 3 s to reach its maximal rate. Both muscle glycogen and 
glucose can be utilised in the glycolytic pathway, however, the intracellular content of 
free glucose is low and the transport across the cell membrane is a slow process in 
comparison to the rate of glycogen degradation (Hultman and Sjoholm, 1983). 
Therefore, muscle glycogen is the main substrate for anaerobic glycolysis during 
sprinting. 
Table 2.1. Muscle metabolite concentrations at rest and after maximal exercise. 
References n ATP %~ PCr %~ Gly %~ 
ATP PCr Gl~ 
Cycle ergometer 
Jacobs et al. (1982) 9F 30s 20.9 34 62.7 60 360 23 
Jacobs et al. (1983) 15M 30 s 
15M 10s 
7F 30 s 
7F 10 s 
Boobis et al. (1983) 7M 30 s 21.2 43 94.4 65 266 21 
Bogdanis et al. (1995) 8M 30 s 25.6 29 77.1 80 322 34 
Bogdanis et al. (1996) 8M 30s 27.0 27 75.2 83 328 30 
Cherry et al. (1998)* 
7.5% 8F 30 s 21.3 9 79.6 69 
11.0% 8F 30 s 24.0 17 78.5 74 
Gaitanos et al. (1993} 8M 6s 24.0 13 76.5 57 317 14 
Non-motorised treadmill 
Cheetham et al. (1986) 8F 30 s 28.2 37 87.7 64 281 25 
Nevill et al. {1989} 4M,4F 30 s 26.7 28 84.0 67 317 32 
/sokinetic cycle ergometer 
Jones et al (1985) 
60 revs.min"1 SM 30 s 21.3 37 70.5 60 
140 revs.min"1 5M 30s 19.1 0 64.8 34 
McCartne~ et al. (1986} 8M 30 s 22.6 40 62.0 70 373 21 
PCr, phosphocreatine; Gly, muscle glycogen; La-, muscle lactate; M, male; F, female 
*Sprint against an applied resistance of7.5% or 11.0% of the individuals' body mass. 
All units are mmol.kg dry muscle-1• 
La" 
post 
61 
74 
46 
47 
25 
98 
119 
108 
110 
113 
29 
78 
86 
135 
126 
126 
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Muscle glycogen content at rest is much larger than that of the high energy 
phosphates ATP and PCr (Table 2.1). In addition, it has been shown that anaerobic 
glycolysis is the dominant source of ATP during sprinting with percentage 
contribution to total anaerobic ATP turnover during a 30 s of 60-70 % (Cheetham et 
al., 1986), resulting in a reduction in muscle glycogen of -32% (Nevill et al., 1996a). 
The fact that muscle glycogen levels at the end of maximal exercise are still relatively 
high infers that glycogen availability does not limit exercise performance. However, 
3 days on a low carbohydrate (CHO) diet resulted in reduced mean power output 
during a 30 s cycle ergometer sprint, compared with a moderate CHO diet (Langfort 
et al., 1997). In this study muscle glycogen was not measured and it is, therefore, not 
entirely clear whether a low CHO diet actually reduced muscle glycogen content 
(Maughan and Williams, 1982). Furthermore, even if muscle glycogen levels were 
depleted, it is possible this acted via an acceleration in PCr degradation, rather than 
having a direct effect (Hultman, 1967). 
Muscle and blood lactate and pH 
During sprint exercise lactic acid is formed as a result of anaerobic glycolysis. At a 
physiological pH lactic acid is almost completely dissociated to lactate (La-) and H+ 
(Sahlin, 1986a), and H+ are, therefore, formed in equivalent amounts to lactate. 
Lactate is considered to be the main origin of H+, and the resulting decrease in pH 
(Hultman and Sahlin, 1980), and the contribution of lactic acid to total H+ production 
in the muscle has been estimated to be more than 85% (Sahlin, 1986a). 
A single maximal 30 s cycle ergometer sprint has been shown to result in an increase 
in muscle lactate concentration from -9 to -61 mmol.kg dry muscle-1 in females 
(Jacobs et al., 1982) and to -74 mmol.kg dry muscle-1 in males (Jacobs et al., 1983). 
Cheetham et al. (1986) reported a good correlation between muscle and blood lactate 
following a 30 s all-out sprint treadmill sprint, with peak blood lactate concentrations 
attained 5-6 min into recovery. Cheetham et al. (1986) also found blood lactate 
concentrations to be highly correlated with peak running speed and peak power output 
corrected for body mass. 
The finding that muscle lactate concentrations increase dramatically during a 10 s 
cycle ergometer sprint, representing 59 % of the changes observed in a 30 s sprint in 
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men, and 46 % in women, provides evidence that glycolysis is important in the early 
part of sprint exercise (Jacobs et al., 1983). Following a single maximal 30 s cycle 
ergometer sprint muscle lactate was found to have increased from -4 mmol.kg dry 
muscle"1 at rest to -119 mmol.kg dry muscle-1 (Bogdanis et al., 1995). This was 
accompanied by an increase in blood lactate concentration from 0.7 mmol.r1 to a 
highest measured mean concentration of 13.6 mmol.r1 6 min after the sprint. In 
addition, blood pH was found to have fallen from 7.38 at rest, to 7.08. 
Allsop et al. (1990) measured muscle pH continuously for 30 min after a single 30 s 
sprint on a non-motorised treadmill. Muscle pH decreased from a resting value of 
7.17 to 6.57 immediately after the sprint. Blood pH also decreased from 7.39, at rest, 
to 7.04 immediately after the sprint, displaying a similar pattern of recovery as muscle 
pH. A correlation between muscle pH and venous blood pH was identified, although, 
the predictability of muscle pH from a given blood pH was poor. 
Table 2.2. Blood metabolite concentrations at rest and following maximal exercise. 
Reference La" pH NH/ 
Pre- Post- Pre- Post- Pre- Post-
Cycle ergometer 
Bogdanis et aL (1995) BM 30 s 0.7 13.6# 7.38 7.08# 29 
Bogdanis et aL (1996) BM 30 s 12.0t 
Cherry et aL (1998)* 
7.5% SF 30 s 11.6:1: 26 
11.0% SF 30 s 10.9:1: 23 
Non-motorised treadmill 
Cheetham et aL (1986) SF 30 s 
Nevill et aL (1989) 4M,4F 30 s 13.0:1: 7.38 7.17 
Allsop et aL (1990) 7M,3F 30 s 0.8 15.8:1: 7.39 7.04§ 
Nevill et aL (1996a) 5M,6FST 30 s 17.9f 7.40 7.04§ 
6M,6FET 30 s 12.3f. 7.40 7.16§ 
/sokinetic cycle ergometer 
McCartney et aL (1983) 
60 revs.min-1 13M 30 s 9.7$ 
100 revs.min-1 13M 30s 10.6$ 
140 revs.min-1 13M 30 s 9.2$ 
Jones et aL (1985) 
60 revs.min-1 5M 30 s -2 -16# 
140 revs.min"1 5M 30 s -1 -14# 
La-, blood lactate (mmoLr1) (NB. McCartney et aL (1983) and Jones et aL (1985) reported plasma 
lactate); NH/, plasma ammonia (~-tmoLr\ *Sprint against an applied resistance of 7.5 %or 11.0% of 
the individuals' body mass; M, male; F, female; ST, sprint-trained; ET, endurance-trained; § 1 min 
post-exercise; $ 3min post-exercise; t 4 min post-exercise; :1: 5 min post-exercise; # 6 min post-
exercise; f mean peak concentration. 
157# 
74:1: 
64:1: 
251f 
163£ 
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Oxidative contribution to energy supply during sprinting 
During a 30 s sprint ATP turnover rates are much higher than can be attained by the 
aerobic energy processes, however, the aerobic contribution might be important for 
the last part of the sprint, and, particularly during repeated sprinting. McCartney et al. 
(1986) found that, during the third and fourth of four 30 s bouts of maximal isokinetic 
cycling, mean power output could be maintained at -60 % of the values recorded in 
the first bout, despite evidence of minimal glycolytic flux. It was suggested that this 
was due to an increased aerobic contribution, and a large increase in plasma glycerol 
concentrations, reflecting the utilisation of intramuscular triglycerides, provided 
further support for this suggestion. 
An increased aerobic contribution in the last of ten 6 s sprints, separated by 30 s of 
recovery, has also been reported by Gaitanos et al. (1993). In that study there was no 
increase in muscle lactate concentration as a result of the last sprint, whilst mean 
power output was only reduced to -73 % of that generated in the first sprint. 
Bogdanis et al. (1996) also considered the aerobic contribution to repeated sprinting, 
and identified a -41 % reduction in anaerobic energy in the second of two 30 s cycle 
ergometer sprints. Despite this, total work done during the second sprint was only 
reduced by -18 % and it was suggested that aerobic metabolism compensated for the 
reduction in anaerobic energy supply, providing -49 % of energy during the second 
sprint. 
AMP deamination and ammonia production 
The accumulation of ADP has been suggested to be involved in fatigue (Section 
2.2.3) and, therefore the ATP/ADP ratio is kept high via the adenylate kinase reaction. 
AMP deamination then occurs to promote continued formation of ATP from ADP 
(Sahlin and Katz, 1988), producing IMP in equivalent amounts to ammonia (NJ4 +). 
IMP remains in the cell, and, since further metabolism of IMP is a relatively slow 
process, the muscle content of IMP might reflect the extent of energy deficiency 
(Sahlin, 1992). In contrast, ammonia diffuses into the blood (Graham et al., 1993) 
where it can be easily measured, and during high intensity exercise almost all 
ammonia production can be attributed to AMP deamination (Terjung and Tullson, 
1992). In addition, Harris et al. (1991) found a significant correlation between plasma 
10 
ammonia and the decline in muscle ATP, which might be useful in the evaluation of 
ATP loss using plasma samples. 
A relationship between both blood lactate and plasma ammonia concentrations has 
been reported (Buono et al., 1984; Itoh and Ohkuwa, 1991). However, it is unlikely 
that there is a causal link, but rather that there is a coincidental acceleration in the 
rates of both glycolysis and AMP deamination with intense short-term exercise 
(Terjung and Tullson, 1992), and it has been demonstrated that ammonia production 
can occur independent of lactate metabolism in patients with glycolytic enzyme 
deficiencies (Sahlin et al., 1990). 
2.2.2. Recovery from sprint exercise 
Although studying metabolic responses to a single sprint provides an insight into the 
importance of different metabolic pathways in energy provision, it does not provide 
very much information regarding the influence of particular metabolites on fatigue. 
Instead, using a repeated exercise model allows the examination of the relationships 
between various metabolites and performance through studying their recovery. The 
advantage of this approach is that some variables that have been identified as 
important in fatigue might recover at different rates (Nevill et al., 1996a). Therefore, 
a large body of research has used repeated exercise models in the study of fatigue. 
Recovery of force and power 
Changes in maximal dynamic power with repeated exercise bouts have been studied 
by McCartney et al. (1986), who employed four 30 s maximal efforts on an isokinetic 
cycle ergometer at a pedalling rate of 100 rev.min-1, with 4 min of recovery between 
each bout. Highest peak power and average power for a pedal revolution in the initial 
few seconds of the first exercise bout and were measured at 1626 W and 992 W, 
respectively. Both were reduced by -20% in the second bout to 1321 W and 775 W, 
respectively. A further decline of -21% was identified in the third bout, but there was 
no decline in the last exercise period. 
The recovery of maximal short term power output was also studied by Hitchcock et 
al. (1989). Power output was measured during leg extensions on an isokinetic 
dynamometer following 0, 1, 2, 3, 4 and 8 min of recovery from prior cycle ergometer 
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exercise equivalent to 60, 80, 100 and 120 % V02max. Short term power output 
immediately after cycle ergometer exercise decreased to 85, 76, 55 and 45 % of initial 
values after exercise at 60, 80, 100 and 120 % V02max, respectively, and recovery 
was found to follow a "two-component exponential pattern" for all intensities of prior 
exercise. In addition, after prior exercise at intensities equivalent to 60 and 80 % V 
0 2max, short term power output had almost fully recovered within 60 s, whereas full 
recovery did not occur until 4 min after exercise at 100 % V02max and 8 min after 
exercise at 120% V02max. It was concluded that most of recovery (50-85 %) occurs 
within 60 s after exercise, and this time-course was compared with the recovery of 
PCr stores following exercise. 
In a study of the recovery of power output using treadmill sprinting (Holmyard et al., 
1994), subjects completed a maximal30 s sprint followed by passive recovery periods 
of 15, 45 and 120 s or 30, 60 and 180 s, before the completion of a second maximal 
sprint of 6 s duration. In a separate trial venous blood samples were taken 60 and 180 
s after a single 30 s maximal treadmill sprint. There was an initial rapid recovery of 
power output, and -80 % of recovery was complete after 60 s, but only a further 12 % 
recovery occurred in the second and third minutes after the 30 s sprint. No 
relationships were found between the recovery of power output and changes in blood 
metabolites, but recovery was suggested to follow a similar time-course as the 
resynthesis of intramuscular PCr reported by Harris et al. (1976). 
During repeated maximal30 s sprints on a friction loaded cycle ergometer, it has been 
demonstrated that peak power output in the second sprint almost recovers to the 
values seen in the first sprint (77 %) within 90 s of recovery (Bogdanis et al., 1995). 
However, peak power output, peak pedal speed and mean power output in the first 6 s 
of the sprint did not reach control values after 6 min of recovery, with peak power 
outputs after 3 and 6 min of recovery equivalent to 86 and 87 % of the peak power in 
the first sprint, respectively. Recovery of PCr was found to be significantly correlated 
with power output restoration for the 90 s and 3 min intervals, but not following 6 min 
of recovery. In addition, no relationship was identified between muscle lactate 
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recovery and power output. Once again, these data provide support for the contention 
that PCr resynthesis plays a dominant role in the recovery of power during repeated 
bouts of high intensity exercise. 
Following 2 min of recovery from a 10 s cycle ergometer sprint, peak power similar 
to that in the first sprint could be generated despite increased muscle lactate, [H+] and 
inorganic phosphate, indicating that both the force and contraction velocity 
components of muscle function were not affected (Bogdanis et al., 1998). However, 
mean power output in the first 10 s of the sprint could not be reproduced and this was 
probably due to a reduction in the total rate of ATP resynthesis in this period. Neither 
peak power output nor mean power output in the first 10 s of the sprint could be 
reproduced following 2 min of recovery from a 20 s sprint. Phosphocreatine stores 
were similar before the 30 s sprints in both trials, and oxygen uptake was the same 
during the sprints, suggesting that the lower work might be related to reduced 
glycolytic ATP regeneration as a result of the higher muscle acidosis in recovery from 
the 20 s sprint. However, force has been shown to recover faster than the 
disappearance of lactic acid in experiments using animal muscle fibres and Sahlin and 
Ren (1989) found a biphasic pattern of force recovery after isometric knee extension 
exercise to fatigue. In this study, maximal voluntary force was restored within 2 min 
of recovery despite high muscle lactate concentrations. 
In summary, there appear to be at least two phases of recovery of power output after 
maximal intensity exercise. Around 80% of the recovery of power output from a 30 s 
sprint occurs within 60-90 s, but full recovery of peak power output and mean power 
output for the first 6 seconds of a sprint is not achieved for at least 6 min after a sprint. 
This pattern of recovery of power output following maximal exercise has been 
suggested to be associated with the resynthesis of PCr following exercise, and also the 
recovery of glycolytic ATP generation. 
The ionic imbalance and very rapid recovery 
At the end of high intensity exercise, net K+ uptake by muscle is rapid with a 90-95% 
recovery of intracellular K+ within 210 s (Lindiger et al., 1995). Cherry (1998) noted 
that just 2-3 s of recovery from a maximal 30 s cycle ergometer sprint against an 
applied resistance of either 7.5% or 11% body mass allowed significant recovery of 
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peak power output in females. The initial rapid phase of recovery was attributed to 
the restoration of ionic balance. This suggestion is consistent with the finding that 
inhibition of Na+-K+ pump activity by preincubation of rat muscle with ouabain, 
resulted in a slower initial rate of force recovery lasting up to 5 min after electrical 
stimulation at 90Hz (Harrison et al., 1996). Balog and Fitts (1996) also identified a 
correlation between rapid initial force recovery and ionic balance restoration 
following electrical stimulation, as well as a secondary, slower phase which was 
linked with the recovery of metabolites. 
Recovery of muscle pH after high intensity exercise 
Sahlin et al. (1976) examined muscle lactate concentrations and muscle pH content 
after cycling exercise calculated to cause exhaustion at -6 min. From a resting value 
of 7.08, pH fell to 6.60 at exhaustion and during recovery pH returned to resting 
levels whilst muscle lactate concentrations remained elevated. These results, 
therefore, suggest that there is a faster rate of efflux for acid equivalents than lactate 
during the early part of recovery from high intensity exercise. The changes in muscle 
metabolites and contraction capacity following isometric knee extensions to fatigue at 
66 % of maximum voluntary contraction were studied by Sahlin and Ren (1989). 
Muscle pH declined from -7.10 at rest to -6.50-6.60 at fatigue and remained low for 
the first 2 min of recovery. This was attributed to a release of H+, as a result of PCr 
resynthesis, balancing the rate of H+ efflux from the muscle. In contrast, contraction 
force was completely restored after 2 min of recovery, suggesting that the capacity to 
generate force in vivo is not limited by high intracellular [H+]. 
Muscle pH has been shown to drop to -6.70 after a maximal 30 s sprint on a non-
motorised treadmill (Cheetham et al., 1986; Cheetham et al., 1987; Nevill et al., 1989) 
and even to 6.50 following repeated 30 s bouts of maximal sprint exercise (Spriet et 
al., 1989). Muscle pH has been measured before, and continuously for 30 min after, a 
single maximal 30 s sprint on a non-motorised treadmill by Allsop et al. (1990). 
Measurements were made using a needle-tipped pH electrode and thermocouple 
placed in the vastus lateralis of healthy subjects. Muscle pH was observed to decrease 
from 7.17 at rest to 6.57 immediately after the sprint, whilst venous blood pH was 
seen to fall from 7.39 to 7.04. Mter an initial increase in muscle pH to 6.70 (2 min 
into recovery), no further recovery was seen in the first 10 min of recovery and 30 
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min after the sprint muscle pH had recovered to 7.03 and venous blood pH to 7.29, 
but these values were still significantly different from the resting values. 
Resynthesis of phosphocreatine in muscle 
Bogdanis et al. (1996) considered the contribution of PCr to energy supply during 
repeated sprint exercise. Subjects completed two cycle ergometer sprints in two main 
trials. The first sprint was 30 s in duration in both trials, whereas the second sprint 
was either 10 s or 30 s. Muscle samples were taken at rest, immediately after the first 
30 s sprint, after 3.8 min of recovery and immediately after the second, 10 s or 30 s, 
sprint. At the end of the first sprint muscle PCr was -17 % of resting concentrations, 
and muscle pH had dropped to -6.70. After 3.8 min of recovery, muscle pH had not 
recovered ( -6.80), but muscle PCr concentrations had been restored to -79 % of the 
resting value. In the second sprint, PCr was almost completely depleted in the first 10 
s. In addition, a relationship between power output recovery and PCr resynthesis was 
identified, whereas no relationship between power output recovery and any other 
metabolite was found. 
The time course of PCr resynthesis was examined by Harris et al. (1976), who took 
repeated muscle biopsy samples during recovery from dynamic exercise (8.7 min of 
cycling at 60 rev.min-1) and isometric knee extension (40-55 sat 66% of maximum 
voluntary force). The data were modelled using a two component exponential 
equation and fast and slow recovery components were identified. There was no 
difference in the half times of the fast component of recovery after dynamic or 
isometric exercise, which were 21 sand 22 s respectively, although the amount of PCr 
resynthesised after 2 and 4 min of recovery was lower following isometric exercise. 
Bogdanis (1994) found that the PCr resynthesis was slower following sprint exercise 
on a cycle ergometer when compared with the dynamic exercise used by Harris et al. 
(1976). This difference was attributed to reduced blood flow to recovering muscles 
during passive recovery from sprinting which, in turn, reduced PCr resynthesis. 
Sahlin et al. (1979) examined the recovery of muscle PCr following cycling to 
exhaustion at an intensity calculated to result in fatigue at -6 min. They observed 
significant recovery of PCR (68 %) in muscle samples incubated in oxygen for 15 
min, but did not see any recovery of PCr in muscle samples incubated in nitrogen. 
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This highlights the importance of oxygen availability for PCr resynthesis, and Harris 
et al. (1976) found that occlusion of blood flow to leg muscles during and after 
exercise to fatigue abolished PCr resynthesis. Further evidence that the initial fast 
phase of PCr resynthesis is limited by the availability of oxygen is that the initial rate 
of PCr resynthesis is not affected in patients with glycolytic enzyme deficiencies, who 
do not produce lactate or H+, but is slower in patients with peripheral vascular disease 
or mitochondrial myopathies (~hance et al., 1982; Radda et al., 1982; Radda, 1986). 
However, the slow phase of PCr resynthesis might be limited by the presence of free 
hydrogen ions (Sahlin et al., 1979). 
PCr has been shown to be decreased to a similar extent in both fibre types following a 
maximal 30 s sprint on a non-motorised treadmill (Greenhaff et al., 1994). However, 
Tesch et al. (1989) found that PCr recovered to 50 and 68 % of resting levels 60 s 
after 30 maximal voluntary knee extensions in fast twitch and slow twitch fibres, 
respectively. In addition, PCr was higher in slow twitch fibres 60 s after -83 s of 
electrical stimulation of the quadriceps at 20 Hz (Soderlund and Hultman, 1991). 
Slower PCr resynthesis in fast, compared with slow, twitch fibres, might be related to 
the higher mitochondrial density and capillarisation of slow twitch fibres (Soderlund 
and Hultman, 1991). 
The effect of active, rather than passive, recovery on power output during cycle 
ergometer sprinting was studied by Connell and Maile (1996), who found enhanced 
recovery of power output when 15 s cycle ergometer sprints were interspersed with 5 
min active recovery periods at an intensity of 40 % V02max, compared with 5 min of 
passive recovery. Similarly, Bogdanis et al. (1996) observed that 4 min of active 
recovery (cycling at 40 % VOzmax) resulted in a significantly higher mean power 
output in the second of two 30 s sprints, compared with a second sprint following 
passive recovery ( 603 vs. 589 W). The enhanced recovery of mean power output 
following active recovery was a result of a 3.1 %higher power generation in the first 
10 s of the second sprint, and it was suggested that active recovery enhanced the 
recovery of power output through increased blood flow to the exercising muscle, 
resulting in increased ion efflux from the muscle, and also increased oxygen 
availability for PCr resynthesis. 
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Trump et al. (1996) studied 3 bouts of isokinetic cycling at 100 rev.min·1 with 4 min 
recovery between bouts and occluded blood flow to one leg for the 4 min period 
between bouts 2 and 3, to prevent PCr resynthesis. Muscle biopsies taken 
immediately before and after bout 3 demonstrated no difference in muscle metabolites 
apart from PCr between the two legs, whilst power output was 15 % lower in the 
cuffed leg compared with the control leg. These results provide further evidence of a 
close relationship between the recovery of power output and PCr resynthesis. 
In summary, muscle has been shown to recover from fatigue in at least two distinct 
phases, a rapid phase, complete within 2 min, and a slower phase lasting 30-60 min 
(Fitts and Holloszy, 1978; Thompson et al., 1992). These distinct phases of recovery 
might represent at least two distinct mechanisms of fatigue (Cherry, 1997), since 
different aspects of performance recover with different time-courses. For example, 
peak power output recovers rapidly as a result of the restoration of ionic balance and 
an initial rapid phase of PCr resynthesis, whilst mean power output recovers more 
slowly, probably related to a slower phase of PCr recovery associated with adverse 
metabolic conditions following a sprint, in addition to reduced inhibition of glycolysis 
with the recovery of pH. 
2.2.3. An overview of fatigue in sprinting 
Edwards (1981) defined fatigue as, "The inability of the total organism to maintain a 
required or expected power output", and it is characterised by a rapid decline in 
mechanical output or tension development in skeletal muscle (Hermansen, 1981). 
The decline in the contractile force of skeletal muscle that occurs with fatigue is 
associated with a decrease in muscle PCr and ATP concentrations and an increase in 
inorganic phosphate (Pi) and its acidic fraction (H2P04"), H+ and ADP, with a 
consequential decrease in free energy available from ATP (Godt and Nosek, 1986). 
Since ATP rarely drops below -50 % of the resting value during sprinting (Boobis, 
1983), and there is a very low Km of myosin ATPase for ATP (Glyn and Sleep, 1985) 
it is unlikely that fatigue is related to reduced energy supply (Jones and Round, 1990). 
It is more likely that the accumulation of products of the hydrolysis of ATP (Pi. ADP, 
H+) and a decrease in pH due to the contribution of anaerobic glycolysis influence 
fatigue. 
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The role of phosphate 
Increases in inorganic phosphate (Pi) have been reported to result in decreases in Ca2+ 
sensitivity and maximal force in skinned skeletal and cardiac muscle preparations 
(Godt and Nosek, 1985). Similarly, Kentish (1985) observed that the addition of Pi to 
skinned cardiac muscle of rats greatly decreased force generation. In addition, it was 
reported that this was neither due to a reduction in the amount of free energy available 
for work from ATP hydrolysis, nor due to inhibition of creatine kinase activity, but 
rather that Pi has a direct action on the contractile machinery. The decreases in force 
generation as a result of the addition of Pi to contracting skinned fibres is probably a 
result of a slowing of the release of phosphate from the actomyosin complex, leading 
to an accumulation of cross-bridges in a state where they are unable to develop force 
(Jones and Round, 1990). However, Cady et al. (1989a) found intact preparations to 
be much less sensitive to Pi than skinned fibre preparations, and showed that, in intact 
preparations, the major changes in Pi occur early in exercise, before force begins to 
decline. 
The role of ADP 
Slowing of relaxation from an isometric contraction is characteristic of acutely 
fatigued muscle, and is thought to be a result of a reduction in the rate of cross-bridge 
detachment. The detachment is thought to involve the binding of ATP with the 
actomyosin complex, and the dissociation of actin and myosin with ATP bound to 
myosin (Figure 2.1). Phosphate does not influence the rate of these reactions and 
does not, therefore, influence the force-velocity characteristics. However, ADP 
accumulation will inhibit the release of ADP, and will therefore reduce the number of 
cross-bridges which will reach the stage where they can dissociate. This reduces the 
force at a given velocity and also a reduction in the maximal velocity of shortening 
(Jones and Round, 1990). 
However, the concentration of ADP at which the rate of cross-bridge detachment is 
reduced ( -4 mmol) is outside the normal physiological range (Jones and Round, 
1990). In any case, the effect of ADP accumulation on force generation is not entirely 
clear, since concentrations in excess of the normal physiological range increased force 
in skinned preparations (Godt and Nosek, 1985), but have been found to result in a 
decrease in force in intact muscle preparations (Cady et al., 1989a). 
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Figure 2.1. Stages in the cross-bridge cycle in relation to the biochemical steps. (i) 
attachment of actin and myosin giving stiffness to the muscle, (ii) Pi is released from 
the actomyosin complex initiating rotation, (iii) ADP released, (iv) actomyosin 
complex binds ATP (v)actin and myosin dissociate with ATP bound to myosin, (vi) 
ATP is hydrolysed activating the myosin head (in Jones and Round, 1990). 
The role of hydrogen ions 
The activity of PFK, which is a key rate-limiting enzyme in glycolysis, shows a 
marked pH dependence and, therefore, H+ accumulation might be expected to result in 
a reduction in glycolysis. However, Sahlin et al. (1975) reported that during isometric 
contraction to fatigue, the glycolytic rate remained unchanged, despite a decrease in 
muscle pH from 7.09 at rest to 6.56 at fatigue. Isometric contraction to fatigue was 
also found to result in increased concentrations of the PFK activators Pi, AMP, ADP, 
fructose 1,6-diphosphate and fructose 6-phosphate (Sahlin et al., 1975) and these 
probably overcame any pH mediated inhibition of PFK. 
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It has also been considered that H+ might be involved in the slowing of relaxation. 
Sahlin et al. (1981) identified a close relation between muscle pH and slowing of 
relaxation rate in normal rat extensor digitorum longus muscle, but not in muscle 
poisoned with iodoacetic acid (which stops glycolysis and prevents a drop in pH). In 
contrast, Cady et al. (1989b) found that slowing of relaxation occurred in both normal 
subjects and one subject with myophosphorylase deficiency (MPD), who could not 
produce H+ from glycolysis. These findings indicate that slowing of relaxation can 
occur independent of H+. However, the recovery of relaxation was faster in the 
subject with MPD than the normal subjects, suggesting that the recovery of relaxation 
is due to persisting low pH. Therefore, there may be at least two processes, one due 
to H+ accumulation and one independent of H+, that cause slow relaxation in fatigue. 
Increased concentrations of H+ are also likely to displace the creatine kinase 
equilibrium so that PCr breakdown increases, thereby reducing high energy phosphate 
stores (Sahlin et al., 1983). Other mechanisms by which accumulation of H+ might 
contribute to fatigue include: 
• Increased binding, and therefore reduced release, of Ca2+ by SR at low pH 
(Nakamura and Schwartz, 1970) 
• Competition with Ca2+ for binding sites on troponin C (Palmer and Kentish, 1994) 
• Decreased activity of the three ATPases by product inhibition, and therefore 
slowing relaxation, reducing force and impairing muscle membrane 
depolarisation. 
• Decreased sensitivity of the force generating apparatus (Metzger and Moss, 1987) 
• Reduced energy release from ATP breakdown (Cooke and Pate, 1990) 
However, force recovery following exercise has been shown to be faster than the 
restoration of H+ to pre-exercise levels (Section 2.2.2). In addition, although Cady et 
al. (1989a) observed that in normal subjects loss of force matched increasing H+ 
concentrations, in one subject with MPD, force loss was independent of H+ 
accumulation. Sahlin et al. (1981) observed similar results, whereby a similar (-50 
%) decline in tension was observed in normal rat extensor digitorum longus muscle 
and muscle in which glycolysis had been blocked by iodoacetic acid during electrical 
stimulation. Although tension decline in unpoisoned muscle was closely related to a 
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decrease in muscle pH, a similar decline in tension in the poisoned muscle suggests 
another mechanism of fatigue, independent of pH. 
The role of calcium 
There are a number of possible cellular mechanisms which link calcium and muscle 
fatigue: 
• A decline in Ca2+ release possibly associated with slow reuptake of Ca2+ by SR 
under adverse metabolic conditions (Cady et al., 1989b) since Ca2+ reuptake is an 
ATP dependent process (Jones and Round, 1990) 
• A reduction of tension at saturating Ca2+ (yvesterblad et al., 1991) 
• A decreased sensitivity of the contractile mechanism to Ca2+ (e.g. H +-Ca2+ 
competition for troponin; Palmer and Kentish, 1994) 
The role of potassium 
The excitability of muscle membrane is dependent on the membrane potential, which 
is, itself, mainly dependent on the K+ gradient across the membrane (Sjogaard, 1987). 
The rise in extracellular potassium observed during high intensity exercise would 
eventually cause a depolarisation block, and therefore might be related to fatigue in 
this type of exercise (Vollestad and Sejersted, 1988). In fact, small increments in 
extracellular K+ concentration have been shown to result in a reduction of muscle 
tension during subsequent electrically stimulated contractions in isolated mouse 
muscle (Juel, 1988). Any loss of intracellular K+ is likely to be due to impairment of 
the function of the Na+-K+ pumps which might be a result of the inhibition of Na+-K+ 
ATPase by accumulation of ADP or H+, or it could be the result of energy deficiency. 
Bangsbo et al. (1996) studied the effect of acidity on fatigue and found that at the end 
of intensive exhaustive leg exercise preceded by arm exercise muscle pH was lower 
than after leg exercise alone. However, fatigue occurred at the same arterial and 
venous plasma potassium concentrations regardless of whether arm exercise preceded 
leg exercise or not. These results suggest that increased muscle acidity is not the only 
cause of fatigue, but that the accumulation of potassium in muscle interstitium might 
be an important factor. It was suggested that the development of fatigue might be a 
result of increased release of K+ from the muscle cell due to a decrease in pH. 
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In summary, there are a number of biochemical changes that have been suggested to 
play a role in the development of muscle fatigue. The products of hydrolysis of ATP, 
namely Pi. ADP and H+, have been reported to have a direct effect on the contractile 
apparatus, although conflicting results in skinned and intact preparations make it 
difficult to assess the importance of these mechanisms. It has also been suggested 
that the accumulation of H+ is involved in a number of other mechanisms of fatigue, 
including the inhibition of glycolysis, promotion of PCr breakdown and interference 
with the normal function of Ca2+ at a number of levels. However, fatigue has been 
found to occur independent of the accumulation of H+ and a role for K+ accumulation 
in the muscle interstitium has been suggested. It is likely that some, or all, of these 
mechanisms contribute to fatigue during sprint exercise. 
2.2.4. The effect of pedalling rate 
One of the advantages of using a friction-loaded cycle ergometer to study power 
output is that both force and velocity components can be measured. Changes in 
pedalling rate occur throughout a 30 s sprint, but it is possible to modify mean pedal 
rate during a sprint by altering the applied resistance, since in an all-out sprint, 
pedalling rate is a function of applied resistance (Cherry, 1997). Mean pedal rate can 
be used as a good indicator of the number of muscle actions that take place, and 
therefore, by altering the applied resistance it is possible to manipulate the number of 
muscle actions during a sprint. 
The effect of pedalling rate on power output 
Sargeant and Dolan (1987) studied the effect of the duration of prior exercise on the 
power output achieved in a 20 s maximal effort under isometric conditions at a 
pedalling rate of 112 rev.min-1• Prior exercise was performed at an intensity 
equivalent to 98% V02max and lasted 0.5, 1, 3 or 6 min. With increasing duration of 
prior exercise, maximal power in the subsequent effort decreased, and 6 min of prior 
exercise resulted in a reduction in maximal power output of 30 % compared with 
control. In the same study the effect of the intensity of prior exercise was considered 
and 6 min bouts of exercise at intensities equivalent to between 32 % and 100 % V 
02max preceded a 20 s maximal effort. Six minutes of exercise at power outputs 
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eliciting 39% and 56% V02max resulted in an increase in maximal power of 15.0% 
and 10.5 % respectively, compared with control. However, prior exercise at power 
outputs equivalent to more than 60 % V02max reduced subsequent maximal power 
compared with control. 
The effect of fatigue on maximal power output at a range of different contraction 
velocities was studied by Beelen and Sargeant (1991). Six healthy male subjects 
completed 25 s maximal efforts on an isokinetic cycle ergometer at pedalling rates of 
60, 75, 90, 105 and 120 rev.min-1 immediately after 6 min of cycling exercise at 90% 
V02max. These results were compared with a 'control condition' whereby prior 
exercise was performed at 30 % V02max. Fatiguing prior exercise did not result in 
significant reductions in maximal power at pedalling rates of 60 and 75 rev.min-1, 
compared with control conditions. However, at the higher pedalling rates (90, 105 
and 120 rev.min-1) maximal power was reduced by 23 %, 28% and 25 %compared 
with control, respectively. These results inferred a velocity dependent effect of 
fatigue which may reflect selective fatigue of fast, fatigue-sensitive, fibres. In human 
mixed muscle all fibre types will contribute to power production and the effect of 
selective fatigue would be small. However, with increasing contraction velocities the 
contribution of faster fibres will become more important and, therefore, fatigue of 
these fibres is likely to affect power production at high, rather than slow, contraction 
velocities. Beelen and Sargeant (1993) studied the effect of prior exercise at different 
pedalling rates on maximal power. The results showed that 6 min of submaximal 
cycling exercise performed at a pedal rate of 120 rev.min-1 reduced maximal power 
output during a 25 s maximal effort at 120 rev.min-1 more than when the prior 
exercise was matched for external work production, but was performed at a pedal rate 
of 60 rev.min-1• These results provided further evidence of the greater involvement of 
fast fatigue-sensitive fibres in exercise at higher pedalling rates. 
Cherry et al. (1996) considered the effect of constant paced compared with all-out 
exercise on a friction loaded cycle ergometer and found that the total work produced 
during a 30 s all-out sprint could be reproduced during 30 s of constant-paced exercise 
at pedalling rates equal to 55 % of the peak pedal speed achieved in the 30 s sprint 
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(CP-55 % ). The performance of a 6 s sprint following only 3 s of recovery from the 
first bout of exercise (all-out sprint or CP-55 %) demonstrated that subjects were less 
fatigued under CP-55 % conditions, since they performed better in the 6 s sprint. This 
suggests that the moderate pedalling rates in the CP-55 % condition resulted in a 
greater contribution of slow type I muscle fibres compared with the all-out sprint, 
allowing faster fibres to make a greater contribution in the 6 s sprint. 
The effect of pedalling rate on the metabolic response to sprint exercise 
Bergstrom and Hultman (1988) used electrical stimulation at a frequency of 20 Hz to 
produce contractions with a duration of 0.8 s in one leg and 3.2 s in the other leg. In 
both experiments the work to rest ratio was 1:1, and the 0.8 s stimulation consisted of 
64 contractions giving a total contraction time of 51.2 s. The 3.2 s stimulation gave 
the same total contraction time and consisted of 16 contractions. Muscle biospies 
were taken at rest and after 22.4 and 51.2 s of contraction. Despite the observation 
that force declined more rapidly with contractions of a shorter duration, no significant 
differences were found in muscle PCr content or muscle lactate concentrations after 
either 22.4 or 51.2 s of contraction, and calculated ATP utilisation rate did not differ 
between trials. However, the inclusion of data from Chasiotis et al. (1987), who 
compared continuous stimulation with 1.6 s intermittent stimulation, resulted in the 
identification of significant differences in muscle lactate concentrations between the 
different stimulation protocols, which was observed to increase as the number of 
muscle actions increased. 
Intermittent electrical stimulation (1.6 s contraction, 1.6 s rest) at two frequencies (20 
and 50Hz) for a total of 25 contractions (total contraction time 40 s) resulted in both 
higher initial force and a greater loss of force at 50 Hz (Hultman and Sjoholm, 1983). 
However, no differences in the magnitude of changes in concentrations of ATP, ADP, 
PCr, Pi or lactate were identified. Soderlund et al. (1992) used the same frequencies 
and stimulation pattern to study changes in muscle metabolites in human type I and 
type 11 fibres. Muscle biopsies were taken from the quadriceps femoris muscle at rest 
and after 10 and 20 s of stimulation (6 and 12 contractions, respectively). The 
decrease in force, represented as a percentage of the initial force, was similar during 
electrical stimulation at the two frequencies. The PCr degradation was higher in type 
11 fibres compared with type I fibres at both frequencies. However, there were no 
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differences in PCr degradation rate at 20 or 50 Hz, and, after 12 contractions, there 
were no differences in the ATP, PCr or glycogen content in mixed muscle. In 
contrast, markedly larger increases in mixed muscle lactate, G-6-P and F-6-P 
concentrations were identified after 12 contractions at 50 Hz compared with 20 Hz. 
Lodder et al. (1991) found that, after 40 stimulated contractions of rat extensor 
digitorum longis muscle at three different shortening velocities (25, 50 and 75 mm.s-
1), muscle PCr and lactate concentrations were similar. In contrast muscle IMP 
concentration was significantly higher following stimulation at 75 mm.s-1 compared 
with either 25 or 50 mm.s-1 despite the fact that the amount of work produced was not 
different. 
A maximal 30 s effort performed on an isokinetic cycle ergometer at three different 
pedalling rates (60, 100 and 140 rev.min-1) resulted in both greater peak power output 
and a greater fatigue index with increasing pedalling rate (McCartney et al., 1983). 
However, no differences in postexercise plasma lactate concentrations were 
identified. Jones et al. (1985) also examined the changes in muscle metabolite 
concentrations following 30 s of maximal exercise on an isokinetic cycle ergometer, 
this time at two different pedalling rates (60 and 140 rev.min-1• Peak power output 
and fatigue index were both greater following exercise at 140 rev.min-I, however, 
maximal exercise at different pedalling rates was observed to induce similar changes 
in the concentrations of metabolites in mixed muscle. In contrast, plasma lactate 
concentrations were higher 4 min after exercise at 140 rev.min-1 compared with 60 
rev.min-1• 
Cherry et al. (1998) studied the effect of pedalling rate during all-out sprinting on a 
friction loaded cycle ergometer. In this study pedalling rate was manipulated by 
altering the applied resistance, since when an all-out sprint is performed on a friction-
loaded cycle ergometer, pedalling rate is a function of the applied resistance (Cherry, 
1997). The results of Cherry et al (1998) demonstrated that changes in pedalling rate 
during all-out cycle ergometer sprinting did not result in differences in the magnitude 
of the subsequent changes in muscle or blood metabolites. Changes in muscle 
concentrations of PCr, creatine, lactate, ATP and pyruvate were not different 
following sprints against applied resistances equivalent to 7.5% and 10.1% of 
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subjects' body mass. In addition, there were no differences in plasma ammonia 
concentrations, blood pH levels or blood lactate concentrations following sprint 
exercise at different pedalling rates. 
In summary, average pedalling rate during cycle exercise can be regarded as a good 
indicator of the total number of muscle actions which take place. It is possible to 
manipulate pedalling rate during sprint exercise on a friction-loaded cycle ergometer 
by altering the applied resistance. The literature suggests that the manipulation of 
average pedalling rate, and the associated changes in the speed and number of muscle 
actions, might alter the metabolic responses to exercise. However, the only available 
data regarding the metabolic responses to sprint exercise where limbs are free to 
accelerate, for example on a friction-loaded cycle ergometer, suggest that pedalling 
rate does not influence the magnitude of changes in either muscle or blood 
metabolites. 
2.2.5. Training 
Short-term sprint or interval training has been shown to result in small, but 
significant, improvements in sprint performance (e.g. Boobis et al., 1983; Sharp et al., 
1986; Cheetham and Williams, 1987; Nevill et al., 1989; Stathis et al., 1994). 
One of the factors involved in the improvement of sprint performance following 
training might be an increase in the number of contractions during the sprint, which 
could be facilitated by a decrease in the time to peak tension of fibers after training 
(Nevill et al., 1989). In fact time to peak tension of the rat soleus muscle has been 
shown to decrease by 14% following sprint training (Staudte et al., 1973) although no 
change was observed in the fast-twitch rectus femoris. The activity of myofibrillar 
ATPase is a very important factor in determining this contractile characteristic and 
this has been shown to increase by 34% following training (Belcastro et al., 1981). 
Myofibrillar ATPase activity could be enhanced by an increase in the activity of 
adenylate kinase, which has been demonstrated to be higher after strength training in 
humans (Costill et al., 1979). If adenylate kinase activity also increased following 
sprint training the rate of ADP deamination to IMP and NH3, and the resultant 
removal of ADP from the contraction site, would rise, thus reducing the inhibition of 
ATP utilization by product inhibition (Nevill et al., 1989). 
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The effect of training on sarcoplasmic reticulum function 
It has also been suggested that decreased contraction time might be due to changes in 
the functional capacity of the SR (Troup et al., 1986). Fitts et al. (1980) postulated 
that the SR regulates contraction and relaxation times, observing an association of an 
increase in SR Ca2+ uptake activity with faster contraction and relaxation in 
thyrotoxic rat soleus. However, Hunter et al. (1999) found that 12 weeks of high-
resistance strength training resulted in an increase in SR Ca2+ uptake and SR Ca2+-
ATPase activity in the vastus lateralis of elderly (64-79) but not young (18-27) 
women and that quadriceps relaxation time did not change in either group as a result 
of training. Similarly, Ortenblad et al. (2000) did not observe any change in Ca2+-
ATPase capacity or SR Ca2+ uptake rate following 5 weeks of sprint training in young 
men, despite a 12 % increase in total work performed. However, peak rate of AgN03-
stimulated Ca2+ release was found to increase by 9%, probably as a result of enhanced 
muscle SR content. The fact that there were no changes in the myosin heavy chain 
(MHC) isoform distribution indicates that there is a different time course in 
development SR Ca2+ regulation properties and MHC isoforms. 
Changes in muscle fibre composition associated with training 
Increases in muscle power might be a result of an increase in the speed of muscle 
contraction, which has a close association with the expression of different myosin 
heavy chain (MHC) isoforms (Harridge et al., 1998). Sprint training in humans has 
been shown to cause an increase in type Ila and a decrease in type lib fibres (Jacobs et 
al., 1987). Similarly, Costill et al. (1979) found an increase in the percentage of the 
muscle's cross-sectional area represented type Ila fibres, along with a decrease in type 
I fibres, following 7 wk of isokinetic strength training. No changes in the percentage 
of type I, type Ila and type lib fibres were observed. Aitken et al. (1989) also found 
the proportion of type Ila fibres increased by 5.9%, whilst the proportion of type I 
fibres decreased by 6.3% following sprint training. 
Six weeks of sprint training on a cycle ergometer was found to increase pedal 
revolutions, and therefore power output, achieved during a 3 s sprint test at three 
different applied resistances (Harridge et al., 1998). However, no changes in MHC 
isoform or fibre-type distribution were identified, and there were no significant 
variations in single-fibre contractile characteristics. In fact, in the knee extensors 
27 
whole muscle twitch, TPT, a marker of contractile speed, was increased following 
training, and this change was attributed to a change in Ca2+ release and reuptake from 
SR. The changes in performance during the 3 s sprints were, therefore, attributed to 
increased strength in the leg muscles and to neural adaptations to cycling. A similar 
conclusion was drawn by Boobis et al. (1983) who identified an improvement in 
sprint performance following 8 weeks of sprint training but did not find a concomitant 
increase in energy provision from glycogenolysis. It was therefore suggested that 
improvements in performance might be attributable to the recruitment of a larger 
muscle mass after training. 
The effect of sprint training on enzyme activity 
High intensity training has been shown to decrease contraction time in the rat soleus 
muscle from 111 to 92 ms (Troup et al., 1986). In addition, the activity of 
phosphofruktokinase (PFK) increased in the soleus and the deep region of the vastus 
lateralis following training. Baldwin et al. (1975) observed a close correlation 
between PFK activity and actomyosin ATPase activity in rats and suggested that the 
glycogenolytic pathway and actomyosin ATPase activity are regulated in parallel. A 
correlation has also been demonstrated between actomyosin ATPase activity and 
speed of shortening suggesting a causal link (Barany, 1967). Staudte et al. (1973) did 
not see a significant change in PFK activity in rats as a result of a sprint training 
programme employing shorter intervals of higher speed than the programme of Troup 
et al. (1986). However sprint and strength training in humans has been shown to 
result in increased PFK activity both in conjunction with (Costill et al., 1979; Hellsten 
et al., 1996; Sharp et al. 1986), and in the absence of (Houston et al., 1981; Jacobs et 
al., 1987), any improvements in performance. Parra et al. (2000) observed increases 
in PFK activity along with an improvement in sprint performance when training was 
carried out with two days of recovery between each training sessions but found a 
larger increase in PFK activity despite finding no improvement in performance when 
training was carried out every day. This highlights the sensitivity of different 
training adaptations to rest distribution and indicates that improvements in the 
performance of maximal exercise may not be dependent on glycolytic enzyme 
activities. Indeed, it has been estimated that the potential of the enzymes in the 
glycolytic pathway exceed the demands during maximal exercise and it is not clear as 
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to why the activity of these enzymes increase with training (Saltin and Gollnick, 
1983). 
Stathis et al. (1994) found sprint training to result in lower post-exercise muscle IMP 
and ammonia concentrations after a 30 s sprint reflecting a reduction in the magnitude 
of ATP depletion. This suggests that the balance between ATP hydrolysis and 
resynthesis is improved after sprint training. The most likely reason for improved 
ATP resynthesis is increased glycolytic capacity (Sharp et al., 1986; Jacobs et al., 
1987; Nevill et al., 1989). Stathis et al. (1994) also observed plasma ammonia 
concentrations to be higher in the 2nd min of recovery but then tended to be lower by 
201h min of recovery (P = 0.06). Snow et al. (1992) found 7 wks of sprint training to 
result in a decrease in plasma ammonia concentrations following exercise. Since 
Nevill et al. (1989) found that sprint training did not result in any changes in ATP 
depletion during sprint exercise, it was suggested that this decrease in plasma 
ammonia was unlikely to be a result of lower muscle ammonia accumulation, but 
rather an attenuation of net efflux of ammonia from the exercising muscles (Snow et 
al., 1992). However, Nevill et al. (1989) did report an increase in glycolytic flux 
following sprint training, and it is, therefore, possible that exercise-induced increases 
in muscle ammonia concentrations were reduced as a result of this. 
The effect of sprint training on the aerobic contribution to sprinting 
It has been suggested that sprint training decreases glycolytic rate in rats (Troup et al., 
1986) and humans (Harmer et al., 2000) and increases the aerobic contribution to 
sprinting (MacDougall et al, 1998; Harmer et al., 2000). The contention of Harmer et 
al. (2000) that sprint training decreases glycolytic rate disagrees with studies 
employing training protocols utilising very short sprints (Linossier et al., 1993), 
combined speed and speed endurance training (Nevill et al., 1989), longer sprints 
(Jacobs et al., 1987) and even studies using a very similar training regime (Stathis et 
al., 1994; MacDougall et al., 1998). Stathis et al. (1994) reported that there is no 
conclusive evidence that training enhances muscle oxygen consumption during a 
single sprint bout, however, MacDougall et al. (1998) saw an increase muscle 
oxidative enzymes in addition to an increase in PFK activity. Furthermore, it has 
been argued that decreased glygolysis and glycogenolysis, evidenced by lower 
glycogen degradation, lower muscle and plasma lactate accumulation, combined with 
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an improved energy balance, indicated by reduced ATP degradation and IMP 
accumulation, meant that the aerobic contribution to sprinting must increase (Harmer 
et al., 2000). However, there was no evidence of an increase in either oxygen 
consumption or oxygen deficit after training. 
An increase in V02max following sprint training was identified by MacDougall et al. 
(1998), in agreement with the results of Harmer et al. (2000) who observed a similar 
trend (P=0.07). When the training protocols used in these studies are considered, 
however, this is not a entirely surprising observation since each session consisted of a 
high volume of training of the type that would be expected to improve speed 
endurance rather than explosive speed. Depite this, studies employing the same speed 
endurance training programme consisting of a progression from four to ten 30 s all-
out sprints on a cycle ergometer with 4 min of passive recovery between sprints have 
shown increases in peak power output in a 30 s sprint of 6-17 % (McKenna et al. 
1993; Stathis et al., 1994; Harmer et al., 2000), although MacDougall et al. (1998) did 
not find any improvement in peak power during a single sprint. The difference in 
training protocols, as well as different testing procedures probably accounts for much 
of the disagreement between studies regarding changes in metabolic responses to 
sprint exercise. 
Changes in buffering capacity associated with sprint training 
It has been reported that alterations in substrate levels, glycolytic enzyme activities 
and fibre composition cannot account for the improvements in performance observed 
following sprint training (Parkhouse and McKenzie, 1984). Nevill et al. (1989) found 
that a single 30 s sprint on a non-motorised treadmill resulted in a decrease in blood 
pH of 0.21 units, and 8 wk of sprint training increased this drop to 0.29 units. It was 
suggested that training might have resulted in enhanced H+ efflux from exercising 
muscles. Buffering capacity, as measured using the homogenate technique, was not 
altered as a result of training, although it was recognised that this method does not 
take into account transmembrane ionic fluxes. In contrast, when buffering capacity 
was calculated from changes in lactate concentrations and pH during the 30 s sprint, it 
was found to increase from 87.9 to 126.7 slykes following training. This increase in 
buffering capacity would allow a greater anaerobic contribution to energy provision 
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for a given change in pH, and increased glycolytic flux was attributed to either an 
increase in PFK activeity, or an increase in H+ efflux from the muscle. These results 
are similar to those of Sharp et al. (1986), who identified a significant increase in 
buffering capacity, PFK activity and performance, without any change in pH, 
following 8 wk of sprint training. 
Further evidence for an important role of an increase in buffering capacity as an 
adaptation during sprint training was provided by Bell et al. (1988), who used one-
legged cycling to investigate the effect of 7 wk sprint training on intramuscular pH 
and nonbicarbonate buffering capacity. Peak and average power outputs during a 
one-legged 60 s maximal power test were significantly greater following training, as 
were blood lactate concentrations after exercise. In addition, buffering capacity, 
defined as the quantity of hydrochloric acid (HCl) required to change the pH of a 
homogenate of 1 g of muscle by 1 pH unit, increased from 49.9 !lmol HCl.g-1.pH-I, 
before training, to 57.8 !lmol HCl.g-1.pH-1• Although Bell et al. (1988) could not 
provide a full explanation of the mechanisms for such a training adaptation, the major 
buffering components are the bicarbonate buffer system, PCr, Pi, protein-bound 
histidine residues and carnosine (Parkhouse and McKenzie, 1984). It is possible that 
increases in one, or more, of these components might be important in training 
adaptations associated with improved buffering capacity, but the larger increase in in 
vivo buffering capacity following training, when compared with in vitro buffering 
capacity, identifies the additional importance of enhanced membrane transporter 
capacity (Juel, 1998). 
Changes in the regulation of ionic balance associated with sprint training 
Potassium has a vital role in muscle function during exercise and has been implicated 
in fatigue (Section 2.2.3). Active 70 year old men have been found to have a 30-40 % 
higher eH]ouabain binding site concentration than age-matched sedentary men, 
suggesting that Na+ -K+ pump concentration can be increased by training (Klitgaard 
and Clausen, 1989). Furthermore, McKenna et al. (1993) reported increased 
eH]ouabain binding site concentration in human skeletal muscle, and improved 
plasma and skeletal muscle K+ regulation after 7 wk of sprint training, possibly 
through an increase in Na+-K+-ATPase activity. The improvement inK+ regulation 
by skeletal muscle following training was accompanied by improvements in sprint 
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performance. Harmer et al. (2000) took a different approach and found that sprint 
training reduced plasma K+ concentrations following exercise when the work done in 
the post-training performance test was matched with that done in the pre-training test. 
This result provides further support for an improvement in K+ regulation as a result of 
training, which might play a role in the improvement of sprint performance. 
In summary, short-term sprint training is likely to result in a change in the kinetics of 
Ca2+ release and reuptake by SR, and this is likely to precede small, if any, changes in 
MHC isoform expression. Improvements in performance as a result of a short period 
of sprint training might also be a result of increased energy provision through 
enhanced glycolytic flux, or even an increase in the aerobic contribution (particularly 
in repeated sprints), depending on the focus of training. In addition, increases in 
muscle buffering capacity as well as improved K+ regulation might be important 
training adaptations. However, the most likely sources of improvement in 
performance over a short period are increases in muscle strength in conjunction with 
neural adaptations. 
2.3. Human Growth Hormone 
2.3.1. The biochemistry, production and secretion of human growth hormone 
Biochemistry 
Human growth hormone (hGH), also known as somatotrop(h)in, differs from the 
growth hormone (GH) of every other species (Merimee, 1979). It is a polypeptide 
hormone and, although not homogenous, the major one is a single chain of 191 amino 
acids, stabilised by two intermolecular disulphide bonds (Kutsky, 1973), with half 
cystines between positions 53 and 65 and between 182 and 189 and a molecular 
weight of approximately 22 000 daltons (Niall, 1971). Human GH is very similar in 
structure to prolactin (PL) and chorionic somatomammotropin (HCS) of the placenta 
suggesting a single progenitor hormone in an earlier stage of evolution (Merimee, 
1979). 
Production 
Mature hGH is synthesised and stored in the acidophilic somatotropes of the anterior 
pituitary. These cells comprise 30-40% of the anterior pituitary (Guyton, 1986) and, 
in total, contain 5-10 mg hGH, constituting the most abundant hormone in the 
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pituitary gland (Haynes, 1986). Human GH is a product of translation on ribosomes 
attached to the endoplasmic reticulum of the somatotropes. It would appear that a 
hGH precursor is formed (Merimee, 1979) which is then probably transported to the 
Golgi apparatus by ER transport vesicles where it is compacted and packaged in 
secretory granules or vesicles. Typical somatotropic cells possess large numbers of 
these round secretory vesicles in the cytoplasmic compartment (Guyton, 1986) which 
are 300 to 400 J..tm in diameter (Merimee, 1979). The secretory vesicles then store 
hGH until its release in bursts as a result of stimulation. Secretion of hGH is, 
therefore, episodic and, at the cellular level, release of hGH appears to involve 
exocytosis or fusion of secretory vesicles with the plasma membrane followed by 
solubilisation and diffusion of the vesicle content into the circulation (Merimee, 
1979). Production rates of hGH have been reported to be -0.5 mg/24 h/m2 in females 
(Thompson et al., 1972), and -0.4 mg/24 h/m2 in males (Alford et al., 1973). 
Secretion 
Secretion of hGH is largely regulated by the balance between two hypothalamic 
hormones; one that stimulates hGH release called growth hormone releasing hormone 
(GHRH) (also known as growth hormone releasing factor/hormone (GRF/GRH) or 
somatocrinin), and one which inhibits hGH secretion called somatostatin (SS) (also 
known as growth hormone inhibiting hormone (GHIH) or somatotrophin release 
inhibiting factor/hormone (SRIF/SRIH)). GHRH and somatostatin are thought to be 
the main factors mediating the effect of a number of exitatory and inhibitory stimuli 
including: 
Exitatory stimuli: 
a) hypoglycaemia 
b) physical exercise 
c) fasting 
d) meals with a high protein content 
e) deep sleep 
f) stress 
g) glucagon 
h) L-DOPA 
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i) clonidine (a central acting a-adrenergic drug) 
j) amino acids 
Inhibitory stimuli: 
a) glucose/hyperglycaemia 
b) cortisol 
c) hGH 
d) free fatty acids 
Growth hormone receptors 
Mter hGH is released into the circulation it is attached to a specific binding protein 
which is, in fact, the extracellular domain of the cell membrane bound hGH receptors 
(Rogol, 1989) and is derived from the membrane receptor by cleavage (Spencer et al., 
1988). Baumann et al. (1987), using rats, showed that in vivo the binding protein 
(BP) lowers the rate of GH clearance six-fold. In addition, at normal levels of BP, 
only 25-45% of hGH is bound, so the effect of the BP might be to dampen pulse 
height and to maintain GH availability in between pulses (Jansson et al., 1985). The 
hGH -bound complex travels to the liver and other tissues to bind with the specific 
membrane bound hGH receptors. GH receptors have been identified in many 
vertebrate cell types including hepatocytes, adipocytes, fibroblasts, chondrocytes, 
osteoblasts, ~-islet cells, macrophages, lymphocytes and ventral prostatic epithelial 
cells (Waters et al., 1990). The interaction of GH with its receptor leads to the 
activation of cytoplasmic tyrosine kinases although the GH receptors themselves do 
not show tyrosine kinase consensus sequences (Waters et al., 1990) 
The importance of hGH binding proteins and receptors is highlighted by the fact that 
children with Laron-type dwarfism are very short , despite high circulating levels of 
hGH, since they are deficient in both the hGH binding protein and the hGH receptor 
(Baumann et al., 1987). 
Clearance 
Hormones are "cleared" from the plasma through metabolic destruction by tissues, 
binding with tissues, excretion by the liver into the bile and excretion by the kidneys 
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into the urine (Guyton, 1986). Human GH is metabolised in the liver and metabolic 
clearance rate (MCR) is usually constant in individuals, however, there appears to be 
large amount of variation between individuals (Thompson et al., 1972). In addition, 
an upright posture has been shown to decrease MCR by 24% (Alford et al., 1973). 
Hall (1971) demonstrated that hGH has a short half-life since, after intravenous 
injection, hGH was seen to peak in 1 h before returning to baseline in 3 h. Veldhuis et 
al. (1995) used deconvolution analysis to produce an estimate for hGH half life of 18 
min. Other half-life estimates have been made and George (1996) reports a range of 
12-45 min. However, the disappearance rate of hGH from plasma is exponential 
(Cameron, 1969) and therefore the significance of such half-life estimates is unclear. 
Various authors have also reported clearance rates of hGH although differing units of 
measurement make comparison difficult. Franchimont and Burger (1975) reported a 
clearance rate of 170 1/24 h/m2, whilst Vahl et al. (1997) reported a significant 
increase in MCR with age from 0.11±0.02 l.min-1 in young (27-34 years) subjects to 
0.19±0.01l.min-1 in older (47-59 years) subjects. 
The short plasma half-life of hGH in addition to the presence of numerous and 
frequent exitatory and inhibitory stimuli results in marked fluctuations in circulating 
levels of hGH throughout a 24 h period. However, typical serum concentrations have 
been reported as 0 - 11.5 mU.r1 (White and Baxter, 1994). Peak concentrations 
appear to occur shortly after the onset of sleep (Kern et al., 1995) although average 
daily hGH concentrations are affected by factors such as sex, age and body 
composition, amongst others. 
2.3.2. The regulation of hGH secretion by neuropeptides 
Growth hormone releasing hormone 
Three approximately equipotent forms of GHRH have been identified from pancreatic 
tumours: GHRH 1-44, GHRH 1-40 and GHRH 1-37 corresponding to the number of 
amino acids in each form (Dieguez et al., 1988). Full biological activity is present in 
the first 29 amino acids (Lance et al., 1984). Two of these forms, GHRH 1-44 and 
GHRH 1-40, have been identified in the human hypothalamus (Bohlen et al., 1983). 
The relative molecular mass of these peptides approximates 13000 daltons (Haynes, 
1986). GHRH is inactivated by a plasma dipeptidylaminopeptidase producing the 
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more stable and biologically less active GHRH 3-44 (Frohman et al., 1986). 
Immunoreactive GHRH is found mainly in the arcuate nucleus (Arc) although it has 
also been identified in ventromedial nucleus (VMN) where it is likely to have an 
exohypophysiotropic role (Muller et al., 1999). 
GHRH stimulates GH synthesis and release after binding to specific GHRH Gs 
protein receptors in the plasma membrane of somatotrope cells, activating adenylate 
cyclase via N5 which, in turn, activates the cyclic 3' ,5' -adenosine monophosphate 
(cAMP) second messenger system. The stimulation of GH secretion occurs through a 
cAMP and Ca2+ dependent mechanism whilst the stimulation of GH synthesis, by 
increasing the transcription rate of the GH gene, is cAMP but not Ca2+ dependent 
(Baringa et al., 1985). 
Somatostatin 
Somatostatin is a tetradecapeptide that inhibits the secretion of most hormones under 
physiologic circumstances (Muller et al., 1999). Somatostatin-14 (SS-14) is part of a 
family of SS-like peptides including somatostatin-28 (SS-28) and a fragment that 
corresponds to the first 12 amino acids of SS-28 [SS-28-(1-12)] (Muller et al., 1999). 
The SS-like peptides are synthesised and located in most regions of the brain although 
somatostatin producing cells are also present throughout the central and peripheral 
nervous system, the gut and the endocrine pancreas (Muller et al., 1999). In neural 
tissues, the predominant form is SS-14 with a ratio of 4:1 (SS-14:SS-28) in the 
hypothalamus and SS-14 is the main form released on K+ depolarisation from slices 
of rat hypothalamus implying that this is the form responsible for hypothalamic 
neurotransmission (Muller et al., 1999). 
Somatostatin producing cells are present throughout the central and peripheral 
nervous systems, as well as the gut and endocrine pancreas, and in smaller numbers in 
other glands and organs. In the hypothalamus, these cells are most common in the 
periventricular nucleus (Pe VN), but they are also found in the Arc and VMN (Muller 
et al.,1999). Somatostatin binds to its own specific receptors in the plasma membrane 
of somatotrope cells and inhibits adenylate cyclase activity via inhibitory nitrogen 
(Ni) although it probably has additional actions on calcium fluxes (Dieguez et al., 
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1988). In turn this inhibits the accumulation of cAMP in the somatotropes and, 
therefore, inhibits GH secretion. 
Interactions between GHRH and somatostatin in the regulation of hGH 
secretion 
Growth hormone secretion occurs in an episodic manner punctuated by pulses of 
relatively short duration which are interspersed by troughs. There has been a great 
deal of debate concerning the mechanisms that exert an influence on this pulsatile 
pattern of secretion, largely focussing on the roles of GHRH and somatostatin. 
However, to assess the relative importance of these hormones is not an easy task since 
it is not possible to measure GHRH and somatostatin in the peripheral circulation and 
extrapolate to the hypophyseal portal circulation. This is because circulating 
somatostatin is likely to be of gastro-pancreatic rather than hypothalamic origin (Patel 
and Srikant, 1986) and it is possible that GHRH is also of nonhypothalamic origin 
(Kashio et al., 1987). Much of the data available are therefore from animal studies. 
Plotsky and Vale (1985) directly measured concentrations of immunoreactive GHRH 
and immunoreactive somatostatin in the hypophyseal portal circulation of rats. In 
addition they took systemic samples from another group of rats. Measurable 
concentrations of immunoreactive GHRH were only found in samples taken during 
periods of expected GH secretory activity. In addition, during the collections 
coinciding with periods of expected GH secretion (i.e. GH pulses), hypophyseal portal 
plasma immunoreactive somatostatin concentrations decreased by 37±5% in two 
consecutive samples and then returned to baseline concentrations. It was, therefore, 
concluded that hypophyseal portal immunoreactive somatostatin and systemic GH are 
inversely correlated and that GHRH is secreted in a strongly pulsatile fashion. In 
addition, these results support the contention that GHRH and somatostatin secretion 
are 180° out of phase (Tannenbaum and Ling , 1984) and suggest that the release 
immunoreactive GHRH into the hypophyseal portal circulation only occurs when 
immunoreactive somatostatin secretion is decreased, implying a regulatory role of 
somatostatin in GHRH secretion.· Therefore, each immunoreactive secretory burst 
was suggested to preceded by, or concurrent with, a reduction in somatostatinergic 
inhibitory tone. However, the major weakness of the study of Plotsky and Vale 
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(1985) was that hypophyseal portal measurements of GHRH and somatostatin were 
taken from a different set of animals to those from which the GH measurements were 
taken. Although rats display a regular 3-4 h pattern of pulsatile GH secretion, this 
pattern is not synchronised between animals (Carlsson and Jansson, 1990). 
The GHRH/somatostatin/GH axis was also studied by Frohman et al. (1990) using 
unanaesthetised sheep. Direct measurements of hypothalamic-portal GHRH and 
somatostatin were made, simultaneous with those of peripheral GH. GHRH was 
found to have a mean pulse interval of 71 min. Somatostatin was also observed to be 
pulsatile with a mean pulse interval of 52- 54 min, whilst GH (measured in jugular 
plasma) had a mean pulse interval of 58-65 min, therefore intermediate between that 
of GHRH and somatostatin. Whilst there was seen to be considerable concordance 
between GHRH and GH and considerable discordance between somatostatin and 
GHRH, no statistically significant results were found. However, a highly significant 
association was observed between peaks of GHRH simultaneous with or immediately 
preceding GH peaks. This association explained 62% of GH peaks identified. In 
contrast no association was seen between somatostatin troughs and GH peaks or 
between GHRH and somatostatin in hypothalamic-portal plasma. These results 
suggested that GHRH has a primary role in the regulation of the pulsatile secretory 
pattern of GH secretion with a lesser role for somatostatin although it was suggested 
that the intensity of the GH pulse might be modified to some extent by the level of 
somatostatin at the time of each GHRH pulse. Frohman et al. (1990) also indicated 
that the fact that GHRH and somatostatin could not explain all of the GH secretory 
bursts might imply that another hypothalamic factor contributes to the regulation of 
the pulsatile pattern of GH secretion. 
Thomas et al. (1991) continued the study of hypophyseal portal GHRH and 
somatostatin and their relationship with circulatory GH, this time in ewes after a long 
period (20 wk) of restricted feeding. Restricted feeding resulted in a significant 
increase in mean plasma GH in comparison with normal feeding. The secretory 
pattern of GHRH was pulsatile in all of the ewes with low interpulse concentrations, 
whereas somatostatin pulses were less regular with generally higher baseline 
concentrations. The occurrence of GH secretory pulses were highly dependent on 
GHRH pulses and between 61-70% of GH pulses were coincident with, or 
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immediately preceded by, a GHRH pulse, whilst 58-61% of GHRH were coincident 
with, or immediately preceded by, a GH pulse. In contrast, pulsatile secretion of 
somatostatin appeared to be more random and the concentration of somatostatin at the 
time of each GHRH was not found to significantly affect the probability of a GH 
pulse. The earlier suggestion that a decrease in somatostatinergic tone might be the 
integral factor in the generation of a GH pulse was therefore not supported by the 
results of this study. The authors did, however, contend that short-term fluctuations in 
somatostatin might be identified using a shorter (i.e. <10 min) sampling interval. In 
addition, the higher GH pulse amplitude in the presence of reduced somatostatin 
concentrations in the underfed sheep suggested that low somatostatin levels might 
increase the pituitary responsiveness to GHRH. 
It must be recognised that there are inter-species differences in the neuroendocrine 
control of GH secretion and therefore animal data cannot be immediately extrapolated 
to humans. For example, acute hypoglycaemia results in a decrease in GH secretion 
in sheep (Frohman et al., 1990) and rats (Tannenbaum et al., 1976), but an increase in 
GH secretion in humans (Blackard and Waddell, 1969). In fact, whilst the importance 
of pulsatile GHRH secretion in the regulation of the pulsatile pattern of GH secretion 
has been demonstrated in sheep (Frohman et al., 1990; Thomas et al., 1991), 
continuous GHRH infusion has been shown to result in highly pulsatile GHRH 
secretion in normal humans (Vance et al., 1985). This suggests an important role for 
somatostatin in the regulation of GH secretory pattern and, in fact, somatostatin 
withdrawal has been observed to elicit a GH response in humans (Davies et al., 1985). 
Jaffe et al. (1993) used (N-Ac-Tyr\D-Arg2)GHRH(1-29)NH2 (GHRH-Ant), a 
competitive GHRH antagonist at the level of the GHRH receptor, to study the 
importance of GHRH in the generation of hGH pulses in humans. Exogenous 
GHRH-stimulated GH secretion was almost completely suppressed by GHRH-Ant. 
In addition, nocturnal integrated and pulsatile hGH release were both suppressed by 
GHRH-Ant treatment. Nocturnal hGH profiles displayed a decrease in peak and 
mean pulse amplitude, but no change in pulse frequency or interpulse hGH 
concentrations. This provided clear evidence that GHRH plays an important role in 
the generation of spontaneous hGH secretory pulses in humans, whilst the lack of any 
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change in the nonpulsatile component of the hGH profile suggests that GHRH is not 
important in determining interpulse levels of hGH in young men. 
The same GHRH antagonist was used to evaluate the role of GHRH in morning 
(08:30 to 11:30) and evening (20:30 to 23:30) plasma pulsatile hGH secretion (Hanew 
et al., 1996). Initial plasma hGH concentrations were higher in the evening than in 
the morning. There was no difference between GHRH-Ant and saline control trials in 
the morning, however, in the evening plasma hGH decreased during GHRH-Ant 
infusion and mean 3 h plasma hGH concentration was significantly lower for the 
GHRH-Ant than for the control trial. It would, therefore, appear that that GHRH 
maintains evening, but not morning, basal hGH secretion. It is possible that this 
reflects the fact that evening hGH secretory pattern is dominated by a more pulsatile 
pattern of hGH secretion than that seen in the morning. If this is the case then the 
results of this study offered further support for the contention that GHRH regulates 
pulsatile hGH secretion whilst somatostatin has a greater regulatory influence on 
interpulse hGH concentrations. However, this study did not give any evidence as to 
whether the postulated increase in hypothalamic GHRH secretion in the evening was 
a result of reduced hypothalamic somatostatin. In addition, since GHRH-Ant could 
not entirely suppress hGH secretion in either the evening or the morning, it is possible 
that there is another mechanism that plays a role in the secretion of hGH. 
Indirect evidence that somatostatin directly modulates the activity of GHRH neurons 
came from Tannenbaum et al. (1998). It had previously been suggested that 
somatostatin played a direct regulatory role in GH secretion through its action on the 
pituitary gland (Brazeau et al., 1973), and also an indirect role through central 
regulation of GHRH-containing neurons (Tannenbaum, 1994). Of the five subtypes 
of somatostatin that have been cloned and characterised (Reisine and Bell, 1995), 
Tannenbaum et al. (1998) colocalised two (sstl and sst2) in GHRH mRNA-containing 
neurons in the Arc. This provides strong anatomical evidence that somatostatin is 
capable of directly modulating the activity of GHRH neurons through interactions 
with both sstl and sst2. 
It is also possible that other, as yet unidentified, peptides occur in the hypophyseal-
portal circulation to stimulate or inhibit GH secretion. For example, a growth 
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hormone-releasing peptide (GHRP)-receptor has been cloned and does not show 
homology with other peptide receptors (Howard et al., 1996), strengthening the 
hypothesis of the existence of a natural GHRP-like ligand (Arvat et al., 1997). In 
addition, there is evidence suggesting that, in the short term, the ultradian rhythm of 
GH secretion is independent of GH feedback, but that the generator of this rhythm is, 
instead, intrinsic to the central nervous system (Willoughby and Kapoor, 1990) 
2.3.3. The role of neurotransmitters in the regulation of hGH secretion 
Although hypothalamic GHRH and somatostatin are thought to have the predominant 
role in the regulation of GH secretion, other neurotransmitters have a role acting both 
directly on GH secretion and through the modulation of GHRH and somatostatin 
release. 
Catecholamines 
a2-adrenoreceptors 
Clonidine (an a2-adrenergic receptor agonist)-induced GH release in rats was shown 
to be completely blocked by passive immunisation with GHRH antiserum (Cella et 
al., 1987), but was not affected by somatostatin antiserum (Eden et al., 1981). These 
results suggest that GH secretion stimulated by a 2-adrenoreceptor activation might be 
mediated by an increase in hypothalamic GHRH secretion, and not a decrease in 
hypothalamic somatostatinergic tone. Evidence supporting this contention was 
provided by the fact that activation of a2-adrenoreceptors, by the administration of 
clonidine and another a2-adrenergic receptor agonist, guanabenz, resulted in an 
increased area under the curve for GHRH, with no effect on somatostatin release, in 
perifused bovine hypothalamic tissue (West et al., 1997). In the same study, 
administration of idazoxan, an a 2-adrenergic receptor antagonist, blocked clonidine-
induced secretion of GHRH with no effect on somatostatin. 
It is possible, however, that clonidine acts through the inhibition of somatostatinergic 
pathways. Pre-treatment with GHRH in humans has been shown to abolish the hGH 
response to a second administration of GHRH, however, the hGH response to 
clonidine was not altered (Valle et al., 1997). In addition, clonidine administered to 
rats at a time of spontaneous peak, when somatostatin secretion is low, failed to 
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stimulate GH release. In contrast, clonidine administration during a trough period 
increased plasma GH concentrations (Lanzi et al., 1994). It would, therefore, appear 
that a2-adrenoreceptor agonists enhance GH secretion via both the stimulation of 
GHRH secretion and the inhibition of somatostatin release. 
a1-adrenoreceptors 
Catecholamines are considered to have a role in the hGH response to hypoglycameia, 
yet administration of the a 1-adrenergic antagonist, prazosin, did not affect the 
hypoglycaemia-induced hGH response in humans (Tatar and Vigas, 1984). This 
finding suggests the same mechanism of action, that is inhibition of hypothalamic 
somatostatin secretion. However, the administration of the a 1-adrenergic receptor 
agonist, methoxamine, has been found to result in a small, not significant, decrease in 
hGH secretion (Al-Damluji, 1993), and it has been suggested that endogenous 
catecholamines acting on a 1-adrenoreceptors do not play a role in the secretion of 
hGH (Muller et al., 1999). 
f3-adrenoreceptors 
(3-adrenergic receptors are known to inhibit GH release. The non-specific (3-
adrenergic receptor antagonist propranolol has no effect on basal hGH secretion in 
Caucasians (Blackard and Heidingsfelder, 1968) although it does enhance the hGH 
response to hypoglycaemia, exercise, glucagon and GHRH (Chihara et al., 1985). In 
contrast, salbutamol, a (3-adrenergic receptor agonist inhibits the hGH response to 
GHRH in humans. Activation of pituitary ~-adrenoreceptors in vitro stimulate GH 
secretion, suggesting that ~-adrenergic receptor agonists do not exert their main effect 
directly at pituitary level (Perkins et al., 1983). It is likely, instead, that the activation 
of (3-adrenoreceptors in vivo is to increase hypothalamic somatostatinergic tone, thus 
inhibiting GH secretion (Muller et al., 1989). 
Dopamine 
Both stimulatory and inhibitory actions of dopaminergic pathways have been 
described. Administration of the direct dopamine agonist apomorphine to normal 
subjects has been shown to cause acute hGH release and increase the hGH response to 
GHRH (Vance et al., 1987 in Muller). However apomorphine blunts the hGH 
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response to hypoglycaemia, L-DOPA and arginine when administered by infusion 
(Woolf et al., 1979; Bansal et al., 1981 in Dieguez). A partial explanation for this is 
the fact that dopamine has been shown to be capable of stimulating the release of both 
GHRH and somatostatin from the rat hypothalamus (Kitajima et al., 1989). However, 
further complication is caused by evidence that dopamine and its agonists inhibit GH 
release from rat (Cronin et al., 1984) and human (Marcowitz et al., 1982) pituitaries in 
vitro. The role of dopamine in the regulation of hGH secretion, therefore, remains 
unclear. 
Serotonin 
Serotoninergic pathways appear to provide stimulatory influence for GH release in 
rats (Arnold and Femstrom, 1981), although the situation is less clear in humans. The 
difficulty in assessing the role of serotonin (5-HT) in the regulation of GH secretion is 
due to the existence of many receptors that mediate the actions of 5-HT, in addition to 
the lack of specific agonist and antagonist drugs (Valverde et al., 2000). Four main 
types of 5-HT receptors have been identified in the brain (5-HT1, 5-HT2, 5-HT3 and 
5-HT4) with further classification of receptor subtypes. Sumatriptan, a selective 5-
HT1D receptor agonist, administration was observed to result in increased 
spontaneous hGH secretion and also to increase the hGH response to exogenous 
GHRH in normal prepubertal children (Mota et al., 1995). However, sumatriptan did 
not change the GH response to clonidine or pyridostigmine. Sumatriptan also induced 
a GH peak in beagle dogs and potentiated GHRH-induced GH release (Valverde et 
al., 2000). Atropine (a specific muscarinic cholinergic receptor blocker, which easily 
crosses the blood-brain barrier) abolished sumatriptan-induced GH secretion, whilst 
pyridostigmine had no effect. These results suggest that 5-HT1D receptors have a 
stimulatory effect on GH secretion, possibly through inhibition of hypothalamic 
somatostatin release. Valverde et al. (2000) also identified a stimulatory role for the 
5-HT2C receptor subtype, since a 5-HT2NC receptor subtype antagonist modified 
the GHRH-induced GH response whilst a 5-HT2A receptor subtype antagonist failed 
to do so. Similarly, a 5-HT3 receptor subtype antagonist had no effect on either the 
basal or GHRH-induced GH response. Thus, different 5-HT receptor subtypes appear 
to have different roles in the regulation of GH. 
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It has also been suggested that 5-HT might stimulate the secretion of GH, and other 
pituitary hormones, acting directly at the pituitary (Balsa et al., 1998). However 
anterior pituitary cell cultures did not respond to 5-HT, apparently requiring the 
presence of posterior pituitary cells in coculture in addition to preincubation with 
corticosterone. These results led the authors to suggest that 5-HT stimulation of GH 
release is a result of a direct action of 5-HT on the posterior pituitary stimulating 
release of an unidentified mediator from melanocytes. Further research is required in 
order to discover whether this mechanism exists, and, if so, to evaluate its importance 
in the regulation of hGH secretion .. 
Acetylcholine 
Casanueva et al. (1984) administered atropine to subjects, and employed three stimuli 
of hGH secretion: arginine, clonidine and physical exercise. Atropine administration 
resulted in a complete blockade of hGH secretion. The completeness of the blockade 
to these three diverse stimuli of hGH secretion indicates the important role of 
acetylcholine (Ach) in regulating hGH release. Indeed, the results of this study 
suggest that a cholinergic synapse might be the final common pathway of a variety of 
different stimuli of hGH release. Atropine has also been demonstrated to suppress 
pulsatile GH secretion (Casanueva et al., 1983) as well as GH secretion induced by 
opioids (Casanueva et al., 1980), glucagon (Delitala et al., 1982) and sleep 
(Mendelson et al., 1978). However, there is evidence that insulin-induced GH 
secretion (Blackard and Waddell, 1969) as well as GH release in response to surgery 
(Desborough et al., 1993) are not blocked by cholinergic blockade, indicating that 
Ach does not mediate all stimuli to GH release. 
In vitro, Ach has been demonstrated to inhibit somatostatin release from the rat 
hypothalamus (Richardson et al., 1980). In addition, passive immunisation with anti-
somatostatin serum abolished the inhibitory effects of atropine in GHRH-induced GH 
secretion (Locatelli et al., 1986). These results suggest that cholinergic antagonists 
enhance somatostatin secretion. However, insulin-induced hypoglycaemia combined 
with GHRH administration has an additive effect on GH release (Page et al., 1987) 
suggesting a role for somatostatin in the GH response to hypoglycaemia. This infers 
that cholinergic antagonists would block the GH response to hypoglycaemia but this 
is not the case (Blackard and Waddell, 1969). In addition, a-adrenergic blockade 
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decreases the effect of cholinergic enhancement of GH secretion (Devesa et al., 
1991), suggesting that adrenergic pathways might act distally to the cholinergic 
system in the control of GH secretion (Desborough et al., 1993) disputing the 
suggestion that a cholinergic synapse is the final common pathway in the control of 
GH release (Casanueva et al., 1984). 
Glutamate 
The actions of essential amino acids (EAAs ), including glutamate, are mediated by a 
number of receptor subtypes, including N-methyl D-aspartate (NMDA), kainate (KA), 
2-amino-3-hydroxy-5 methyl-4-isoxazol proprionic acid (AMPA) and metabotropic 
receptors. Systemic administration of N-methyl-D,L-aspartic acid (NMA), a NMDA 
receptor agonist, to castrated male sheep (Estienne et al., 1989) has been shown to 
result in GH release, whilst intravenous injection of boars with NMA increased 
circulating GH in a dose-dependent manner (Estienne et al., 2000). Kainic acid has 
also been demonstrated to increase GH secretion in male rats (Pinilla et al., 1986). 
Furthermore, administration of AMP A to prepubertal rats resulted in an increase in 
serum GH concentrations, whilst injection of an antagonist of AMPA receptors, 
1,2,3,4-tetrahydro-6-nitro-2, 3-dioxo-benzo (f) quinoxaline-7-sulfonamide (NBQX), 
resulted in the opposite effect, decreasing serum GH levels (Gonzalez et al., 1999). In 
fact it has been suggested that activation of NMDA, KA and AMPA receptors results 
in a 'clear-cut' stimulation of GH secretion in animals (Tena Sempere et al., 2000), 
and taken with the evidence that metabotropic glutamate receptors were found in 
almost all immunoreactive GHRH neurons of the arcuate nucleus of male rats, 
providing anatomical evidence of a direct effect of glutamate on GHRH secretion 
(Kiss et al., 1997), glutamate appears to have an important role in GH secretion. 
However, there is very little information about the effect of glutamate administration 
on hGH secretion, and a large oral dose of monosodium glutamate (MSG) had no 
effect on plasma concentrations of hGH in men (Fernstrom, 2000). This finding 
probably reflects the fact that diet-derived glutamate does not penetrate hypothalamic 
regions controlling anterior pituitary function, and extrapolation of the results of 
animal studies suggests that glutamate probably has a role in the regulation of hGH. 
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GABA 
Injection of y-aminobutyric acid (GABA) into the third ventricle of rats has been 
shown to result in GH release (McCann et al., 1984). Furthermore, Cavagnini et al. 
(1980) found that a single oral dose of GABA to 19 subjects resulted in a significant 
elevation in hGH concentrations, compared with 18 placebo control subjects, with 
five and a half fold increases in plasma growth hormone 90 min after oral 
administration. The mechanism for GABA action on GH secretion is unclear, but 
Willoughby et al. (1986) suggested an action of GABA on the hypothalamus to inhibit 
somatostatin secretion, and facilitate GH secretion. Conversely, Murakami et al. 
(1985) suggested that GABAergic stimulation of GHRH release increases basal GH 
secretion, since passive immunisation with anti-GHRH antibodies abolished this 
effect. However, Fiok et al. (1981) demonstrated a decrease in plasma GH levels 
when endogenous GABA levels were increased by pretreatment of rats with GABA-
transaminase inhibitors, and identified an increase in plasma GH following a 
reduction of GABAergic activity by administration of the GABA receptor blocker, 
bicuculline. In addition, administration of sodium valproate, which is thought to act 
via a GABA mechanism, increased basal hGH secretion (Steardo et al., 1986), but has 
been found to inhibit exercise-induced increases in hGH secretion (Steardo et al., 
1985; 1986), suggesting dual GABAergic control of hGH secretion. 
2.3.4. Factors affecting the secretion ofhGH 
Sex 
A number of studies have considered the sex-related differences in GH secretion in 
rats. Jansson et al. (1985) described high amplitude GH pulses with low GH 
concentrations between pulses in male rats compared with less regular pulses with 
higher interpulse concentrations in females. The role of GHRH and somatostatin in 
these different secretory patterns of male and female rats was studied by Painson and 
Tannenbaum (1991) using passive immunisation with specific antisera. In female 
rats, a single acute dose of anti-somatostatin serum resulted in increased plasma GH 
concentrations at all time points for 6 h after administration, as well as an increase in 
GH peak amplitude, GH nadir levels, and overall mean 6 h GH levels. In contrast, an 
acute dose of anti-somatostatin serum to male rats increased only GH nadir levels. In 
addition, administration of an acute dose of anti-GHRH serum raised GH nadir levels 
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in females but had no effect in males. These findings suggest that the secretory 
pattern of somatostatin plays an important role in the sexually dimorphic GH 
secretion patterns in rats. 
Women have been identified as secreting more hGH than men (Ho et al., 1987) 
although the same study showed that higher integrated serum hGH concentrations in 
young women were determined by serum oestradiol concentrations. Jaffe et al. 
(1998) compared hGH secretion in women in the early follicular phase of the 
menstrual cycle, when oestrogen levels are comparable between sexes, with hGH 
secretion in men and found it to be similar in both groups. In addition, Jaffe et al. 
(1998) demonstrated a positive correlation between plasma oestradiol concentrations 
and hGH secretion. These findings suggest that higher oestradial concentrations in 
women, rather than sex per se, result in greater GH secretion in women than in men. 
However, the level(s) at which oestradiol exerts its regulatory control is not clear 
(Muller et al., 1999). The apparent importance of oestradiol in determining average 
daily hGH secretion means that women using the contraceptive pill, different types of 
which contain different amounts of oestradiol, will have markedly different levels of 
daily GH secretion from women not using the contraceptive pill as well as from those 
using other types of contraceptive pill. 
Despite the fact that total secretion rates are similar for males and females matched 
for age, relative adiposity and oestradiol concentrations, there do appear to be 
differences in patterns of hGH secretion between men and women (Jaffe et al., 1998). 
Women were shown to have more hGH pulses with interpulse concentrations twice as 
high as those of men. The reported higher interpulse hGH concentrations bears a 
similarity to the differences in GH secretory patterns in male and female rats (Jannson 
et al., 1985). In addition, Jaffe et al. (1998) found that hGH secretion in men was 
dominated by large nocturnal pulses with relatively low hGH secretion throughout the 
rest of the day, in contrast to women who had a much more uniform pulsatile pattern 
of secretion throughout the day, spending nearly twice as much time in active hGH 
secretion than men. It is possible that the differences in the pattern of hGH secretion 
between men and women is attributable to a lesser role of somatostatin in women 
(Jaffe et al., 1998). 
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Age 
"That aging [sic] lowers GH secretion m mammals IS almost a tenet of 
neuroendocrinology." (Muller et al., 1999). 
Whilst Muller et al. (1999) report that there is evidence that the pituitary hGH pool is 
preserved with increased age, daily hGH secretion rate has been negatively correlated 
with age (Iranmanesh et al., 1991; Veldhuis et al., 1995). This age related fall in hGH 
secretion appears to be more pronounced in men than in women (Weltman et al., 
1994). However, which aspect, or aspects, of secretion rate contribute to the observed 
changes in secretion rate with age (mass of secretory burst, frequency of secretory 
burst or basal secretion rate) is not entirely clear. Iranmanesh et al. (1991) observed 
age to be a major negative statistical determinant of hGH burst frequency and also 
endogenous hGH half life. However later research found that hGH secretory burst 
amplitude varied inversely with age, without identifying any significant correlation 
between age and burst frequency or endogenous hGH half life (Veldhuis et al., 1995). 
From the results of that study Veldhuis et al. (1995) suggested that the primary impact 
of age, acting with altered body composition, is to diminish the amount or mass of 
hGH secreted per burst, possibly mediated by an increase in somatostatinergic 
inhibitory tone and/or decreased activity of hypothalamic GHRH. In addition, 
Veldhuis et al. (1995) used an approximate entropy statistic to evaluate the relative 
degree of serial orderliness or regularity of 24 h serum hGH concentration profiles 
and observed a reduced regularity of hGH release with age. This suggests that with 
increasing age there is disruption in the pathways directing hGH secretion, possibly as 
a result of a reduction in the co-ordination of the release of GHRH and somatostatin. 
It has been estimated that for men with a normal body mass index (BMI), an indirect 
measure of obesity, each decade of increasing age reduces the hGH production rate by 
14% and the hGH half-life by 6% (Iranmanesh et al., 1991). Vahl et al. (1997) 
studied the significance of age on the pharmacokinetics of a single exogenous pulse, 
mimicking endogenous conditions, in normal adults and found age to be the most 
important predictor of hGH area under the curve in all subjects along with a greater 
metabolic clearance rate (MCR) in older individuals. 
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Body composition 
Mean (24 h) serum GH concentration has been demonstrated to be negatively 
correlated with percentage body fat allied with a progressive increase in entropy of 24 
h hGH profiles with increasing percentage boy fat (Veldhuis et al., 1995). In addition, 
intraabdominal fat mass has been shown to be the major determinant of stimulated 
hGH secretion in healthy non-obese adults (Vahl et al., 1996). Iranmanesh et al. 
(1991) estimated that each unit increase in BMI, at a given age, reduced the daily 
secretion rate by 6%. 
In addition to sex, age and body composition factors such as sex steroid hormones, 
nutritional status, physical fitness/exercise training, quality and quantity of sleep and 
medication use also affect hGH secretion. All of these factors must be considered in 
the design and interpretation of experimental research. 
2.3.5. Actions of hGH 
The somatomedin-hypothesis (Salmon and Daughaday, 1957) suggests that most 
growth-promoting actions of GH are mediated by insulin-like growth factor-I (IGF-I). 
However, GH also exerts metabolic effects either directly or indirectly mediated via 
IGF-1. 
Glucose metabolism 
GH has both an insulin-like and an anti-insulin effect on glucose metabolism. GH 
administration in the post-absorptive state result in a decrease in plasma glucose 
concentrations, suppression of glucose production and an increase in glucose 
clearance (Adamson et al., 1977), although this insulin agonistic effect is short-lived. 
In contrast, sustained elevations of GH concentrations has been shown to result in 
decreased insulin sensitivity of the liver and decreased sensitivity of other tissues to 
glucose (Moller et al., 1989). It has been suggested that GH reduces glucose 
metabolism in favour of increased lipid oxidation, reducing the need for protein 
degradation and gluconeogenesis (Moller et al., 1990). GH also induces increased 
secretion of IGF-I, which has been shown to have insulin-like effects, but only when 
IGF-I is in its free form or bound to IGF-binding protein (BP)-3 when it can bind to 
membrane-bound insulin receptors. In vivo the majority of IGF-I circulates bound in 
a ternary complex and is not free to exert its insulin-like effects in this way. 
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Lipid metabolism 
Children (Parra et al., 1979) and adults (Salomon et al., 1989) with GHD display 
increased body fat compared with healthy individuals which is reduced with GH 
treatment. Yeh et al., (1994) demonstrated that 16 wk of GH administration 
suppressed age-related fat gain compared to control in rats. Chronic administration of 
GH to animals has also been reported to result in depleted adipose stores and an 
increase in the transfer of lipids to the liver (Merimee, 1979). In addition, GH 
treatment of GHD increases circulating FFA and glycerol indicating increased 
lipolysis. This increase in lipolysis is a result of a direct effect of GH in enhancing 
the activity of hormone sensitive lipase (Dietz and Schwarz, 1991). It has also been 
suggested that GH might enhance the conversion of FFA to acetyl-CoA in the tissues 
with subsequent utilisation for energy (Guyton, 1986). IGF-I infusion over several 
days resulted in increased levels of circulating FF A and increase lipid oxidation, 
possibly through an IGF-I-induced reduction in insulin secretion (Hussein et al., 
1994) but there is no evidence that IGF-I acts directly on adipose tissue in vivo 
(Bemeis and Keller, 1996). 
Protein metabolism 
GH treatment has been demonstrated to increase nitrogen retention in patients 
recovering from thermal injury (Wilmore et al., 1974), and Cuneo et al. (1991a) have 
demonstrated that exogenous GH increases lean body mass and thigh muscle mass in 
adults with GHD. In addition, studies using stable isotope-labelled amino acids in 
post-operative patients treated with recombinant (r)hGH demonstrated an increase in 
protein synthesis versus protein breakdown of 39% when compared to placebo treated 
patients (Ward et al., 1987). 
It has been suggested that GH has an anabolic effect independent of insulin and IGF-I 
(Copeland and Nair, 1994) since the administration of rhGH and somatostatin 
together resulted in an acute inhibition of leucine oxidation, with no changes in 
plasma insulin, glucagon, cortisol, IGF-I or glucose concentration. Similarly, 6 h of 
intravenous methionyl-GH infusion after 10 days of underfeeding followed by 10 
days of hypocaloric feeding resulted in increased transcription or decreased 
degradation of myofibrillar protein mRNA in the vastus lateralis of normal men 
independent of an increase in circulating IGF-I (Fong et al., 1989). In addition, 
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forearm muscle synthesis has been shown to increase with short term GH infusion and 
in the absence of any changes in circulating IGF-I concentrations (Fryburg et al., 
1991). However, it must be considered that circulating IGF-I levels might not reflect 
tissue levels of the hormone and that locally produced IGF-I might be mediating the 
anabolic effect of GH. 
However, there is other evidence that GH can have an anabolic effect independent of 
IGF-I. For example, the actions of GH and IGF-I on protein metabolism may be 
different, since GH administered to normal subjects resulted in an increase in protein 
synthesis (Horber and Haymond, 1990) and the predominant anabolic action of IGF-I 
has been postulated to be an inhibition of proteolysis (Laager and Keller, 1993). 
There is also evidence that a combination of rhGH and recombinant (r)hiGF-1 has a 
greater anabolic effect than IGF-I alone in calorically restricted humans (Clemmons et 
al., 1992). These findings support the suggestion that GH might act to promote cell 
differentiation making cells sensitive to the action IGF-1 (Green et al., 1987). 
Alternatively this may reflect the importance of the IGF-I acid-labile subunit, since 
both GH and IGF-I have been shown to induce IGF-BP-3 in hypophysectomised rats, 
yet only GH treatment resulted in the formation of the acid-labile subunit of the 
complex (Cohick and Clemmons, 1993). 
Water and electrolyte homeostasis 
A common symptom of acromegaly is swelling of soft tissues particularly in the 
hands and feet and supraphysiological doses of rhGH have been shown to increase 
body mass due to water retention in addition to increasing sodium retention (Binnerts 
et al., 1988). Since GH stimulates Na-K-ATPase activity in several tissues, including 
the kidney (Shimura et al., 1982), it is likely that this mediates GH-induced sodium 
retention. 
2.3.6. Insulin-like growth factors 
Insulin-like growth factors (IGFs), otherwise known as somatomedins, are 
polypeptides with a structure similar to insulin. In fact, insulin, IGF-I and IGF-II 
have approximately 50% of their amino acids in common. IGFs are important in the 
function of almost every organ in the body (Daughaday and Rotwein, 1989). IGF-I 
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appears to have the predominant role in regulating growth whilst the physiologic role 
of IGF-11 is less clear. 
IGFs are not stored in granules but are continuously synthesised and secreted by most, 
if not all, tissues in the body (Cooper, 1994). Circulating IGFs are synthesised by the 
liver although IGFs produced locally by most tissues also act in an autocrine and 
paracrine manner (Le Roith, 1997). IGFs circulate in nanomolar concentrations (Le 
Roith, 1997), not in a free form but non-covalently bound to one of six specific 
binding, or carrier, proteins (IGF-BP-1 to -6, Baxter, 1993). Like the IGFs, IGF-BPs 
are synthesised both in the liver and in most other tissues (Le Roith, 1997). IGF-BP-3 
binds the majority (>95%) of the IGF-I in serum (Le Roith, 1997). This IGF - IGF-
BP-3 dimer forms a ternary complex with another protein subunit, the acid-labile 
subunit (Le Roith, 1997). This stable complex prolongs IGF half life and acts as a 
reservoir for IGFs. The stability is probably determined by the acid labile subunit 
since IGF- IGF-BP-3 complexes leave the circulation rapidly (Donaghy and Baxter, 
1996). Circulating IGF-BPs also restrict the permeability of IGFs through capillaries 
and also inhibit their access to membrane receptors, thereby limiting their 
bioavailability (Daughaday et al., 1980). Once released from the ternary complex, 
IGF-I leaves the circulation and enters its target tissues assisted by other IGF-BPs. 
Acute administration of IGF-I in hypophysectomised rats has been shown to have 
insulin-like effects including a 35% reduction in blood sugar levels, although longer 
term infusion does not appear to have this effect (Zapf et al., 1985). It is thought that 
this is a result of the binding capacity of IGF-BPs being overridden with a single IGF-
I injection allowing free IGF-I to circulate and reach tissue receptors and exert its 
insulin-like effects. In contrast, free IGF-I is not detectable during IGF-I infusion, 
probably as a result of equilibration with carrier proteins (Zapf et al., 1985). 
Both IGF-I and IGF-11 are under the control of GH secretion, since growth hormone 
deficiency (GHD) has been reported to be associated with a fall in both peptides 
(Rogol, 1989), although IGF-I reductions are of a greater magnitude than IGF-11 (Zapf 
et al., 1981a). In addition, changes in circulating IGF-I with age change in parallel 
with changes in GH secretion (Le Roith, 1997). Growth hormone induces tissue 
production of IGF-I and elevations in serum IGF-I concentrations, with most current 
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evidence indicating that circulating IGF-1 is of hepatic origin (Maiter et al., 1988). 
Marcus et al. (1990) demonstrated an increase in serum IGF-I concentrations several 
hours after the administration of exogenous rhGH administration in healthy elderly 
individuals. This rhGH-induced increase in circulating IGF-I required the synthesis 
of IGF-1 and then its transportation into the circulation, accounting for the time-lag 
between an increase in circulating GH and circulating IGF-1. Hypophysectomised 
rats have been shown to be deficient in serum IGF-BPs in addition to IGFs 
themselves, and GH administration stimulates synthesis and secretion of this carrier 
protein (Zapf et al., 1985). 
Whilst hepatic IGF-I synthesis and secretion is under the control of GH (Schwander et 
al., 1983), diurnal patterns of circulating IGF-I have not been found in man 
(Vermuelen, 1987) or other mammals (Donaghue et al., 1990), and serum 
concentrations of IGF-1 usually parallel 24 h mean GH concentrations. GH also 
increases the serum concentrations of both the acid-labile subunit and IGF-BP-3 
(Jones et al., 1995). Like insulin, IGF-I and IGF-11 specifically bind to membrane 
bound tyrosine kinase receptors. Insulin binds to its own receptor and, with less 
affinity, to the IGF-I receptor. IGF-1 and IGF-11 both activate their own specific 
receptor, as well as the IGF-I receptor and the insulin receptor (Ruderman et al., 
1994). Liver and fat cells express only insulin receptors whilst muscle cells express 
both insulin and IGF-I receptors (Le Roith, 1997). 
IGF-I mediates many, if not most, of the anabolic effects of circulating GH. Six days 
of IGF-1 administration to hypophysectomised rats stimulated three indices of growth 
in the absence of GH; tibial epiphyseal cartilage width, thymidine-incorporating 
activity of costal cartilage and body mass (Zapf et al., 1985). IGF-11 administration 
did not increase body mass and stimulated the other two growth indices much less 
strongly than IGF-I, suggesting that IGF-11 mediates growth via IGF-1 receptors (Zapf 
et al., 1985). In humans, patients with IGF-I deficiency as a result of GH insensitivity 
have been used to test the therapeutic use of recombinant IGF-1. In this disorder, 
known as Laron dwarfism, IGF-I treatment resulted in increases in circulating IGF-I 
and an associated stimulation of bone growth as well as an alteration in body 
composition due to increased protein accretion and a reduction in body fat mass 
(Laron et al., 1992; Wilton, 1992). 
53 
The role of GH in promoting growth was thought to be mediated by circulating IGF-1 
synthesised in the liver. However, it would appear that locally produced IGF-1, acting 
in an autocrine or paracrine manner, might play an important role. Whilst 
experimental increases in IGF-1 have resulted in general somatic growth in rats (Bates 
et al., 1993), direct local infusion of nonsystemic (i.e. doses that avoid generalised 
somatic growth) doses of IGF-1 into the tibialis anterior muscle of rats resulted in 
muscle hypertrophy with no apparent effect on nearby muscles or the hearts or body 
mass of the rats (Adams and McCue, 1998). It had previously been demonstrated that 
IGF-1 peptide production increases in the overloaded plantaris muscle of rats (Adams 
and Haddad, 1997). These results, taken together, suggest a role for locally produced 
IGF-1 in muscle hypertrophy. 
Local production of IGF-1 is under different control in different tissues. For example, 
GH, parathyroid hormone and sex steroids regulate the production of IGF-1 in bone, 
whilst sex steroids have the predominant role in production of IGF-1 in the 
reproductive system (Le Roith, 1997). IGF-1 also appears to have an essential role in 
the CNS system with influence over proliferation, differentiation and survival in the 
developing brain (Muller et al., 1999). IGF-1 has a further role in the inhibition of the 
secretion of GH by the pituitary (Le Roith, 1997), and the infusion of rhiGF-1 has 
been demonstrated to suppress pulsatile and GHRH-stimulated GH secretion in male 
subjects (Jaffe et al., 1998). This inhibitory effect probably occurs at both the 
hypothalamic and pituitary levels with an apparent role for somatostatin, since IGF-1 
has been shown to directly stimulate the acute release of somatostatin from rat 
hypothalamic fragments in culture (Sheppard et al., 1978). 
Physical exercise is a potent stimulus of GH release and Cappon et al. (1994) 
identified both a GH-dependent and an acute GH-independent, exercise-induced, 
increase in circulating IGF-1 following high intensity exercise. It has also been 
suggested that the anabolic response to training might involve both GH-dependent 
increases in hepatic IGF-1 production and GH-independent increases in IGF-1 in the 
active muscles since training did not increase hepatic IGF-1 mRNA in GH suppressed 
rats (Zanconato et al., 1994). 
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Figure 2.2. A comparison of the metabolic effects of GH and IGF-1 (from Bemeis and 
Keller, 1996). 
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2.3.6. Growth hormone use and misuse 
Growth hormone pathophysiology and therapeutic use 
There are a number of disease states that are either a consequence or cause of 
abnormal hGH production and control. When these alterations occur as the result of, 
rather than being the primary cause of, disease, it is common for hGH production and 
control to return to normal if the primary disease is treated satisfactorily (Dieguez et 
al., 1988). However, in instances of growth hormone deficiency it may be necessary 
to provide exogenous hGH. Originally hGH extracted from human cadavers was 
employed in hGH replacement therapy, but this was withdrawn due to the potential 
for the transmission of Creutzfeldt-Jakob disease. 
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GH has been approved by the US Food and Drug Administration (FDA) for the 
treatment of GHD in both children and adults, short stature associated with chronic 
renal insufficiency (CRI) before renal transplantation, short stature in patients with 
Turner syndrome and human immunodeficiency virus-associated wasting in adults 
(AACE, 1998). 
Growth hormone deficiency 
Growth hormone deficiency (GHD) as a result of hypothalamic-pituitary disease must 
be distinguished from the physiologically reduced hGH secretion that occurs with 
ageing (AACE, 1998). The clinical features of GHD in adults include: 
a) increased mass and body fat mass 
b) decreased lean body mass 
c) decreased exercise capacity 
d) decreased muscle mass and strength 
e) reduced cardiac performance 
f) reduced bone density and increased fracture rate 
g) poor sleep 
h) impaired sense of well-being 
(AACE, 1998) 
GHD-related increases in body fat mass also result in increased abdominal fat mass, 
therefore increasing waist-to-hip ratio and GH-deficient patients are reported to be 
susceptible to the development of premature cardiovascular disease (AACE, 1998). 
It has been demonstrated that rhGH treatment in adults with long standing GHD can 
increase lean body mass and thigh muscle mass (Cuneo et al., 1991a) and also 
improve both maximal and submaximal exercise cycling performance with associated 
subjectively reported improvements in the ease of completion of daily tasks (Cuneo et 
al., 1991b ). In addition, longer term rhGH treatment has been demonstrated to 
increase both isometric and isokinetic muscle strength (Johannsson et al., 1997) 
although the combination of exercise and rhGH treatment has been suggested to 
provide the optimal regimen for improving muscle function in adults with GHD 
(Grindeland et al., 1994). Another important role for rhGH treatment in hGH-
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deficient adults was considered by Christ et al. (1997) who demonstrated that rhGH 
treatment stimulates the otherwise impaired erythropoiesis in adults with GHD. The 
observed increases in plasma volume and total blood volume observed with rhGH 
treatment were suggested to contribute to increased exercise performance in OH-
deficient adults (Christ et al., 1997). 
The use of hGH treatment to prevent weight loss and reduce recovery time following 
thermal trauma has also been suggested. Human GH treatment as part of the care for 
patients recovering from bums was studied by Wilmore et al. (1974). In this study a 
dose-related improvement in nitrogen retention was identified when hGH treatment 
was combined with adequate nutrient loading for 7 days in patients with bums from 
34 to 76% of the body surface. These results a possible role for hGH therapy in this 
situation. 
Child onset-GHD might result from abnormalities in the hypothalamus, most 
commonly as a result of deficient hypothalamic GHRH secretion, or from pituitary 
pathologic conditions such as pituitary tumours (AACE, 1998). The specific cause of 
GHD is particularly important in determining appropriate treatment to prevent 
contraindication. Turner syndrome occurs in 1 in 2000 live born girls and is due to 
abnormalities or absence of an X chromosome (AACE, 1998). This disorder is 
frequently associated with short stature, which may be ameliorated by GH treatment. 
Rosenfeld et al. (1988) found methionyl hGH (met-hGH) alone, and in combination 
with oxandrolone, a weak androgen, to stimulate linear growth in girls with Turner 
syndrome. However, primary hypogonadism is also associated with this disorder and 
therefore treatment with estrogens may be required. Delay in the replacement of 
oestrogen until after the normal age of puberty may help to optimise the effect of GH 
treatment, but this must be weighed against the need for feminisation (AACE, 1998). 
Some children with intrauterine growth retardation (IUGR) have been shown to 
respond to hGH treatment. Tanner et al. (1971) found that a small number of children 
without Russell-Silver syndrome responded to hGH treatment. In addition the AACE 
(1998) report that children with IUGR and those with Russell-Silver syndrome might 
benefit from GH therapy. Prader-Willi syndrome may result in impaired hGH 
secretion and consists of hypothalamic obesity, short stature, developmental delay, 
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hypogonadotropic hypogonadism, small hands and feet and hypotonia. Preliminary 
studies suggest that some patients with Prader-Willi syndrome might benefit from GH 
treatment through accelerated growth, reduced hyperphagia, changes in lipolysis and a 
decrease in obesity (AACE, 1998). GH treatment can also be employed in the 
treatment of children with a growth delay as a result of abnormalities in the GH-IGF 
axis caused by Chronic Renal Insufficiency (CRI) (AACE, 1998). Resistance to hGH 
at the receptor level has ~lso been observed and presents as Laron dwarfism (Laron et 
al., 1980). Children with Laron dwarfism will not respond to exogenous GHRH or 
rhGH treatment, although the administration of exogenous IGF-I may be of 
therapeutic use (Dieguez et al., 1988). 
Excessive hGH secretion 
The effect of excessive hGH secretion is highly dependent on the age of onset. If 
hGH hypersecretion begins in childhood there is an increase in growth velocity with 
soft tissue swelling and minimal bone deformity (Haynes, 1986). This is a rare 
condition known as pituitary gigantism. Acromegaly results from the occurrence of 
hGH hypersecretion after epiphyseal closure and the onset of this disorder is typically 
insidious. The aetiology of acromegaly is not clear: ectopic GHRH production and 
ectopic GH production are both possible causes although both are uncommon 
(Thomer et al., 1984; Melmed et al., 1985) and it is likely that the most common 
cause is a primary pituitary disease (Dieguez et al., 1988). The clinical manifestations 
of acromegaly are numerous, including: 
a) soft tissue swelling of the feet and hands 
b) protruding lips 
c) an increase in coarse body hair 
d) increased size and function of the sebaceous and sweat glands 
e) enlargement of hands and feet 
t) changes in the anatomy of the skull Gaw and nose) 
g) thoracic kyphosis 
h) joint pain (ranging from common arthralgia to degenerative arthritis) 
i) articular cartilage degeneration 
j) deepening of the voice 
k) peripheral neuropathy 
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1) hypertension 
m) diabetes mellitus 
In addition, sleep apnoea and daytime somnolence are common and the sleep related 
hGH peak disappears. There is also a paradoxical glucose-induced rise in hGH 
concentration (Melmed et al., 1983). 
Incidence of abuse in sport 
There appear to be four major abuses of hGH in sport, 1) to increase muscle mass and 
strength, 2) to increase lean body mass, 3) to improve the 'appearance of musculature' 
4) to increase final adult height (George, 1996). It would appear that hGH is used by 
athletes because it is perceived to be more effective than anabolic steroids in 
maximising size, strength and performance and because the improved techniques for 
the detection of anabolic/androgenic steroids increase the risk of disqualification from 
competition as a result of steroid abuse (Lombardo et al., 1992). In contrast hGH 
abuse is appealing to some athletes because most drug testing screens cannot detect it 
(Clarkson and Thompson, 1997). Salva and Bacon (1989) reported that 15 out of 100 
physicians surveyed reported a total of 52 inquiries about growth hormone which 
identifies an interest in GH but not the incidence of use. Other information in this 
area takes the form of anecdotal reports (Cowart, 1988). It is clear, however, that 
hGH is being abused and The Underground Steroid Handbook, first published in 
1981, touts hGH as: 
" ... the only drug that can remedy bad genetics as it will make anybody grow. A few 
side effects can occur however. It may elongate your chin, feet and hands but this is 
arrested with cessation of the drug ... GH is the biggest gamble that an athlete can take, 
as the side effects are irreversible. Even with all that, we love the stuff." 
Previously, the only source of hGH was from human cadavers and supply of the 
hormone was very limited. However, hGH has become available biosynthetically in 
unlimited quantities and the recombinant hGH (rhGH) that is produced has an amino 
acid sequence identical to pituitary derived hGH (Healy and Russell-Jones, 1997). 
The release of a recombinant form, and the associated increase in availability, has led 
to increased anecdotal evidence of use of hGH by athletes (Cowart, 1988; Catlin & 
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Hatton, 1991). Other indications that abuse of hGH is increasing include evidence 
that a number of burglaries from pharmacies seem to have focussed on obtaining hGH 
(Healy and Russell-Jones, 1997). In addition, customs officials have seized quantities 
of hGH from the luggage of competitors and coaches prior to the 1998 Swimming 
World Championships in Perth and the Sydney 2000 Olympics. Under Australian law 
anyone taking hGH into the country faces the prospect of a fine of up to £40 000 or 
even a five year prison sentence. 
However, prohibitively high costs currently limit hGH abuse and it is claimed that 
abusers in the US have had to spend $30 000 per year (£20 000) to obtain 
"worthwhile effects" (Smith and Perry, 1992). In addition there is evidence that a 
large quantity of the hGH being supplied to users is either counterfeit, adulterated, of 
animal origin or some other product (Smith and Perry, 1992). Therefore, abusers are 
injecting bovine growth hormone stolen from farms (useless in humans), other peptide 
hormones such as human chorionic gonadotrophin (hCG), which actually mimics the 
natural stimulation of testosterone production by luteinizing hormone (LH), or even 
anabolic steroids (Cowart, 1988; Smith and Perry, 1992). 
The potential adverse effects of hGH abuse in athletes include the clinical 
manifestations associated with hGH hypersecretion in addition to the health risks 
associated with the administration of the hormone. The means of hGH administration 
is by injection and this means that the risks of transmission of the hepatitis B virus 
and human immunodeficiency virus (HIV) are increased in the event of needles being 
shared. In addition several deaths due to Creutzfeldt-Jakob disease have been 
associated with the administration of hGH derived from human cadavers (Lazarus, 
1985). 
The side effects from the recommended standard replacement dose of hGH prescribed 
for hypopituitary patients are reported to be mild and probably only occur after long 
term usage as a result of the suppression of endogenous hGH secretion (Rogol, 1989). 
However, it has been suggested that athletes abusing hGH are taking 10 times this 
dose (Smith and Perry, 1992). Such high doses may result in conditions similar to 
acromegaly with its potential to disfigure in addition to increased mortality (Rogol, 
1989). Long term abusers may suffer from skeletal changes (enlargement of fingers 
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and toes, growth of the orbit and lengthening of the jaw), enlargement of internal 
organs (including cardiomegaly, which is one of the causes of death associated with 
hGH abuse) and thickening of the skin (George 1996). Further reported 
complications include atherosclerotic cardiovascular disease, often with heart failure 
and cardiomyopathy, neuropathy, myopathy (especially proximal) in apparently 
hypertrophied muscles and impaired glucose regulation eventually resulting in 
diabetes mellitus (Rogol, 1989). Early hGH therapy using doses higher than those 
currently recommended also resulted in oedema in the extremities, carpal tunnel 
syndrome, arthralgia and myalgia (MCE, 1998). Increased incidence of leukaemia 
in hGH-treated patients in Japan, but not in the United States, has also been reported 
and acromegaly is also associated with and increased risks of malignant lesions 
(particularly colon cancer) although there is no evidence that this can be extrapolated 
to hGH-replacement individuals (MCE, 1998) or, therefore, those who abuse hGH. 
In addition, arthritis and impotence often occur after chronic hGH abuse (Kicman and 
Cowan, 1992). 
2.3.7. Exercise as a stimulus ofGH release 
The mechanisms controlling the magnitude of the hGH response to exercise are not 
fully understood. The roles of blood lactate (e.g. Karagiorgos et al., 1979; 
Chwalbinska-Moneta et al., 1996), blood pH (e.g. Gordon et al., 1994) and oxygen 
demand and availability (e.g. Van Helder et al., 1987) in the regulation of hGH 
release have been studied. In addition intensity and duration of exercise may 
influence the hGH response (Sutton et al., 1976). 
Blood Lactate 
Sutton et al. (1969) observed a correlation between blood lactate concentrations and 
hGH concentrations. However, artificial manipulation of blood lactate levels using 
sodium lactate (Vigas et al., 1974; Sutton et al., 1976) have been shown to have no 
consistent effect on hGH concentration. The metabolic and hormone responses to 
continuous and intermittent exercise of equal external work were studied by 
Karagiorgos et al. (1979). hGH concentrations tended to be higher during and in 
recovery from intermittent exercise, although the difference did not reach statistical 
significance until 20 min after exercise, this being the last blood sampling time point. 
In contrast, blood lactate concentrations were higher in every blood sample after the 
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resting samples during and in recovery from intermittent exercise. The similar hGH 
responses in the two trials despite a divergent pattern of blood lactate concentration 
suggest that the hGH response to exercise is independent of lactate accumulation in 
the blood. 
In contrast, Van Helder et al. (1984a) reported significant positive correlations 
between plasma lactate concentrations and plasma hGH levels during 20 min of 
continuous "aerobic" exercise and 20 min of intermittent "anaerobic" exercise of 
equal external work. The results of this study disagree with those of Karagiorgos et 
al. (1979), despite similar exercise protocols. The difference in the results was 
attributed to the fact that "anaerobic" exercise was not employed by Karagiorgos et al. 
(1979) reflected by higher measured blood lactate concentrations in the study of Van 
Helder et al. (1984a). Similarly, the serum hGH concentration after arm cranking 
exercise, leg bicycle exercise and treadmill running at an intensity eliciting similar 
oxygen consumption in all trials, was found to be positively correlated with blood 
lactate concentrations (Kozlowski et al., 1983). However, both Van Helder et al. 
(1984a) and Kozlowski et al. (1983) reflected on the findings of Sutton et al. (1976) 
and accepted that their results should not be considered to demonstrate a causal link 
between blood lactate and serum hGH concentrations. 
Chwalbinska-Moneta et al. (1996) identified what they considered to be a "hGH-
threshold" which occurred at approximately the same work load as that at which they 
defined the "lactate threshold" during an incremental exercise test to exhaustion. In 
the same study Chwalbinska-Moneta et al. (1996) also found a significant correlation 
between blood lactate concentration and plasma hGH concentration. In addition, 
different weight lifting exercise protocols have also demonstrated a significant 
correlation between plasma lactate (0-20 min) and plasma hGH concentrations (16-36 
min), that is with a 16 minute delay (Van Helder et al., 1984b). However, Kraemer et 
al. (1990) found no consistent systematic relationship between blood lactate and 
serum growth hormone concentrations during or after heavy resistance protocols. 
Hydrogen ion concentration 
It has been suggested that any stimulus for hGH release associated with lactate 
accumulation would be more likely act through hydrogen ion (H+) accumulation 
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(Gordon et al., 1994). Sutton et al. (1976) studied the role of acid-base balance during 
exercise in the regulation of the exercise-induced hGH response. Acidotic, alkalotic 
and control conditions were considered during a -45 min graded exercise test (last -5 
min at 90% V02max to exhaustion). Although in the first 20 min of the exercise test 
acidosis resulted in a significantly higher circulating hGH concentration than the other 
two conditions, this did not extend to the second 20 min or the last 5 min stage. It 
was therefore concluded that, although exercise is a clear stimulus for hGH release, 
the stimulatory mechanism acts independently of blood [H+]. 
However, it was not clear whether the same conclusion could be drawn for short-term, 
high-intensity exercise. Therefore, male subjects were administered with NaHC03 or 
NaCl placebo in a randomised double-blind counterbalanced experiment with a 
crossover design (Gordon et al., 1994). All-out high intensity exercise of 90 s 
duration resulted in a larger and faster rise in serum hGH concentrations in the 
placebo trial in all 10 subjects. Correlational analysis in the placebo trial alone 
demonstrated significant correlations between highest measured "peak" hGH and both 
peak [H+] and peak lactate concentrations. Overall correlations, combining data from 
both trials, showed that highest measured "peak" hGH concentration was correlated 
with peak [H+] but not peak lactate concentration, suggesting that the hGH response 
to high intensity exercise is more highly associated with peak venous [H+] than with 
peak venous lactate concentration. However, it is not clear whether the highest 
measured hGH concentrations in this study represent the true peak of the hGH 
response since blood sampling only continued for 30 min after the exercise bout and it 
may be that, in some subjects at least, hGH concentrations were still rising. 
Elias et al. (1996) used combined oral and intravenous administration of either 
NaHC03 (base) or NaCl (placebo) to study the effect of acid-base balance on hGH 
release during an incremental exercise test to exhaustion. Base administration tended 
to suppress the exercise-induced hGH at rest and during recovery from exercise 
except for the peak value at 60 min which was similar in the two trials. However, the 
mechanism by which an acute rise in blood [H+] acts as a stimulus for hGH release is 
not clear. 
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The Oxygen Demand/Availability Ratio 
It is known that hGH levels increase as oxygen demand increases and Lassarre et al. 
(1974) identified a significant correlation between initial 0 2 deficit and peak hGH 
concentrations during 1 h of cycle ergometer exercise. In addition, Raynaud et al. 
(1981) demonstrated that individuals dwelling at sea level who were non-adapted to 
hypoxia had a greater hGH response to exercise under acute hypoxic conditions and 
when exercising at altitude than when exercising under normal conditions. This 
highlights a possible role for oxygen availability in regulating the hGH response to 
exercise. 
Therefore, it was suggested that the hGH response to exercise should be proportional 
to the ratio of oxygen demand/availability (Van Helder et al., 1987). As a result of 
this contention Van Helder et al. (1987) developed an oxygen Demand/Availability 
ratio and used it to study whether there is a correlation between circulating hGH 
levels and the D/A ratio using previously published data from their laboratory and 
from other laboratories. Their results showed a highly significant relationship 
between the hGH response and the D/A ration for continuous "aerobic" and 
intermittent "anaerobic" exercise using data previously published by Van Helder et al. 
(1984a). Perhaps more surprising was the finding that there was a highly significant 
relationship between hGH and the D/A ration in the data of Karagiorgos et al. (1979). 
This finding was despite the fact that originally the results of that study identified no 
significant relationship between blood lactate concentrations and the hGH response to 
exercise or even between the oxygen deficit in continuous exercise and serum hGH 
concentrations. The data from these studies, as well as those from other previously 
published studies (e.g. Sutton et al., 1978; Raynaud et al., 1981), were combined and 
resulted in the demonstration of a close association between the D/A ratio and the 
hGH response to exercise for a wide range of "aerobic" and "anaerobic", intermittent 
and continuous exercise with a duration of between 20 and 60 min. This was 
proposed to support the suggestion that metabolic receptors exist in the muscle with a 
regulatory role in the hGH response to exercise. 
Catecholamines 
During progressively incremental exercise, blood catecholamines, adrenaline (A) and 
noradrenaline (NA) have been shown to rise with increasing exercise intensity 
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(Weltman et al., 1994). In addition, it has been demonstrated that catecholamines can 
directly stimulate GH secretion from rat pituitary tissue in vitro (13). In exercising 
humans, Kozlowski et al. (1983) identified a significant positive correlation between 
plasma [NA] and serum hGH concentrations. These findings were supported by those 
of Chwalbinska-Moneta et al. (1996) who also demonstrated significant correlations 
between catecholamine concentrations and serum hGH concentrations during and 
after an incremental exercise test. In addition, the "hGH-threshold" identified by 
Chwalbinska-Moneta et al. (1996) during incremental exercise was reported to occur 
at a similar work load as both the "[A)-threshold" and the "[NA]-threshold", as well 
as the "lactate threshold". Weltman et al. (2000) demonstrated that peripheral 
markers of heightened adrenergic outflow, that is [A] and [NA], precede and correlate 
with exercise-induced hGH concentrations. A time delay between peak-[A] or peak-
[NA] and peak-[hGH] of -20 min was identified and changes in exercise intensity did 
not alter this interval. In addition, increasing intensity resulted in a linear relationship 
between the increment (change from baseline to peak) in hGH and the increment in A 
as well as the increment in NA. Multiple linear regression showed that the dominant 
relationship was between incremental changes in hGH and NA. These results suggest 
that higher exercise intensities might drive increased hGH release, at least in part, by 
central adrenergic activation. 
The poor permeability of the blood-brain barrier to catecholamines (Kozlowski et al., 
1983) and the contention that only NA in the brain is effective in the control of hGH 
secretion (Hansen et al., 1971) infer that links between blood catecholamine levels 
and hGH release are not causal. However, it has been suggested that a decrease in pH 
in contracting muscles due to accelerated lactate production and associated metabolic 
changes may stimulate the sympathetic outflow by neural afferent signals from 
muscle metabolic receptors causing rapid release of catecholamines (McCloskey and 
Mitchell, 1972; Kjaer et al., 1989a). To take this a step further, catecholamines 
released following afferent signals from muscle metabolic receptors might, in turn, 
play a role in the regulation of hGH secretion. 
Afferent signals from muscle metabolic receptors 
It has been suggested that a combination of factors related to anaerobic metabolism 
are involved in controlling hGH release (Kraemer et al., 1990; Nevill et al., 1996b). 
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However, Karagiorgos et al. (1979) found no correlation between any "anaerobic" 
metabolite or oxygen deficit and hGH concentration. Even if "anaerobic" metabolites 
in the blood do not have a role to play in the regulation of exercise-induced hGH 
release, it would not preclude the possibility that they are detected in the muscle 
(Kozlowski et al., 1983; Van Helder et al., 1984a; Van Helder et al., 1984b; Van 
Helder et al., 1987; Nevill et al., 1996b; Scheen et al., 1998; Viru et al., 1998). 
It has been suggested that neural afferent signals from muscle metabolic receptors, 
activated by local changes in lactate concentration, oxygen concentration or pH, 
might participate in the activation of catecholamine release (McCloskey and Mitchell, 
1972; Kjaer et al, 1989). Van Helder et al. (1987) cited the close association between 
hGH and the D/A ratio as support for the suggestion that similar metabolic receptors 
occur in the muscle with a role in GH regulation during exercise. Further support was 
given by the finding of a significant correlation between plasma glucose and plasma 
hGH concentrations following prolonged exercise (Scheen et al., 1998). Ischaemic 
exercise, resulting in enhanced accumulation of lactate in the muscle, has been 
associated with a 2-fold increase in hGH concentrations compared to normal exercise 
and this was attributed to the activation of muscle receptors (Viru et al., 1998). 
However, Kjaer et al. (1989b) blocked afferent nerve activity by epidural anaesthesia 
in order to test the hypothesis that afferent nervous activity from exercising muscle 
regulates hGH release. Epidural blockade had no effect on the hGH response to 
exercise although it was not concluded that afferent nervous activity does not have a 
role to play in the regulation of exercise-induced hGH secretion, since it was 
postulated that central motor activity might compensate for the reduction in afferent 
sensory signals. 
Furthermore, exercising under hypoxic conditions would be expected to exaggerate 
metabolic changes in contracting muscle, and, if afferent feedback from muscle 
metabolic receptors contributes to the regulation of hGH secretion, enhance the hGH 
response to exercise. Epidural anaesthesia would be expected to blunt this response, 
yet Kjaer et al. (1999) demonstrated that epidural anaesthesia during leg cycling 
exercise at -50% VOzmax, under hypoxic conditions, enhanced rather than blunted 
the exercise-induced hGH response. Epidural anaesthesia also reduced muscle 
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strength and increased perceived exertion, suggesting a role for "central command" in 
the exercise-induced hGH release, rather than regulation by afferent feedback from 
receptors in exercising muscle. 
Motor centre activity 
Activity in motor centres may directly stimulate pituitary hormone secretion, 
including GH, during exercise (Kozlowski et al., 1983; Kjaer et al., 1987; Kjaer et al., 
1989b; Kjaer et al., 1996a). Administration of tubocurarine is reported to induce a 
partial neuromuscular blockade, which increases voluntary effort during exercise and 
therefore necessitates higher activity in motor centres (Asmussen et al., 1965). Kjaer 
et al. (1987) administered tubocurarine prior to exercise and demonstrated higher 
motor activity, through increased rate of perceived exertion, compared to exercise 
without tubocurarine administration. At the same time exercise with tubocurarine 
elicited a greater hGH response than exercise alone, suggesting that central motor 
activity might play a role in the regulation of the hGH response to exercise. In a 
further study using epidural anaesthesia to block afferent nerve activity, decreased 
muscle strength and higher rates of perceived exertion during exercise with epidural 
blockade inferred increased motor centre activity (Kjaer et al., 1989b ). Since epidural 
anaesthesia had no apparent effect on the hGH response to exercise it was suggested 
that this increase in motor centre activity compensated for the lack of afferent nervous 
input. 
However, Kjaer et al. (1996a) did not observe any decrease in the hGH response to 
exercise with both afferent sensory blockade by epidural anaesthesia combined with 
electrically induced cycling, to offset motor centre activity. These results suggested 
that blood-borne humoral feedback mechanisms and autonomic (i.e. spinal) reflexes 
are capable of inducing the hGH response to exercise. It was postulated that a 
decrease in plasma glucose, as observed in this study, was of great importance in the 
control of the hGH response to exercise. A further study by Kjaer et al. (1996b) 
compared electrically induced leg cycling in tetraplegic human with voluntary arm 
cranking at a work rate similar to that achieved during the involuntary leg stimulation 
trials. It was observed that hGH concentrations increased as a result of voluntary arm 
exercise, but not with involuntary leg stimulation. These results returned to the 
suggestion that an intact central nervous system and activity in motor centres as well 
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as afferent nerves from exercising muscles are needed for the hGH response to 
exercise. In addition, arm cranking exercise appeared to result in an exaggerated hGH 
response, probably due to higher motor centre activity relative to work output, since 
the subjects' arm muscles were weakened by partial paralysis. This finding provides 
further support for a role of motor centre activity in the regulation of the hGH 
response to exercise. 
Therefore, a proposed model for the regulation of the hGH response to exercise 
suggests that, at the onset of exercise, impulses in motor centres of the brain elicit a 
work load dependent increase in increase in hGH. Blood-borne metabolic error 
signals may then feed back to modulate further hGH secretion (adapted from Kjaer et 
al., 1987). 
The role of somatostatin and GHRH in the regulation of the hGH response to 
exercise 
It has been proposed that relatively low intensity exercise induces moderate hGH 
responses through activation of the central cholinergic system, resulting in a reduction 
in hypothalamic somatostatin secretion (Maas et al., 2000). However, this is a 
saturated process and at higher exercise intensities, with complete suppression of 
hypothalamic somatostatinergic tone, further increases in hGH secretion must be 
mediated by an increase in GHRH secretion. 
The importance of the inhibition of somatostatinergic tone as a result of exercise was 
demonstrated by Di Luigi et al. (1997), who observed a suppression of the hGH 
response to treadmill exercise, at 60% V02max, following pretreatment with 
octreocide, a somatostatin analogue, in humans. Pyridostigmine administration has 
also been shown to enhance exercise-induced hGH secretion, although it could not 
reverse the age-related decline in the hGH response to exercise (Marcell et al., 1999). 
In addition, administration of GHRH at the start of an incremental exercise test lasting 
25 min, with an additional stage at 100% V02max until exhaustion, had an additive 
effect on the hGH response (Maas et al., 2000). All of these results suggest that 
somatostatin has a role to play in the regulation of hGH secretion during, and in 
recovery from, exercise. However, eo-administration of GHRH and GH-releasing 
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peptide-2 (GHRP-2) at the start of exercise further potentiated hGH release, possibly 
via a mechanism potentfating the effect of GHRH (Maas et al., 2000). Since GHRP-2 
has been shown to have its own specific receptor (Camanni et al., 1998) it is possible 
that an endogenous GHRP-2-like ligand exists and exerts its influence on the hGH 
response to exercise. 
Effect of exercise at different times of day on the hGH response to exercise 
A 20 min incremental treadmill running test, with the last 5 min at 90% V02max, has 
been shown to induce an increase in hGH regardless of whether the exercise was 
performed in the morning (between 0700 and 0800) or the afternoon (between 1500 
and 1600) in women Galliven et al. (1997). Peak hGH concentrations were measured 
at the end of each exercise bout and returned to resting levels 20 min after exercise 
and no changes were identified in either the magnitude or the pattern of the exercise-
induced hGH response in the morning or afternoon. These results agree with a study 
showing no diurnal variation in hGH release in response to insulin-induced 
hypoglycaemia (Nathan et al., 1979) since it does not seem that there is a diurnal 
variation in the pituitary response to exercise at 90% V02max. 
Scheen et al. (1998) compared continuous bed-rest with 3 h of mixed high (60%) and 
low (40%) intensity, arm cranking and leg cycling exercise at three different times of 
day, where exercise was initiated at approximately 0500, 1430 and 2330. The results 
of this study demonstrated that exercise elicits a clear hGH response regardless of 
time of day with 5- to 6-fold increases in plasma hGH concentrations. In addition, 
there was no difference in the magnitude of the exercise-induced hGH response at 
three different times of day suggesting that there is no diurnal rhythm in the hGH 
response to prolonged submaximal exercise. 
Effect of exercise on night time hGH release 
Resistance exercise was reported to induce a marked acute hGH response compared to 
a no-exercise control trial in male trained weight lifters (McMurray et al., 1995). 
However, there was no difference in the magnitude of the nocturnal hGH response to 
this resistance exercise session completed in the evening, and the peak hGH responses 
appeared to occur at about the same time (between 0100 and 0200 hours) as in a 
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control trial. These results suggest that resistance exercise does not affect nocturnal 
hGH release. 
Kern et al. (1995) compared prolonged low-intensity exercise, comprising of 40 km of 
bicycle exercise between 1800 and 2030, with prolonged moderate-intensity exercise, 
comprising of 120-150 km of bicycle exercise between 1600 and 2030 hours, and a 
no-exercise control trial. Average nocturnal hGH concentrations were not different 
between each trial, suggesting that endurance exercise does not alter nocturnal hGH 
secretion. However, the pattern of nocturnal hGH secretion was altered by exercise 
during the previous day. When the effect of exercise on the previous day was 
compared with the control trial, both low- and moderate-intensity exercise were 
shown to suppress hGH secretion in the first part of nocturnal sleep, when hGH 
concentrations are usually at their peak, and increased hGH secretion in the second 
part of sleep, when hGH concentrations are normally lower. It is interesting to note 
that cortisol demonstrated the opposite response resulting in a change from the typical 
nocturnal secretory pattern whereby the first part of sleep is characterised by high 
hGH and low cortisol concentrations and the second part of sleep by an inverse 
relationship between hGH and cortisol concentrations. It would appear, therefore, 
that although average nocturnal hGH secretion is not altered by daytime exercise, the 
secretory pattern of hGH may be affected. In addition, different types and intensities 
of exercise might have an affect on this relationship, as well as the time of day that the 
exercise bout is completed. 
Growth hormone responses to sprint exercise 
There is relatively little literature available regarding the hGH response to sprint 
exercise. Some studies report the use of "anaerobic" exercise (e.g. Van Helder et al., 
1984a; Weltman et al., 2000), whilst others have considered resistance exercise (e.g. 
Van Helder et al., 1984b; Kraemer et al., 1990) however, very few have studied the 
hGH response to sprinting (Gordon et al., 1994; Nevill et al., 1996b). Gordon et al. 
(1994) employed a 90 s high-intensity cycle exercise test against an opposing force 
equivalent to 5% of subjects' body mass. Subjects were instructed not to pace 
themselves during the 90 s, therefore the test was an all-out effort. This exercise 
protocol induced a marked hGH response, with highest measured hGH concentrations 
30 min after the exercise bout. Unfortunately, the 30 min blood sample was the last 
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so relatively little information was provided regarding the time-course of the hGH 
response to sprint exercise. 
Nevill et al. (1996b) examined the hGH response to sprinting in male and female 
sprint- and endurance-trained athletes. The subjects completed a single 30 s maximal 
treadmill sprint which resulted in a marked hGH response with a peak between 20 and 
30 min or between 1 and 10 min after the sprint for the sprint- and endurance-trained 
athletes respectively. Peak hGH concentrations were approximately three times 
greater in the sprint-trained athletes compared with the endurance-trained athletes and 
in the sprint-trained group hGH concentrations were still approximately 10 times the 
baseline value after 60 min of recovery. The response seen in this study was similar 
to that induced by a combination o exercise and the neuropeptide galanin (Davis et al., 
1987), which led the authors to suggest that sprint exercise might induce a "near 
maximal" hGH response. However, there is no information available regarding the 
hGH response to sprints of different duration, repeated sprints or sprints where the 
number of muscle actions have been manipulated by exercising against different 
applied resistance. In essence, very little is known about the hGH response to 
sprinting. 
The effect of exercise training on the hGH response to exercise 
A number have studies have concluded that exercise training has no effect on resting 
hGH concentrations when comparing sedentary individuals and athletes (Bloom et al., 
1976; Mikines et al., 1985; Bunt et al., 1986; Barreca et al., 1988), sprint-trained and 
endurance-trained athletes (Nevill et al., 1996b) and following endurance (Bonifazi et 
al., 1998) or resistance (Kraemer et al., 1998; McCall et al., 1999) training. However, 
all of these studies found very low resting hGH concentrations, probably accounting 
for the lack of any differences between groups. In fact, it is likely that in some cases 
the assays employed to determine hGH concentrations would have been unable to 
satisfactorily measure the low levels of hGH associated with human subjects at rest 
(Veldhuis et al., 1995). However, 14 days of detraining of power athletes has been 
shown to increase resting hGH concentrations (Hortobagyi et al., 1993) whereas one 
year of endurance run training has been observed to increase resting hGH 
concentrations in women (Weltman et al., 1992). The effect that training has on 
resting hGH concentrations is, therefore, unclear. 
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Some studies have considered the effect of training state on the hGH response to an 
acute bout of exercise. There is little agreement between these studies as to whether 
exercise training increases (Bunt et al., 1986; Bonifazi et al., 1998; McCall et al., 
1999), decreases (Bloom et al., 1976; Weltman et al., 1997) or has no effect (Kraemer 
et al., 1998) on the hGH response to a single exercise bout. 
Bunt et al. (1986) identified a significantly greater hGH response to a 30 min run at 
60% of V02max in runners (minimum mileage of 40 miles per week) compared with 
moderately active controls. In agreement with the findings of this study Bonifazi et 
al. (1998) found that the hGH response to a standard training session (15 x 200 m 
with 20 s rest between sets) was enhanced in 9 top-level male endurance swimmers 
(national team members). There is also evidence that high volume resistance training 
elicits an increase in the hGH response to resistance exercise in young men with 
recreational resistance training experience (McCall et al., 1999). In addition, it has 
also been shown that endurance-trained athletes have a greater hGH response to 
insulin-induced hypoglycaemia than untrained individuals (Mikines et al., 1985). 
However, other studies have identified a lower hGH response to exercise in well-
trained compared with untrained cyclists (Bloom et al., 1976) and an attenuated hGH 
response to a 20 min constant load cycle ergometer test exercise following training 
(Weltman et al., 1997). Weltman et al. (1997) suggested that reduced exercise-
induced hGH concentrations following training may be a result of a combination of 
reduced hGH secretion and enhanced hGH clearance. In support of this contention is 
the suggestion that the half-life of endogenous hGH is shorter in exercising than 
resting individuals (Thompson et al., 1993). On the other hand, Kraemer et al. (1998) 
did not find any change in the exercise-induced hGH response following resistance 
training, although it was postulated that other hGH variants might adapt differently to 
training and that different variants are different in their biological activity. The effect 
that exercise training has on the hGH response to exercise is, therefore, not entirely 
clear and might depend on a number of factors including the type, frequency and 
duration of the training period. In addition, only three of the studies mentioned 
(Bloom et al., 1976; Bunt et al., 1986; McCall et al., 1999) compared the response of 
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trained individuals with untrained control subjects and of these only McCall et al 
(1999) completed longitudinal study incorporating a control group. It would appear, 
therefore, that further research is required in this area. 
Weltman et al. (1992) observed an increase in 24 h integrated hGH concentrations 
following one year of run training in women. It has also been reported that serum 
IGF-1 concentrations, taken as a measure of integrated hGH secretion because it is 
hGH dependent, increase following two weeks of endurance training (Roelen et al., 
1997). A similar trend was described by Weltman et al. (1997) although this increase 
was not found to be significant. It is, therefore, possible that 24 h hGH concentrations 
are elevated following training independent of the acute hGH response to exercise. 
2.3.8. Human GH negative feedback mechanisms 
There is a great deal of evidence suggesting that GH, like a number of other hormones 
(Guyton, 1986), regulates its own secretion via a negative feedback mechanism, 
although the nature of this autoregulation is not entirely clear. A number of 
possibilities exist and the role of GH autofeedback, increased somatostatinergic tone 
and/or decreased GHRH release, increased circulating FFA and modulation by IGF-1 
have all been considered. 
Lanzi and Tannenbaum (1992a) found spontaneous GH release to be inhibited within 
1 to 2 h after a single subcutaneous (se) injection of rhGH in rats, and it remained 
completely suppressed for up to 4 h after the rhGH injection. They also demonstrated 
no difference in the duration or magnitude of attenuation of the GH response 
according to an acute (single se injection) or chronic (5 day) injection regimen. 
Passive immunisation with specific somatostatin antiserum reversed the rhGH-
induced blunting of the spontaneous GH response by restoring the amplitude of the 
GH secretory bursts. The fact that immunoneutralisation of somatostatin prevented 
the attenuation of spontaneous GH release after GH pre-treatment provides strong 
support for a role for somatostatin in GH autoregulation .. However, since the normal 
pattern of pulsatile GH secretion was not restored by passive immunisation with 
somatostatin antiserum, the possibility of a GH-induced inhibitory effect on 
hypothalamic GHRH cannot be discounted. 
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In a further study Lanzi and Tannenbaum (1992b) also demonstrated a role for 
somatostatin in the attenuation of exogenous GHRH-induced GH release in rats. 
Serial injections of GHRH at 2 h intervals elicited 4- to 6-fold increases in GH release 
when GHRH was administered at times of peak spontaneous GH secretion, but only a 
minimal GH response was observed during trough periods. There was no evidence of 
desensitisation of somatotropes since high GH responsiveness to exogenous GHRH 
was maintained at a time of spontaneous secretory episode following a previous 
exogenous GHRH challenge during a trough period. These results demonstrate the 
importance of the cyclical increase in endogenous hypothalamic somatostatin 
secretion in preventing desensitisation of the pituitary to GHRH. In the same study a 
single subcutaneous rhGH injection 3 h prior to GHRH administration severely 
attenuated the GHRH-induced GH response. Passive immunisation with specific 
somatostatin antiserum reversed the blunted GH response and completely restored GH 
responsiveness to GHRH. This was consistent with the contention that GH feedback 
is exerted, at least in part, by somatostatin. In addition, the understanding that GH 
receptor mRNA is colocalized in somatostatin-positive neurons in the Periventricular 
nucleus of the rat hypo thalamus (Burton et al., 1991) further supports these findings. 
In normal adults repeated GHRH administration has been shown to result in an 
attenuated hGH response to the second stimulus (Ghigo et al., 1991). However, the 
administration of arginine, which acts to suppress somatostatin release, with the 
second bolus of GHRH restored the responsiveness of the somatotroph and, in fact, 
even potentiated the hGH response. This suggests that the attenuation of the hGH 
observed using repeated boluses of GHRH alone was not due to a GHRH-induced 
reduction in the size of the pool of hGH available for release. In addition, the fact that 
arginine administration reinstated the GHRH-induced hGH response following the 
second stimulation implies an important role for somatostatin in hGH autoregulation. 
The GH response to repeated bouts of exercise has also been studied. Somewhat 
surprisingly, Kanaley et al. (1997) demonstrated an augmented hGH response to 
repeated bouts of 30 min exercise at 70% V02max separated by either 60 minor 210 
min of recovery. Each exercise bout resulted in a distinct hGH pulse and the apparent 
progressive increase in hGH response tended to be greater with a longer (210 min) 
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recovery period. The augmented response with repeated bouts of exercise provided 
evidence that the depletion of pituitary stores with repeated stimuli to hGH release is 
unlikely. Jaffe et al. (1993) supported this viewpoint, suggesting that pituitary GH 
content far exceeds the amount of GH released in their study and yet they 
demonstrated a suppression of the GH response to repeated GHRH administration. 
Kanaley et al. (1997) concluded that exercise provides sufficient stimulus to 
overcome the autonegative feedback demonstrated using pharmacological 
interventions. 
In contrast, Cappon et al. (1994) demonstrated the hGH response to 10 min of 
constant power cycling exercise, at an intensity corresponding to SO% of the 
difference between the lactate threshold and V02max, to be dramatically attenuated as 
a result of previous exercise bouts. In addition, they demonstrated an acute, hGH 
independent, exercise-induced increase in IGF-1. A purified IGF-I preparation has 
been shown to inhibit GH release from pituitary cells in culture (Berelowitz et al., 
1982), and the infusion of rhiGF-I has also been demonstrated to suppress pulsatile 
and GHRH-stimulated GH secretion in male subjects (Jaffe et al., 1998). There is an 
apparent role for somatostatin in this long-loop feedback, since Berelowitz et al. 
(1982) also observed IGF-I to stimulate a dose-related release of somatostatin from 
hypothalamic explants. However intraventricular IGF infusion in ewes had no effect 
on GH secretion, whereas intrapituitary infusion resulted in the inhibition of GH 
release (Fletcher et al., 199S) providing strong evidence for a direct effect of IGF-I at 
the level of the pituitary. 
However, Cappon et al. (1994) found that exercise-induced IGF-I levels were not 
significantly higher than baseline within 30 min of recovery, whilst the recovery 
between exercise bouts was SO min, suggesting that IGF-I did not play a role in the 
attenuation of the hGH response to exercise in their study. In addition, it would 
appear that exercise-induced IGF-I would not have a role in the regulation of the 
exercise-induced hGH response in exercise bouts separated by more than 30 min. 
Lanzi and Tannenbaum (1992a) also measured IGF-I and did not observe an increase 
in plasma IGF-I concentration, but reported hGH release to be suppressed for 4 h after 
rhGH administration in rats. This implies that the GH negative feedback loop can 
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function independently of IGF-1, although there does remain the possibility that 
locally synthesised IGF-1 in the pituitary gland might play a role. 
Cappon et al. (1994) also considered hGH autoinhibition, whereby hGH feeds back on 
itself directly, however, this seemed unlikely as GH was only slightly elevated at the 
end of each recovery period. Alternatively, an increase in FFA as a result of the first 
exercise bout might have blocked hGH secretion directly at the pituitary level, as 
demonstrated by Casanueva et al. (1987). The potential role of FFA in the hGH 
feedback loop was studied by Pontiroli et al. (1991). Infusion of methionyl-GH (met-
GH) blocked the response to exogenous GHRH and administration of acipimox, an 
antilipolytic agent, and pyridostigmine, to block hypothalamic somatostatin release, 
did not restore the hGH response to GHRH. This indicates that inhibition of the hGH 
response to GHRH can occur independently of circulating plasma FFA levels and 
hypothalamic somatostatin release and was probably mediated by hGH autofeedback 
at the pituitary gland. 
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CHAPTER3 
GENERAL METHODS 
3.1. Introduction 
The methods common to all studies presented in this thesis (Chapters 4, 5, 6 and 7) 
are described in this chapter. Each testing protocol was approved by the Ethical 
Advisory Committee of Loughborough University (see Appendix A). This Chapter 
describes the equipment, instruments and calibration routines used, gives information 
about subjects, familiarisation procedures and standardised testing procedures, 
including performance variables measured and describes the procedures employed to 
collect, handle and analyse blood samples. Further details of blood metabolite and 
hormone assays can be found in Appendix B. The present chapter also includes a 
description of calculations done and statistical techniques used throughout this thesis. 
The final four sections of this chapter describe four pilot studies. Sections 3.9 and 
3.10 show the results of using two different methods of assessing the repeatability of 
two key performance measures, peak (PPO) and mean (MPO) power output; firstly by 
calculating the coefficients of variation for both PPO and MPO, and, secondly, using 
the method described by Bland and Altman (1986). Section 3.11 considers the effect 
of the insertion of a cannula on resting serum concentrations of hGH and cortisol, and 
the final section of this chapter is a storage study which determines how long serum 
samples can be stored for without a significant change in serum hGH concentrations 
at the time of analysis. 
3.2. Equipment 
In all of the studies in this thesis a modified friction-loaded cycle ergometer (Monark, 
model 864), interfaced with a microcomputer (BBC, model B), was used in order to 
calculate "corrected" instantaneous power generated during maximal sprint exercise 
(Lakomy, 1986). This method corrects for the inertia characteristics and 
instantaneous changes in angular velocity of the flywheel. Lakomy (1986) found that 
employing the protocol of Bar-Or (1978) resulted in a 32% underestimation of peak 
power output when compared with the "corrected" method with an averaging period 
of 1 s. Time to reach peak power was also reduced, as it was reached before peak 
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pedal speed. In contrast, there was no difference in total work over an entire 30 s 
sprint when using the different methods. 
In order to obtain the "corrected" power output values, a high speed data collection 
system was used (Lakomy, 1986). An electric generator was attached to the frame of 
the ergometer such that it was driven by the ergometer flywheel, giving an analogue 
signal proportional to the angular velocity of the flywheel. The signal was logged by 
the microcomputer via an analogue-to-digital (A-D) converter, combined with a 
timing signal derived from the computer's internal jiffy clock. The sampling rate was 
20Hz. 
The important factor included in the "corrected" method developed by Lakomy 
(1986) was the "acceleration balancing load" which was the force required at any 
instant to stop the subject from accelerating the flywheel. Instantaneous power output 
could then be calculated as the product of the speed of the flywheel and the 
"effective" load (resistive load + acceleration balancing load). The values for 
instantaneous speed and power were averaged over 1 s intervals. At the conclusion of 
the test the computer was programmed to calculate, display and print both the 
"corrected" and "uncorrected" results. Figure 3.1 shows a typical power output and 
pedal speed profile for a maximal 30 s sprint. 
Before and at the end of each study the relationship between the angular velocity of 
the flywheel and the output from the generator and the A-D converter was calibrated. 
This calibration was also checked prior to each individual trial. The ergometer was 
pedalled by one of the experimenters for approximately 100 s at a pedal speed of 60 
rev.min-1, and the number of pedal revolutions was counted. In addition, the 
deceleration time of the flywheel at three different loads was determined by setting 
the flywheel in motion, pedalling in excess of 120 rev.min-1 and ceasing pedalling. 
The microcomputer recording the time it took the flywheel to stop and calculated a 
linear regression equation of load vs. flywheel deceleration enabling the "acceleration 
balancing load" to be calculated (for a full explanation see Lakomy, 1988). 
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Figure 3.1. Power output and pedal speed profiles generated during a 30 s sprint on 
the modified cycle ergometer 
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The magnitude of the measured power output may be influenced by a number of 
factors in addition to those that the experiments in this thesis attempted to manipulate. 
Such factors include crank length, degree of pelvic tilt and saddle height (Nordeen-
Snyder, 1977; Yoshihuku and Herzog, 1996). In order to eliminate the effect of 
different crank length, as well as any other confounding variables associated with the 
choice of ergometer, the same cycle ergometer was used throughout each study. In 
fact one cycle ergometer was used for the study described in chapter 5 whilst the 
studies described in chapters 4, 6 and 7 were all carried out using another ergometer 
(same model, Monark, model 864). On the first visit to the laboratory optimal saddle 
height was determined for each subject whereby slight knee flexion occurred at the 
bottom of the pedal stroke. Subjects' then used this saddle height on all further visits 
to the laboratory. 
In order to restrict exercise as much as possible to the lower limbs and prevent 
subjects from rising out of the saddle, a wide restraining harness was passed around 
the subject's waist. The harness was positioned so that it did not interfere with the 
subject's breathing and did not place uncomfortable pressure on the subject's 
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stomach. Two side-straps on the harness were fixed to a metal rail bolted to the floor 
behind the cycle ergometer. A number of holes were drilled in the metal rail so that 
the tension of the straps could be adjusted for different subjects; the same setting was 
used for all trials. 
The effects of the restraining harness on power output during maximal sprint cycling 
have been examined by Bogdanis (1991). It was suggested that the use of a 
restraining harness does not affect peak power output (Bogdanis 1991), although it is 
possible that peak power output is increased slightly. This may be due to the fact that 
the harness holds the subject on the seat allowing most of the power generated in the 
legs to be applied to the flywheel rather than to lifting the subject off the saddle. 
During each trial toe clips (reinforced with adhesive tape) were used to secure the 
subjects' feet on the pedals. 
Figure 3.2. The ergometer and restraining harness used in the studies in this thesis. 
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3.3. Subjects 
Due to the demanding nature of the exercise performed in the studies described in this 
thesis, only physically active individuals, many of whom were involved in regular 
exercise training and sport, were recruited. All subjects were informed in verbal and 
written form about the purposes and requirements of the study and any known risks or 
discomforts associated with the protocol. It was also clearly stated that all subjects 
had the right to terminate their participation at any time, with no obligation to give a 
reason for their decision. Subjects expressed their understanding by signing a 
statement of informed consent (Appendix A). A short questionnaire was attached to 
the statement of informed consent in order to obtain information about the 
sporting/exercise activities of each individual. A medical history questionnaire 
(Appendix A) was also completed in the presence of an experimenter (to provide 
clarification and assistance), and subjects with medical conditions that posed potential 
problems were excluded. Participation was voluntary and no remuneration was given 
to any of the subjects, although food and drink was provided after each trial. 
3.4. Familiarisation 
Prior to any experimental testing each subject completed 3-6 (typically 4) sprinting 
practice sessions when optimal seat height and restraining harness arrangement were 
determined for future tests. Body height (Holtain stadiometer) and body mass (A very 
3306 ABV balance) measurements were also taken during these visits. The purpose 
of the familiarisation sessions was so that subjects could: 
• get accustomed to all-out sprinting on the cycle ergometer 
• get accustomed to sprinting whilst wearing a restraining harness 
• learn to accelerate maximally on the command "3-2-1-GO" 
• get accustomed to maintaining maximal effort throughout the full 30 s of a sprint 
Typically the first 1-2 familiarisation sessions consisted of a warm-up, at least 5 (but 
up to 10 depending on how comfortable the subject was) sprints of brief duration ( -6 
s) followed by a 20 s all-out sprint. Later familiarisation sessions consisted of a warm 
up and 2 all-out 30 s sprints separated at least 10 min passive recovery. All results for 
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the 30 s sprints were recorded and when performance improvements had stopped 
subjects were deemed to be ready to start the experimental tests. 
Following familiarisation the mean coefficient of variation for peak power in a 30 s 
all-out sprint on a cycle ergometer from a standing start, against an applied resistance 
equivalent to 7.5% of the subjects' bodymass, was 5.5±1.5% (Cherry, 1997). Section 
3.9 Describes a pilot study that determines the coefficients of variation for two 
performance parameters measured in this thesis. 
3.5. Standardised testing procedures 
On the day preceding each main trial subjects were asked to refrain from alcohol and 
physical training or heavy exertion and to consume their normal diet. Subjects arrived 
at the laboratory on the day of each trial following an overnight fast or, if this were 
not possible, at least 4 h postprandial. 
Ambient (Ball et al., 1997) and muscle (Sargeant, 1994) temperature have been 
reported to influence power output in maximal exercise. Although it was not possible 
to accurately control ambient temperature in the laboratory, all experiments in this 
thesis were conducted in a thermoneutral environment (18-23°C). In addition, each 
testing protocol incorporated a standardised warm-up and subjects completed their 
trials at a similar time of day, so the inter-trial variation in muscle temperature was 
probably not too great. The standardised warm-up consisted of 4 min pedalling at 
60W, 30 s pedalling at 80 Wand 30 s pedalling at lOOW, with 30 s rest between each 
intensity. The warm-up was followed by 5 min of rest on the cycle ergometer while a 
blood sample was taken and the subject prepared for the sprint. 
Following the 5 min rest, subjects completed a sprint from either a rolling start of 70 
rev.min-1 against no resistance (Chapter 4) or a stationary start (Chapters 5, 6 and 7). 
In both cases a countdown (3-2-1) was given, followed by the command "GO". On 
this command the subjects completed the all-out sprint. Subjects were instructed to 
sprint maximally throughout each sprint and to avoid pacing. The importance of 
attaining maximum speed as soon as possible after the start of the sprint was 
emphasised and strong verbal encouragement was given during each sprint. Sprints 
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were separated by passive recovery seated upright on a couch maintaining 
approximately the same body position as on the cycle ergometer. On a few occasions 
subjects found it necessary to lie flat on the couch for a few minutes following the 
sprint to overcome feelings of nausea, however, they were encouraged to return to an 
upright seated position as soon as they felt they had recovered. 
3.6. Performance variables 
The following performance parameters were recorded for each sprint from the 
computer print out: 
• Peak power output (PPO) -highest 1 s average power output 
• Peak power output corrected for each subject's bodymass (PPO-corr) -
PPO/bodymass 
• Mean power output for the whole 30 s sprint (MP030) 
• Mean power output corrected for each subject's bodymass (MPO-corr) -
MP03o/bodymass 
• Mean power output for the first 6 s (MP06) 
• Peak pedal revolutions (PPR)- highest 1 s average pedal speed 
• Mean pedal revolutions for the whole 30 s sprint (MPR30) 
• Mean pedal revolutions for the first 6 s (MPR6) 
• Total work completed during the 30 s sprint 
• Fatigue index (FI) - the percentage decline from peak to end power output 
FI = PPO- end power output x 100 
PPO 
3.7. Collection, storage and analysis of blood samples 
Venous blood samples were obtained from an antecubital forearm vein vm an 
indwelling cannula (Venflon 2, 18 guage) inserted under local anaesthetic (0.5 ml of 
1% lignocaine). The cannula was placed while the subjects rested on an examination 
couch. Repeated sampling was facilitated by a 3-way stop cock and tubing 
(Connecta®) connected to the cannula and strapped securely with surgical tape. The 
Figure 3.3. Summary of the procedures 
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first (resting) blood sample was taken at least 15 min after the cannula was inserted. 
Patency was maintained by displacing the blood contained in the cannula with sterile 
isotonic saline. Further blood samples were obtained at pre-determined times either 
seated on the cycle ergometer or in an upright seated position on the couch. 
Venous blood samples were dispensed into three tubes, as summarized in Figure 3.3: 
(i) One portion ( 4 to 5 ml) was placed into a lithium heparinised tube (Sarstedt 
LH/5 ml). Blood pH was measured immediately (Radiometer ABL5 pH/blood 
gas monitor) and thereafter, 20 ~-tl aliquots of blood were removed, 
deproteinized in 2.5% perchloric acid and stored at -20°C for later 
determination of blood lactate concentrations (Maughan, 1982). Further 
aliquots were removed for the measurement of haematocrit by 
microcentrifugation (Hawksley Ltd.) and haemoglobin concentration (by the 
cyanmethaemoglobin method) for the calculation of percentage change in 
plasma volume (Dill and Costill, 1974). 
(ii) A further 1.5 ml was placed in a calcium heparinised eppendorf tube. This 
was immediately centrifuged (Eppendorf Centrifuge 5415C) and the plasma 
removed and stored at -70°C for the determination of ammonia concentration 
within 48 h (for procedure see Appendix B). A pilot study on the effect of 
freezing and storage conditions on plasma ammonia concentrations conducted 
in this laboratory (Tzintzas and Wilson; unpublished observations) showed 
that plasma samples could be stored at -70°C for up to 48 h without any 
significant change in ammonia concentration. The ammonia assay (Sigma 
Diagnostics, kit 171- C) had an intra-assay coefficient of variation (cv) of 1.7-
4.2% and an inter-assay cv of2.1-3.3%. 
(iii) The remaining blood ( 4 to 5 ml) was allowed to clot for 1 h in a plain tube 
(Sarstedt Serum Z/5 ml). This was then centrifuged at 3°C for 15 min at a 
speed of 6000 rev.min-1 (Burkard Koolspin) and the serum was removed and 
stored at -70°C for the determination of serum hGH (Chapters 4, 5, 6 and 7), 
insulin (Chapter 5), cortisol (Chapters 4, 5, 6 and 7) and IGF-1 (Chapter 7) 
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concentrations by routine ELISA (for procedures see Appendix B). The GH 
assay (Medgenix HGH-Biosource) had a sensitivity of 0.11 mU.r\ an intra-
assay cv of 2.1-3.6% and an inter-assay cv of 6.8-7.1 %. The insulin assay 
(Medgenix insulin-Biosource) had a sensitivity of 0.15 mU.r1, an intra-assay 
cv of 3.0-5.3% and an inter-assay cv of 5.6-9.8%. The sensitivity of the 
cortisol assay (Milenia, DPC cortisol) was 8.3 nmol.r1 with an intra-assay cv 
of 5.9-8.0% and an inter-assay cv of 8.3-9.0%. The IGF-1 assay (R&D 
Systems Europe) had a sensitivity of 2.6 mg.mr1, and intra-assay cv of 3.5-
4.3% and an inter-assay cv of 7.5-8.3%. 
3.8. Calculations and statistical analysis 
Mean integrated serum hGH concentrations (area under the curve - AUC) were 
calculated using the trapezium method (Parsons and Dawson, 1980) whereby the area 
was divided into a number of strips and the points where the ordinates meet the curve 
were joined by a straight line to form trapezia. The area of each trapezium was 
calculated using the equation: 
Area = Cxt + V£) x d 
2 
Figure 3.4. The trapezium method of calculating area under the curve. 
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The mean integrated serum hGH concentration was calculated as the sum of the area 
of all trapezia. 
A commercially available statistical computer package (Statistica release 5.0, StatSoft 
Inc.) was used to analyse data using t tests and two-way, three-way and four-way 
analyses of variance (ANOVA) with repeated measures where appropriate. 
Relationships between variables were examined by calculating the Pearson product 
moment correlation coefficient (r). Statistical significance was accepted at the P < 
0.05 level. All results are expressed as mean ± standard error of the mean (SEM). 
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3.9. The coefficients of variation for peak and mean power output during a 30 s 
cycle ergometer sprint. 
Methods 
Ten physically active male subjects volunteered to take part in this study. Following 
familiarisation they completed 10 trials on separate visits to the laboratory. Each trial 
consisted of a standardised submaximal warm-up, followed by 5 min rest, and then a 
single 30 s sprint from either a rolling (subjects A-E) or a stationary (subjects F-J) 
start (see section 3.5). 
The coefficients of variation (V) for peak power output (PPO) and mean power output 
(MPO) were calculated for each subject using the following formula: 
V=100S.D.% 
Ms 
Where, S.D. is the standard deviation and Ms is the mean of the sample (Cohen and 
Holliday, 1982). 
Results 
The individual data are depicted in Tables 3.1-3.4, and the coefficients of variation are 
summarised in Table 3.5. There were no differences in the coefficients of variation 
for PPO and MPO, or between a stationary and a standing start. 
Discussion 
The coefficients of variation for PPO from both a rolling start and a stationary start in 
the present study are similar to that reported by Cherry et al. (1997) who found that, 
following familiarisation, the mean coefficient of variation for PPO in a 30 s all-out 
cycle ergometer sprint from a stationary start was 5.5±1.5 %. Both the results in the 
present study and those of Cherry et al. (1997) are higher than the test-retest value of 
2.6% reported by Winter et al. (1996). However, for the group as a whole, a 
coefficient of variation of 4.8 % for both PPO and MPO suggests that, once subjects 
are familiarised, there is not much variation in PPO and MPO measured during cycle 
ergometer sprinting on separate occasions, and, therefore, measurements of 
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performance can be considered to be representative of the subjects' mean 
performance. 
Table 3.1. Peak power output (PPO) achieved by 5 subjects from a rolling start (70 
rev.min-1 against no applied resistance) on 10 separate occasions. 
SUBJECT 
A B c D E 
1 904 1164 1074 1092 1305 
2 842 1046 1048 1068 1194 
3 878 1122 1103 1132 1268 
4 878 1176 1105 1198 1311 
5 859 1134 985 1123 1248 
6 950 1107 1026 1126 1217 
7 865 1159 1017 1156 1367 
8 985 1072 1066 1230 1521 
9 961 1131 1073 1159 1291 
10 925 1170 1052 1080 1185 
Mean 905 1128 1055 1136 1291 
SD 48 43 38 51 99 
CV(%) 5.4 3.8 3.6 4.5 7.7 
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Table 3.2. Mean power output (MPO) achieved by 5 subjects from a rolling start (70 
rev.min"1 against no applied resistance) on 10 separate occasions. 
SUBJECT 
A B c D E 
1 623 574 570 617 755 
2 573 555 584 612 739 
3 583 570 560 621 772 
4 606 567 544 648 763 
5 600 655 616 604 752 
6 609 613 584 663 744 
7 620 638 549 664 744 
8 653 642 616 651 836 
9 659 658 603 675 836 
10 663 569 590 649 829 
Mean 619 604 582 640 777 
SD 31 41 26 25 40 
CV(%) 5.0 6.8 4.4 3.9 5.2 
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Table 3.3. Peak power output (PPO) achieved by 5 subjects from a stationary start on 
10 separate occasions. 
SUBJECT 
F G H I J 
1 1403 1819 1670 1561 1397 
2 1383 1720 1570 1551 1389 
3 1487 1615 1674 1722 1274 
4 1304 1754 1693 1643 1256 
5 1361 1752 1609 1664 1458 
6 1451 1673 1641 1624 1382 
7 1409 1800 1577 1661 1297 
8 1397 1580 1620 1645 1308 
9 1438 1802 1646 1690 1229 
10 1640 1645 1515 1593 1345 
Mean 1427 1716 1622 1635 1334 
SD 90 84 55 54 73 
CV(%) 6.3 4.9 3.4 3.3 5.5 
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Table 3.4. Mean power output (MPO) achieved by 5 subjects from a stationary start 
on 10 separate occasions. 
SUBJECT 
F G H I J 
1 676 873 819 696 765 
2 685 789 815 684 697 
3 682 724 799 726 706 
4 702 793 813 702 790 
5 744 822 821 709 818 
6 735 750 868 779 697 
7 685 797 779 738 677 
8 688 754 791 725 741 
9 717 761 782 730 719 
10 700 792 757 724 747 
Mean 701 786 804 721 736 
SD 23 42 31 26 45 
CV(%) 3.3 5.3 3.8 3.7 6.1 
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Table 3.5. Summary of the coefficients of variation for peak power output and mean 
power output 
PPO MPO 
Rolling start (A-E) 5.0±0.7% 5.1±0.5% 
Stationary start (F-J) 4.7±0.6% 4.5±0.5% 
All subjects (A-J) 4.8±0.4% 4.8±0.4% 
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3.10. The repeatability of sprinting on a cycle ergometer. 
Methods 
The results of 16 of the physically active male volunteers that took part in the studies 
in this thesis were used in this study. Following familiarisation (see section 3.4), they 
completed two trials on separate days. Each trial consisted of a standardised 
submaximal warm-up, followed by 5 min rest and then a sprint from either a rolling or 
a stationary start. Ten subjects performed sprints from a rolling start during both 
trials, whilst eight subjects completed two sprints during both trials (two subjects 
completed the trials from both a rolling and a stationary start). The method described 
by Bland and Altman (1986) was then used to assess the repeatability of the peak 
(PPO) and mean (MPO) power output of the sprints. 
Results 
The individual data are depicted in Figures 3.5-3.8, and the coefficients of 
repeatability are summarised in Table 3.6. Table 3.6 shows that, when using linear 
data, the coefficients of repeatability for PPO and MPO were 8.9 to 5.8 % of average 
PPO and MPO, respectively, for cycle ergometer sprints from a rolling start, and 6.7 
to 6.3 % for cycle ergometer sprints from a stationary start. 
Discussion 
The coefficients of repeatability calculated for the linear data, when expressed as a 
percentage of average power output, were slightly higher than the coefficients of 
variation for PPO and MPO reported in Section 3.9. However, heteroscedasticity in 
the measurement of power output during sprint tests (Nevill et al., 1995) lends itself to 
the use of log-transformed data when applying the Bland and Altman method of 
assessing repeatability (Bland and Altman, 1986). When the coefficients of 
repeatability were calculated for log-transformed data, and expressed as a percentage 
of the average log-transformed power output, they were around 1 %(Table 3.7). This 
infers good repeatability in measurements of both PPO and MPO during sprinting on 
a cycle ergometer, both from a rolling start and from a stationary start. 
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Figure 3.5. The relationship between mean PPO, for sprint 1 and sprint 2, and the 
absolute difference between sprint 1 and sprint 2, for sprints from a rolling start. 
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Figure 3.6. The relationship between mean MPO, for sprint 1 and sprint 2, and the 
absolute difference between sprint 1 and sprint 2, for sprints from a rolling start. 
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N.B. The y-axis crosses the x-axis at the point of mean difference between sprint 1 
and sprint 2 (i.e. the bias). The upper and lower limits of they-axis represent the bias 
± the coefficient of repeatability (calculated as 2 x the standard deviation of the 
differences between sprint 1 and sprint2). 
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Figure 3.7. The relationship between mean PPO, for sprint 1 and sprint 2, and the 
absolute difference between sprint 1 and sprint 2, for sprints from a stationary start. 
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N.B. The y-axis crosses the x-axis at the point of mean difference between sprint 1 
and sprint 2 (i.e. the bias). The upper and lower limits of they-axis represent the bias 
± the coefficient of repeatability (calculated as 2 x the standard deviation of the 
differences between sprint 1 and sprint2). 
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Figure 3.8. The relationship between mean MPO, for sprint 1 and sprint 2, and the 
absolute difference between sprint 1 and sprint 2, for sprints from a stationary start. 
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N.B. The y-axis crosses the x-axis at the point of mean difference between sprint 1 
and sprint 2 (i.e. the bias). The upper and lower limits of they-axis represent the bias 
± the coefficient of repeatability (calculated as 2 x the standard deviation of the 
differences between sprint 1 and sprint2). 
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Table 3.6. Summary of the coefficients of repeatability, expressed as the calculated 
value and as the % of average power output. 
Average 
power output 
(Y{) 
Rolling start PPO 1146 
MPO 657 
Stationary start PPO 1476 
MPO 710 
Average 
difference 
from mean 
21.3 
-6.4 
23.0 
1.8 
Coefficient 
of 
Repeatability 
102 
38 
99 
44 
%of average 
power output 
8.9 
5.8 
6.7 
6.3 
Table 3.7. Summary of the coefficients of repeatability for the log-transformed data, 
expressed as the calculated value and as the % of average power output. 
Coefficient %of average 
of power output 
Repeatability 
Rolling start PPO 0.04 1.27 
MPO 0.02 0.87 
Stationary start PPO 0.03 0.90 
MPO 0.03 0.94 
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3.11. The effect of the insertion of a cannula on resting concentrations of hGH 
and cortisol 
Introduction 
It has been suggested that hypodermic puncture might elicit an increase in both serum 
hGH concentration and serum cortisol concentration. It is important to determine that 
exercise itself is the stimulus for hGH and cortisol secretion that is being evaluated in 
the experimental chapters of this thesis. Therefore, the purpose of the present study 
was to determine whether the insertion of a cannula results in a detectable increase in 
serum hGH and cortisol concentrations in resting subjects. 
Methods 
Subjects 
Six healthy male volunteers aged 20 to 27 years (24.0±1.3 years) gave their written 
informed consent for this study which had the approval of the Loughborough 
University Ethical Committee. Body mass ranged from 73.8 to 87.0 kg (80.2±2.9 kg) 
and height ranged from 170.5 to 186.1 cm (177.8±2.5 cm). 
Protocol 
Following an overnight fast, subjects rested for 2 h whilst seated on a couch 
(maintaining approximately the same body position as they would on a cycle 
ergometer) whilst venous blood samples were collected. 
Blood sampling and analysis 
Venous blood samples were taken via a cannula inserted into an antecubital forearm 
vein under local anaesthetic (1% lignocaine). Patency was maintained by displacing 
the blood contained in the cannula with isotonic saline. Blood samples were taken in 
a seated position at rest 15, 30, 35, 45, 55, 65, 85, 115 and 145 min after the insertion 
of the cannula. These times corresponded to the resting sample (-10 min) and then 
what would be 5, 10, 20, 30, 40, 60, 90 and 120 min after a sprint in the protocols 
used in the experimental chapters of this thesis. 
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Samples were dispensed into three tubes: (i) One portion ( 4 to 5 ml) was placed into a 
lithium heparinised tube (Sarstedt LH/5ml). Blood pH was measured immediately 
(Radiometer ABL5 pH/blood gas monitor) and thereafter, 20~1 aliquots of blood were 
removed, deproteinized in 2.5% perchloric acid and stored at -20°C for later 
determination of blood lactate concentrations (Maughan, 1982). Further aliquots were 
removed for the measurement of haematocrit by microcentrifugation (Hawksley Ltd.) 
and haemoglobin concentration (by the cyanmethaemoglobin method) for the 
calculation of percentage change in plasma volume (Dill and Costill 1974). (ii) A 
further 1.5 ml was placed in a calcium heparinised eppendorf tube. This was 
immediately centrifuged and the plasma removed and stored at -70°C for the 
determination of ammonia concentration within 48 h (Sigma Diagnostics, kit 171 - C). 
(iii) The remaining blood ( 4 to 5 ml) was allowed to clot for 1 h in a plain tube 
(Sarstedt Serum Z/5ml). This was then centrifuged at 3°C for 15 min at a speed of 
6000 rev.min-1 (Burkard Koolspin) and the serum was removed and stored at -70°C 
for the determination of hGH concentrations. Serum GH and cortisol were measured 
by routine ELISA. The GH assay (Medigenix HGH-Biosource) had a sensitivity of 
0.11 mU.r\ an intra-assay coefficient ofvariation (cv) of2.1-3.6% and an inter-assay 
cv of 6.8-7.1 %. The sensitivity of the cortisol assay (Milenia, DPC cortisol) was 8.3 
nmol.r1 with an intra-assay cv of 5.9-8.0% and an inter-assay cv of 8.3-9.0%. 
Statistical analysis 
A one-way analysis of variance with repeated measures was used to discover any 
changes over time. Statistical significance was accepted at the P<0.05 level. All 
results are reported as mean±SEM. 
Results 
No significant changes in blood lactate concentrations, pH or plasma ammonia 
concentrations were identified during the study (Table 3.8). Similarly, there were no 
significant differences over time in serum hGH (Figure 3.9) or serum cortisol (Figure 
3.10) concentrations. Only two of the six subjects showed a marked increase in serum 
hGH concentrations at any time throughout the trial, with one subject demonstrating a 
peak hGH concentration of 27.81 mU.r1• Highest measured mean serum hGH 
concentration was 5.9±4.5 mU.r1 and was identified 85 min after insertion of the 
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cannula. This corresponds to 60 min after a sprint in the protocols used in the 
experimental chapters in this thesis. However, four of the six subjects did not 
demonstrate any clear increase in hGH concentration during the trial. In addition, two 
of the six subjects maintained undetectable serum hGH concentrations throughout the 
trial, and a further subject's hGH levels were undetectable until 145 min after the 
insertion of the cannula (the last blood sampling time point). 
Highest measured mean serum cortisol concentration was identified 15 min after the 
insertion of the cannula as 451.8±81.3 nmol.r1• Throughout the rest of the trial serum 
cortisol concentrations steadily declined with a lowest measured mean concentration 
of 321.5±85.2 nmol.r1 145 min after insertion of the cannula. There was no 
significant change in plasma volume during the study. The greatest mean decrease in 
plasma volume was 2.7±1.3%. 
Table 3.8. Blood lactate concentrations, blood pH and plasma ammoma 
concentrations during 120 min following the insertion of a cannula (n=6). 
Time (min) 0 5 10 20 30 40 60 90 120 
Blood Lactate 0.17± 0.14± 0.12± 0.15± 0.15± 0.14± 0.12± 0.18± 0.12± 
(mmol.r1) 0.03 0.05 0.04 0.05 0.05 0.04 0.03 0.03 0.03 
Blood pH 7.37± 7.38± 7.38± 7.38± 7.37± 7.37± 7.37± 7.36± 7.36± 
0.01 0.00 0.00 0.00 0.00 0.01 0.00 0.00 0.00 
Plasma Ammonia 15.1± 22.1± 18.7± 17.0± 15.1± 23.1± 18.6± 18.2± 16.8± 
(~ol.r1) 3.7 7.9 4.5 5.9 3.9 5.6 3.2 4.3 2.5 
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Figure 3.9. Resting serum hGH concentrations following the insertion of a cannula at 
Omin. 
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Figure 3.10. Resting serum cortisol concentrations following insertion of a cannula at 
Omin. 
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Discussion 
The main result of this study was that the insertion of a cannula does not elicit a 
significant increase in serum hGH concentrations. However, there is variation 
between individuals since, in three subjects, hGH levels were undetectable using the 
assay employed in the present study for the majority of the trial, whilst, in one subject, 
serum hGH concentrations increased dramatically. The responses of the other two 
subjects were intermediate between these extremes. The hGH concentrations 
measured in the present study compare favourably with resting samples taken in other 
studies. For example, Barreca et al. (1988) reported resting concentrations of -4 
mU.r1 in both athletes and sedentary subjects. Similarly, Mikines et al. (1985) 
reported resting levels of hGH of 5±3 mU.r1 and 4±2 mU.r1 in trained and untrained 
men. In addition, the highest measured mean serum hGH concentrations observed in 
the present study are much lower than highest measured mean hGH concentrations of 
59.8±13.3 mU.r1 following a single 30 s treadmill sprint in men (Nevill et al., 1996b). 
It is possible that the reason for the interindividual differences in the hGH response to 
the insertion of a cannula was a variation degrees of anxiety or stress experienced by 
each subject as a result of this procedure. In addition, it might be that anxiety 
associated with being in the laboratory environment under experimental conditions 
caused an increase in circulating hGH levels. However, this seems unlikely on the 
basis that the individual who demonstrated by far the highest response was, himself, 
experienced in working in the laboratory environment both as experimenter and 
subject, in contrast to some of the other participants. 
The serum cortisol concentrations measured in the present study are similar to the 
resting samples taken in other studies. For example, Barreca et al. (1988) measured 
resting cortisol concentrations prior to physical exercise of -550 nmol.r1 in blood 
drawn from a cannula. Resting concentrations of 493±44 nmol.r1 were also reported 
by Del Corral et al., 1998). Mean resting cortisol levels of 193.1 nmol.r1 for healthy 
men aged 28-56 reported by Comil et al. (1965) were much lower than those observed 
in the present study. However, Comil et al. (1965) observed a small decrease, to 
184.9 nmol.r1, in plasma cortisol concentration over 50 min of rest, in agreement with 
the findings of the present study. If cortisol is taken as a marker of anxiety, as 
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considered by Follenius and Brandenburger (1975), then the insertion of a cannula did 
not appear to result in any apprehension in the present study, unless serum cortisol 
concentrations were elevated within 15 min of the insertion of the cannula. 
Alternatively, if apprehension due to being under experimental conditions were a 
factor, cortisol concentrations may have been elevated even before the cannula was 
inserted. 
However, since only two of the subjects demonstrated an increase (n.s.) in hGH 
concentrations, and no significant changes in serum cortisol concentrations were 
identified, it would appear that any anxiety felt by the subjects was not reflected in the 
circulating hormone levels measured in this study. The marked increases in serum 
hGH concentrations in one of the subjects remains unexplained, although it may be 
that this reflects the inter-individual variation in the growth hormone response to a 
stimulus for hGH secretion. 
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3.12. Storage Study 
Methods 
One physically active male subject completed a single 30 s cycle ergometer sprint, 
and 30 min later, a 20 ml venous blood sample was taken from an antecubital forearm 
vein by venepuncture. The blood was allowed to clot in a plain tube and then 
centrifuged at 3°C for 15 min at 6000 rev.min-1• The serum was removed and -0.5 ml 
aliquots were dispensed into 40 Eppendorf tubes for storage at -70°C. Serum 
concentrations of hGH were determined by routine ELISA (for procedures see 
Appendix B) as soon as was possible (1 week), 1 month, 4 months and 18 months 
after the trial. 
Results 
The serum hGH concentrations for the four analysis runs are shown in Table 3.9. No 
statistically significant differences were found in the serum hGH concentrations 
measured at any time. 
Discussion 
The results of this pilot study show that the analysis of serum for the determination of 
hGH concentrations can be undertaken up to 18 months after blood sample collection 
without any significant changes in the concentrations measured. 
107 
Table 3.9. Serum hGH concentrations measured 1 week, 1 month, four months and 18 
months after the collection of a post-exercise blood sample. 
Time to analysis 
1 week 1 month 4 months 18 months 
1 10.8 11.0 11.8 10.8 
2 9.0 12.4 10.5 12.6 
3 10.7 12.1 10.7 11.7 
4 12.4 11.8 11.1 10.2 
5 10.7 10.0 11.0 11.5 
6 12.2 11.5 11.7 11.8 
7 12.1 11.9 10.8 10.6 
8 10.7 11.8 10.4 11.6 
9 11.4 12.4 9.8 10.8 
10 11.3 10.4 11.2 9.3 
Mean 11.1 11.5 10.9 11.1 
SEM 0.3 0.3 0.2 0.3 
CV(%) 9.0 7.1 5.6 8.5 
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CHAPTER4 
THE TIME-COURSE OF THE HUMAN GROWTH HORMONE RESPONSE TO 
A 6 SAND A 30 S CYCLE ERGOMETER SPRINT 
Introduction 
A number of studies have shown exercise to be a potent stimulus for the release of 
human growth hormone (hGH). Most of these studies have considered prolonged 
submaximal exercise whilst only a few have studied high intensity or maximal sprint 
exercise (Gordon et al. 1994; Nevill et al. 1996b). 
Gordon et al. (1994) found considerably elevated hGH concentrations following 90 s 
of high intensity exercise. However, blood samples were only taken for 30 min 
following the exercise bout, at which time hGH concentrations were higher than at 
any other time point. Nevill et al. (1996b) studied metabolic and hormonal responses 
for a 60 min period following a 30 s treadmill sprint, again demonstrating a 
significant hGH response to high intensity exercise. In this study the blood lactate 
and plasma ammonia concentrations and blood pH had returned to resting levels 
within 60 min of recovery, however, hGH was still elevated. There is, therefore, a 
need to measure hGH concentrations for longer than 60 min after a bout of high 
intensity exercise to establish the full time-course of the hGH response. 
The mechanisms controlling the magnitude of the hGH response to exercise are not 
fully understood. It has been suggested that blood lactate (Karagiorgos et al., 1979; 
Chwalbinska et al., 1996), blood pH (Gordon et al., 1994) and oxygen demand and 
availability (Vanhelder et al., 1987) may have roles in controlling hGH release. In 
addition intensity and duration of exercise may influence the hGH response (Sutton et 
al., 1976). No study has considered the effect that the duration of a bout of maximal 
sprint exercise has, either directly or mediated by other factors, on the hGH response 
to a sprint. Therefore the purpose of this study was to determine the time-course of 
the hGH response to a 6 s and a 30 s maximal cycle ergometer sprint. 
Methods 
Subjects 
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Nine healthy male volunteers aged 18 to 28 years (23±1 year) gave their written 
informed consent for this study which had the approval of the Loughborough 
University Ethical Committee. Body mass ranged from 72.5 to 88.0 kg (82.1±1.9 kg) 
and height ranged from 175.1 to 186.1 cm (180.8±1.4 cm). 
Equipment 
The exercise tests were carried out on a modified friction-loaded cycle ergometer 
(Monark 864), which was interfaced to a microcomputer (BBC). This allowed 
instantaneous power output, corrected for flywheel acceleration, to be monitored and 
recorded accurately. Performance data were averaged over 1 s intervals. Lakomy 
(1986) has described the equipment used in detail. A restraining harness was also 
placed around the subjects' waists in order to prevent them from rising out of the 
saddle, thereby concentrating movement in the lower limbs. The same harness setting 
and saddle height were used for each trial. Toe-clips and tape held the subjects' feet 
securely in the pedals. 
Protocol 
After familiarisation, the subjects arrived in the laboratory after a 4 h fast on two 
separate occasions, completing one trial on each visit using a crossover design. 
During one trial subjects completed a single all out 6 s effort and during the other trial 
they completed a single all out 30 s effort. 
Before the first sprint of each trial all subjects completed a standardised sub-maximal 
warm-up on the cycle ergometer, consisting of 4 min pedalling at 60W, 30 s pedalling 
at 80W and 30 s pedalling at lOOW. Five minutes after the warm-up, the subjects 
performed the maximal sprint from a stationary start on the cycle ergometer against 
an applied resistance equal to 7.5% (75g.kg"1) of their body mass. Subjects were 
instructed to sprint maximally for the duration of the sprint and were encouraged 
verbally whilst sprinting. Following the sprint subjects were seated in an upright 
position on a couch (maintaining approximately the same body position as on the 
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ergometer). They remained on the couch and blood samples were obtained for 3 h 
after the sprint. 
Three of the subjects completed an additional control trial on another occasion, 
arriving at the laboratory after a 4 h fast. During this trial the subjects did not perform 
any exercise but remained seated in an upright position on the couch for 2 h whilst 
blood samples were obtained. 
Blood sampling and analysis 
Venous blood samples were taken via a cannula inserted into an antecubital forearm 
vein under local anaesthetic (1% lignocaine). In the exercise trials blood samples 
were taken in a seated position at rest (-10 min) and post warm-up (-4 min) prior to 
the first sprint and 5, 10, 20, 30, 40, 60, 90, 120, 150 and 180 min after the sprint. 
The first blood sample was taken at least 15 min after the cannula was inserted. 
Patency was maintained by displacing the blood contained in the cannula with 
isotonic saline. In the control trial the first blood sample was taken at least 15 min 
after the cannula was inserted and then at 5, 10, 20, 30, 40, 60, 90 and 120 min after 
the first sample 
Samples were dispensed into three tubes: (i) One portion ( 4 to 5 ml) was placed into a 
lithium heparinised tube (Sarstedt LH/5ml). Blood pH was measured immediately 
(Radiometer ABL5 pH/blood gas monitor) and thereafter, 20~-tl aliquots of blood were 
removed, deproteinized in 2.5% perchloric acid and stored at -20°C for later 
determination of blood lactate concentrations (Maughan, 1982). Further aliquots were 
removed for the measurement of haematocrit by microcentrifugation (Hawksley Ltd.) 
and haemoglobin concentration (by the cyanmethaemoglobin method) for the 
calculation of percentage change in plasma volume (Dill and Costill 1974). (ii) A 
further 1.5 ml was placed in a calcium heparinised eppendorf tube. This was 
immediately centrifuged and the plasma removed and stored at -70°C for the 
determination of ammonia concentration within 48 h (Sigma Diagnostics, kit 171 - C). 
(iii) The remaining blood ( 4 to 5 ml) was allowed to clot for 1 h in a plain tube 
(Sarstedt Serum Z/5ml). This was then centrifuged at 3°C for 15 min at a speed of 
6000 rev.min-1 (Burkard Koolspin) and the serum was removed and stored at -70°C 
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for the determination of hGH concentrations. Serum GH was measured by routine 
ELISA. The GH assay (Medigenix HGH-Biosource) had a sensitivity of 0.11 mU.r\ 
an intra-assay coefficient of variation ( cv) of 2.1-3.6% and an inter-assay cv of 6.8-
7.1%. 
Statistical analysis 
A paired t test was used to ascertain whether there were any differences in 
performance between the 6 s trial and the first 6 s of the 30 s trial. A two-way 
analysis of variance with repeated measures was used to discover any differences in 
biochemical responses between 6 s and 30 s trials (main effect - trial) and the 
response of each subject with respect to time (main effect - time). Statistical 
significance was accepted at the P < 0.05 level. All results are expressed as mean 
±SEM. 
Results 
Performance 
Table 4.1 summarises the performances achieved by the subjects in this study. There 
was no difference in peak power output (PPO) or mean power output during the first 
6s (MP0-6) between the 6 sand 30 s trials. Similarly, peak pedal revolutions (PPR) 
and mean pedal revolutions over the first 6 s (MPR-6) showed no difference between 
trials. However, total work done in the 30 s trial was more than three times greater 
than that done in the 6 s trial (20903±480 vs. 6179±155 J, P<0.05). 
Table 4.1. Peak power output (PPO), mean power output (MPO), peak pedal rate 
(PPR), mean pedal rate (MPR), work done and fatigue index for the 6 s and the 30 s 
sprints. a P<0.05 
6s 30 s 
PPO (W) 1494±43 1468±42 
MP0-30 (W) 697±16 
MP0-6 (W) 1030±26 1010±25 
PPR (rev.min"1) 160±4 158±4 
MPR-30 (rev.min"1) 118±3 
MPR-6 (rev.min"1) 139±4 137±4 
Work(J) 6179±155 20903±480 a 
Fatigue Index (%) 68±1 42±1 
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Metabolic responses to cycle ergometer sprinting 
The blood lactate, blood pH and plasma ammonia responses are shown in Figures 4.1, 
4.2 and 4.3. Highest measured mean blood lactate concentrations, observed 5 min 
post-exercise in both exercise trials, were more than three times greater following the 
30 s sprint than they were following the 6 s sprint (11.81±0.52 vs. 3.59±0.32 mmol.r\ 
P<0.05). Blood lactate concentrations returned to resting levels between 40 and 60 
min after the 6 s sprint but not until between 90 and 120 min following the 30 s sprint 
(trial-time interaction effect, P<0.05). In the control trial mean blood lactate 
concentrations did not exceed 0.20 mmol.r1• 
Lowest measured mean blood pH was observed 5 min following the sprint in each 
exercise trial. Following the 6 s sprint blood pH reached 7.32 compared with 7.16 
following the 30 s sprint (P<0.05). Blood pH had returned to resting levels between 
20 and 30 min after the 6 s sprint compared with between 30 and 40 min following 
the 30 s sprint (trial-time interaction effect, P<0.05). During the control trial mean 
blood pH remained at 7.37 for the duration of the trial. 
Highest measured mean plasma ammonia concentrations were almost three times 
greater following the 30 s sprint than they were following the 6 s sprint (166.8±26.3 
vs. 56.7±9.8 ~-tmol.r\ P<0.05). Plasma ammonia concentrations also demonstrated a 
trial-time interaction effect as the concentrations returned to resting levels 30 to 40 
min after the 6 s sprint compared with approximately 120 min after the 30 s sprint. 
During the control trial the highest measured mean plasma ammonia concentration 
was 25.7 ~-tmol.r1 • 
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Figure 4.1. Mean blood lactate concentrations at rest and during 3 h of recovery after 
a single 6 s or a single 30 s sprint and for 2 h in the CON trial (n=3). Exercise trial 
statistics: Trial main effect P<0.05, time main effect P<0.05, trial-time interaction 
effect P<0.05. 
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Figure 4.2. Mean blood pH at rest and during 3 h of recovery after a single 6 s or a 
single 30 s sprint and for 2 h in the CON trial (n=3). Exercise trial statistics: Trial 
main effect P<O.OS, time main effect P<O.OS, trial-time interaction effect P<O.OS. 
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Figure 4.3. Mean plasma ammonia concentrations at rest and during 3 h of recovery 
after a single 6 s or a single 30 s sprint and for 2 h in the CON trial (n=3). Exercise 
trial statistics: Trial main effect P<0.05, time main effect P<0.05, trial-time 
interaction effect P<0.05. 
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Hormone responses to cycle ergometer sprinting 
Figure 4.4 shows the mean serum hGH response to a 6 s or a 30 s maximal cycle 
ergometer sprint. In this study, a 30 s sprint resulted in a distinct hGH pulse with 
highest measured mean concentrations of 37.01±6.19 mU.r1 40 min after the sprint. 
This represents a 530% increase in mean serum hGH concentration above resting 
levels. Serum hGH remained elevated for between 90 and 120 min after the 30 s 
sprint. In contrast a 6 s sprint resulted in a smaller hGH response with a highest 
measured mean hGH concentration of 8.01±2.90 mU.r1 40 min after the sprint, 
representing an increase of 217% over resting levels. hGH concentrations returned to 
resting levels less than 60 min after the 6 s sprint. Thus, highest measured mean hGH 
concentrations were more than four and a half times greater following a 30 s sprint 
than they were following a 6 s sprint (P<0.05). In the control trial mean serum hGH 
concentrations did not exceed 0.30 mU.r1• 
The GH response to a 30 s sprint was greater than the response to a 6 s sprint in all 
subjects. However, Figure 4.5 demonstrates the large inter-individual variation in 
serum hGH concentration following a 30 s sprint. Highest measured concentrations 
ranged from 4.5 mU.r1 to 79.3 mU.r1 and time to reach the highest measured 
concentration ranged from 20 min in three subjects to 60 min in one subject. Because 
of these variations it is more appropriate to consider the hGH response as an 
integrated value rather than concentrations at specific time points. Figure 4.6 shows 
the hGH response as a mean area under the curve (AUC); the hGH response to a 30 s 
sprint was more than three and a half times greater than the response to a 6 s sprint 
(3615±180 vs. 963±294 mU.r1, P<0.05). 
Changes in plasma volume 
The estimated changes in mean plasma volume at 5-min postexercise were -5.1±1.4 
%and -14.8±1.0% for the 6 s sprint and 30 s sprint respectively (P<0.05). Estimated 
changes in plasma volume had returned to baseline by 20-min postexercise in the 6 s 
trial and by 40 min postexercise in the 30 s trial. 
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Figure 4.4. Mean serum hGH concentrations at rest and during 3 h of recovery after a 
single 6 s or a single 30 s sprint and for 2 h in the CON trial (n=3). Exercise trial 
statistics: Trial main effect P<0.05, time main effect P<0.05, trial-time interaction 
effect P<0.05. 
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Figure 4.5. Individual serum hGH concentrations at rest and during 3 h recovery after 
a single 30 s sprint. 
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Figure 4.6. Mean integrated 3 h serum hGH concentration (AUC) during recovery 
after a single 6 s or a single 30 s sprint. a P<0.05 
5000 
4500 
-:::: 4000 
::5 
E 3500 
'-" 
u 3000 ;:J 
< 
0 2500 s:: 
0 
E 2000 .... 0 
..r:: 
..r:: 1500 a ~ 
0 bb 1000 
500 
0 
30s 6s 
119 
120 
Discussion 
This study shows that the duration of a bout of maximal sprint exercise determines, 
either directly or indirectly, the magnitude of the growth hormone response. A single 
30 s sprint elicits a marked increase in serum hGH concentration when compared with 
a single 6 s sprint. This study also highlights the inter-individual variability in the 
hGH response to an exercise stimulus. 
The amount of work done in a 30 s sprint is much greater than that completed in a 6 s 
sprint, however, in this study the first 6 s of the 30 s sprint was similar to the 6 s sprint 
itself. Therefore the differences observed in the metabolic and hormonal responses 
between the two sprints were likely to be due to the total amount of work done in the 
sprints as opposed to the work done in the first few seconds of the sprints. It is 
possible that the amount of external work per se determined the hGH concentrations 
during recovery, or it may be that factors such as the different metabolic responses to 
the sprints had a controlling effect on the hGH response. The results for the three 
subjects that completed the control trial indicate that, in these individuals, the hGH 
response seen in the exercise trials was not caused by the procedure of inserting the 
cannula since mean serum hGH concentrations did not exceed 0.30 mU.r1 in the 
control trial. 
Activity in motor centres may directly stimulate pituitary hormone secretion, 
including hGH, during exercise (Kozlowski et al. 1983; Kjaer et al. 1987; Kjaer et al. 
1989; Kjaer et al. 1996a). It is likely that in the present study there was greater 
central motor activity over the duration of the 30 s sprint than there was over the 6 s 
sprint, which could have resulted in a greater hGH response. Takarada et al. (2000) 
found a larger hGH response to low intensity exercise with vascular occlusion than to 
the same amount of exercise without occlusion. When exercise was completed with 
vascular occlusion the relative integrated electromyogram (iEMG) was approximately 
1.8 times greater than when exercise was completed without occlusion. It is possible 
that this reflects the fact that in the hypoxic intramuscular environment motor units of 
more muscle fibres are activated to maintain the same level of force generation 
(Moritani et al., 1992). Miller et al. (1996) have also demonstrated that accumulation 
of lactate promotes recruitment of additional motor units in seriously fatigued 
muscles. In the present study it is likely that there was greater activation level of 
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muscle in the 30 s sprint than in the 6 s sprint since a higher fatigue index was seen 
and a higher blood lactate concentration, reflecting higher muscle lactate 
concentration, was observed. This may have influenced the magnitude of the hGH 
response to the sprints. 
Other work by Kjaer et al. (1996b) suggests that humoral feedback mechanisms and 
autonomic nervous reflexes, without efferent motor centre activity, may exert 
redundant control of pituitary hormonal responses. Gosselink et al. (1998) found 
evidence of a proprioceptive mechanism for the regulation of bioassayable GH but not 
of immunoassayable GH in rats. However, they also showed that stimulation of a 
large muscle mass resulted in elevated immunoassayable GH. It was suggested that 
this might be due to metabolic perturbations, although metabolites were not measured. 
In the present study there would have been more proprioceptive feedback during the 
30 s sprint than there was during the 6 s sprint and it is possible that this 
proprioceptive feedback played a role in the regulation of the hGH response. 
Although Sutton et al. (1969) found a correlation between blood lactate 
concentrations and hGH concentrations, artificial manipulation of lactate levels using 
sodium lactate (Vigas et al., 1974) and lactic acid (Sutton et al., 1976) have been 
shown to have no consistent effect on hGH concentration. This does not, however, 
preclude lactate as a regulator of hGH concentrations as it may be that lactate is 
detected in the muscle and is therefore not related to blood lactate concentrations. 
Other authors have suggested that a combination of factors related to anaerobic 
metabolism are involved in controlling hGH release (Kraemer et al., 1990; Nevill et 
al., 1996b). However, Karagiorgos et al. (1979) found no correlation between any 
anaerobic metabolite or oxygen deficit and hGH concentration. 
There is relatively little literature regarding the time course of the hGH response to 
exercise. Raynaud et al. (1981) considered the time course of plasma growth 
hormone during exercise in humans at altitude. Their results only extend for 90-120 
min post-exercise at which point hGH was still slightly elevated above baseline 
concentrations. Other studies considering the hGH response have similarly taken 
measurements for 2 h post-exercise or less (Prange Hansen, 1973; Raynaud et al., 
1983; Kraemer et al., 1990). The results of the present study show that in response to 
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a 6 s sprint serum hGH concentrations return to pre-exercise levels less than 60 min 
post-exercise. In contrast following a 30 s sprint serum hGH concentrations remain 
above baseline values for between 90 and 120 min post-exercise and that in some 
individuals (Figure 4.5) hGH levels remain elevated for even longer. This is in 
agreement with the findings of Raynaud et al. (1983) who employed a number of 
different types of work but this is the first time it has been demonstrated using sprint 
exercise. 
The highest measured mean concentrations of hGH occurred at around 40 min of 
recovery from both the 6 s and the 30 s sprint. However there was some 
interindividual variation in time to highest measured concentration with a range from 
20 to 60 min after the sprint. Raynaud et al. (1981) suggested that the time sequence 
of hGH should be characterised by parameters other than maximal value, giving mean 
concentration over the period of observation as an example. In view of this, in the 
present study the hGH response was reported using AUC as an integrated measure in 
addition to considering individual time-points. Using this method it was found that 
the hGH response to the 30 s sprint was more than three and a half times greater than 
the response to a 6 s sprint. This is slightly less of a difference than the four and a 
half times greater following a 30 s compared with a 6 s sprint using highest measured 
mean concentrations but is still significant and is, perhaps, a better indicator of the 
overall hGH response to a sprint. 
There was greater variation in the time to highest measured concentration following 
the 30 s sprint than there was following the 6 s sprint. Figure 4.5 shows the large 
inter-individual variation in the serum hGH concentration following a 30 s sprint. It is 
important to note that there was no apparent relationship between any performance 
variable and hGH concentration following a 30 s sprint in these subjects. Therefore 
the large interindividual differences are not a result of differences in performance. 
Raynaud et al. (1983) described this intersubject variability in the hGH response to 
exercise and suggested that care should be taken when drawing conclusions from 
averaged hGH results when there is inherent variability between individuals' 
responses. Previous studies have described their results by dividing subjects into 
groups based on the magnitude of their hGH responses to a stimulus (Raastad et al., 
2000). However, as Figure 4.6 shows, in the present study it is difficult to determine 
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distinct groups of subjects with similar responses, but rather there is a range of highest 
measured concentrations as well as time taken to reach highest measured 
concentration. 
In conclusion this study has determined that the duration of a bout of maximal sprint 
exercise affects the magnitude of the hGH response. The mechanism for this effect is 
not clear, it may be the total amount of work done during the sprint per se or may be 
mediated by other factors. Nevertheless a single 30 s sprint elicits a significant hGH 
response when compared to a 6 s sprint. This study also highlights the inter-
individual variation in the hGH response to a bout of sprint exercise and illustrates the 
care that must be taken when drawing conclusions from data with such variability. 
CHAPTERS 
GROWTH HORMONE RESPONSES TO REPEATED MAXIMAL CYCLE 
ERGOMETER EXERCISE AT DIFFERENT PEDAL SPEEDS 
Introduction 
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Growth Hormone (hGH) is released in a pulsatile manner from the anterior pituitary 
gland. The release of hGH is believed to be regulated by the antagonistic effects of 
the hypothalamic neuropeptides growth hormone releasing hormone (GHRH) and 
somatostatin, with modulation by feedback mechanisms (Dieguez et al., 1988). 
A number of studies, have shown exercise to stimulate hGH release although only a 
few have considered high intensity or sprint exercise (Gordon et al., 1994; Nevill et 
al., 1996b ). A single 30 s treadmill sprint produces a near maximal hGH response 
when compared with the results from pharmacological intervention studies, with hGH 
levels remaining elevated for at least 60 min post-exercise (Nevill et al., 1996b ). 
However, the mechanisms controlling the magnitude of the hGH response to exercise 
are not well understood. Intensity and duration of exercise have been suggested to 
influence the hGH response (Sutton et al., 1976), whilst the possible roles of blood 
lactate (Karagiorgos et al., 1979; Chwalbinska-Moneta et al., 1996), blood pH 
(Gordon et al., 1994) and Oz demand and availability (Vanhelder et al., 1987) have 
also been considered. 
Repeated 30 mm bouts of submaximal exercise have been shown to elicit an 
augmented hGH response (Kanaley et al., 1997). This finding is in contrast to studies 
showing that repeated administration of pharmacological stimuli results in an 
attenuated GH response in rats (Lanzi and Tannenbaum, 1992a; Lanzi and 
Tannenbaum, 1992b) and in humans (Ghigo et al., 1991). In addition, Cappon et al. 
(1994) found that, in humans, three heavy 10 min exercise bouts resulted in 
progressive attenuation of the hGH response to exercise. At present, therefore, the 
evidence regarding the hGH response to repeated bouts of exercise is equivocal. 
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The muscle metabolic responses to maximal cycling at fast (140 rev.min-1) and slow 
(60 rev.min-1) pedal speeds have been shown to be similar despite greater fatigue 
being evident when pedalling at 140 rev.min-1 (Jones et al., 1985). In addition, 
Cherry et al. (1998) found no difference in blood or muscle metabolites when 
sprinting on a friction loaded cycle ergometer against different applied resistance, 
although subjects' performance appeared to recover more quickly following exercise 
involving fewer muscle actions. No studies have yet considered the hormonal 
responses to exercise at different pedal speeds yet if the metabolic response to 
exercise determines the magnitude of the hGH response it is likely that the hGH 
response to exercise would be unaffected by the applied resistance. 
Therefore, the aim of this study was firstly to test the hypothesis that repeated bouts of 
maximal sprint cycling result in an attenuation of the hGH response whilst secondly 
studying, for the first time, the effect of sprint cycling at different pedal speeds on 
hGH release. 
Methods 
Subjects 
Ten healthy male volunteers aged 21 to 32 years (24.5 ± 1.1) gave their written 
informed consent for this study, which had the approval of the Loughborough 
University Ethical Committee. Body mass ranged from 68.2 to 84.5 kg (77.1 ± 1.8) 
and height ranged from 174.4 to 186.0 cm (179.1 ± 1.6). 
Equipment 
The exercise tests were carried out on a modified friction-loaded cycle ergometer 
(Monark 864), which was interfaced to a microcomputer (BBC). This allowed 
instantaneous power output, corrected for flywheel acceleration, to be monitored and 
recorded accurately. Performance data were averaged over 1 s intervals. Lakomy 
(1986) has described in detail the equipment used. A restraining harness was also 
placed around the subjects' waists to prevent them from rising out of the saddle, 
thereby concentrating movement in the lower limbs. The same harness setting and 
saddle height were used for each trial. Toe-clips and tape held the subjects' feet 
securely in the pedals. 
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Protocol 
Mter familiarisation, the subjects arrived in the laboratory after a 4 h fast on two 
separate occasions, completing one trial on each visit using a crossover design. In 
each trial the subjects completed two all-out 30 s efforts separated by one hour of 
passive recovery. During one trial the subjects completed both sprints against an 
applied resistance equal to 7.5% (75 g.kg"1) of their body mass, whereas in the other 
trial both sprints were completed against a resistance equal to 10% (100 g.kg-1) of the 
subject's body mass. The purpose of this intervention was to manipulate the number 
of muscle actions through altering the pedal rate in each trial; the 7.5% body mass 
(FAST) trial would result in a higher average pedal rate than the 10% body mass 
(SLOW) trial. 
Before the first sprint of each trial all subjects completed a standardised sub-maximal 
warm-up on the cycle ergometer, consisting of 4 min pedalling at 60 W, 30 s 
pedalling at 80 Wand 30 s pedalling at 100 W, with 30 s rest between each intensity. 
Five min after the warm-up, the subjects performed the first of two maximal 30 s 
sprints from a rolling start (70 rev.min-1 against no resistance) on the cycle ergometer. 
Subjects were instructed to sprint maximally for the duration of each sprint and were 
encouraged verbally whilst sprinting. 
Following the first sprint subjects remained on the ergometer for 3 min to allow blood 
samples to be taken. They were then seated in an upright position on a couch 
(maintaining approximately the same body position as on the ergometer). Subjects 
remained on the couch and further blood samples were obtained until approximately 
55 min after the sprint. Subjects then returned to the cycle ergometer where a further 
blood sample was taken 60 min after the first sprint. The subjects then performed a 
second maximal 30 s sprint from a rolling start. Subjects remained on the ergometer 
for 3 min and were then seated in an upright position on the couch until 60 min after 
the second sprint for the remainder of the blood samples. 
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Blood sampling and analysis 
Venous blood samples were taken via a cannula inserted into an antecubital forearm 
vein under local anaesthetic (1% lignocaine). Blood samples were taken in a seated 
position at rest (-10 min) and post warm-up (-4 min) before the first sprint and 10 s, 2, 
4, 10, 30 and 60 min after each sprint. The first blood sample was taken at least 15 
min after the cannula was inserted. Patency was maintained by displacing the blood 
contained in the cannula with isotonic saline. Samples were dispensed into three 
tubes: (i) One portion ( 4 to 5 ml) was placed into a lithium heparinised tube (Sarstedt 
LH/5 ml). Blood pH was measured immediately (Radiometer ABL5 pH/blood gas 
monitor) and thereafter, 20 ~-tl aliquots of blood were removed, deproteinized in 2.5% 
perchloric acid and stored at -20°C for later determination of blood lactate 
concentrations (Maughan, 1982). Further aliquots were removed for the measurement 
of haematocrit by microcentrifugation (Hawksley Ltd.) and haemoglobin 
concentration (by the cyanmethaemoglobin method) for the calculation of percentage 
change in plasma volume (Dill and Costill, 1974). (ii) A further 1.5 ml was placed in 
a calcium heparinised eppendorf tube. This was immediately centrifuged and the 
plasma removed and stored at -70°C for the determination of ammonia concentration 
within 48 h (Sigma Diagnostics, kit 171 - C). (iii) The remaining blood ( 4 to 5 ml) 
was allowed to clot for 1 h in a plain tube (Sarstedt Serum Z/5 ml). This was then 
centrifuged at 3°C for 15 min at a speed of 6000 rev.min-1 (Burkard Koolspin) and the 
serum was removed and stored at -70°C for the determination of hGH, insulin and 
cortisol concentrations. Serum hGH, insulin and cortisol were measured by routine 
ELISA. The hGH assay (Medigenix HGH-Biosource) had a sensitivity of 0.11 mU.r 
\ ~n intra-assay coefficient of variation (cv) of 2.1-3.6% and an inter-assay cv of 6.8-
7.1 %. The insulin assay (Medgenix insulin-Biosource) had a sensitivity of 0.15 mU.r 
\ an intra-assay cv of 3.0-5.3% and an inter-assay cv of 5.6-9.8%. The sensitivity of 
the cortisol assay (Milenia, DPC cortisol) was 8.3 nmol.r1 with an intra-assay cv of 
5.9-8.0% and an inter-assay cv of 8.3-9.0%. 
Statistical analysis 
A two-way analysis of variance was used to ascertain whether there were any 
differences in performance between the FAST and SLOW trials (main effect- trial) 
and between the first and second sprints in each trial (main effect- sprint). A three-
128 
way analysis of variance was used to discover any differences in biochemical 
responses between FAST and SLOW trials (main effect - trial), between first and 
second sprints in each trial (main effect- sprint) and the response of each subject with 
respect to time (main effect- time). A two-way analysis of variance was used to find 
any differences in integrated hGH concentrations (area under the curve - AUC) and 
peak values of hGH between trials and sprints. A Pearson product moment 
correlation was also employed. Statistical significance was accepted at the P < 0.05 
level. All results are expressed as mean ±SEM. 
Results 
Performance 
There was no difference in peak (PPO) or mean (MPO) power output in the FAST 
and SLOW trials, however PPO was found to be greater in sprint 1 than sprint 2 (P 
<0.05). Similarly, peak pedal revolutions (PPR) were found to be greater in sprint 1 
than in sprint 2. Both PPR and mean pedal revolutions (MPR) were greater in the 
FAST trial when compared with the SLOW trial (P <0.05). Fatigue, as measured by 
drop in power from PPO to power output at the end of the sprint, was found to be 
greater in sprint 1 than sprint 2 (Table 5.1). 
Table 5.1. Peak (PPO) and mean (MPO) power output, peak (PPR) and mean (MPR) 
pedal rate and Fatigue index for sprints1 and 2 in the FAST and SLOW trials. 
FAST SLOW 
Sprint 1 Sprint 2 Sprint 1 Sprint 2 
PPO (W) 1178 ±51 1132 ± 44 1124 ±59 
707 ±32 
130 ±5 
95 ±4 
56 ±3 
1099 ± 70 
702 ±34 
126 ±5 
95 ±4 
54±3 
MPO(W) 654 ± 21 660 ±22 
PPR (rev.min-1) 159 ±4 154±5 
MPR (rev.min-1) 117±3 118±3 
Fatigue Index (%) 61 ±2 59±2 
* P<0.05 main effect sprint 
t P<0.01 main effect trial 
* P<0.01 main effect sprint 
* 
t:l: 
t 
* 
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Metabolic responses to cycle ergometer sprinting 
The blood lactate, blood pH and plasma ammonia responses are shown in Figures 5.1, 
5.2 and 5.3. Blood lactate and pH responses did not differ between trials (mean peak 
blood lactate, FAST 9.69 ± 0.63 compared with SLOW 9.86 ± 0.58 mmol.r1; mean 
lowest pH, FAST 7.08 ± 0.02 compared with SLOW 7.06 ± 0.02) or sprints (mean 
peak blood lactate, sprint 110.12 ± 0.52 compared with sprint 2 10.40 ± 0.62 mmol.r 
1
; mean lowest pH, sprint 1 7.07 ± 0.02 compared with sprint 2 7.08 ± 0.02). Plasma 
ammonia demonstrated a sprint-time interaction (P <0.05) reflecting higher peak 
ammonia concentrations and faster recovery following sprint 1 than sprint 2, and a 
trial-time interaction (P <0.05) reflecting higher peak ammonia and faster recovery in 
the FAST trial than in the SLOW trial. 
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Figure 5.1. Mean blood lactate concentrations at rest and during 1 h of recovery after 
two 30 s maximal cycle ergometer sprints for the FAST and SLOW trials. Sprint 
main effect n.s., trial main effect n.s., time main effect P<O.Ol, sprint-trial interaction 
effect n.s., sprint-time interaction effect n.s., trial-time interaction effect n.s., sprint-
trial-time interaction effect n.s. 
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Figure 5.2. Mean blood pH at rest and during 1 h of recovery after two 30 s maximal 
cycle ergometer sprints for the FAST and SLOW trials. Sprint main effect n.s., trial 
main effect n.s., time main effect P<O.Ol, sprint-trial interaction effect n.s., sprint-
time interaction effect n.s., trial-time interaction effect n.s., sprint-trial-time 
interaction effect n.s. 
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Figure 5.3. Mean plasma ammonia concentrations at rest and during 1 h of recovery 
after two 30 s maximal cycle ergometer sprints for the FAST and SLOW trials. Sprint 
main effect n.s., trial main effect n.s., time main effect P<O.Ol, sprint-trial interaction 
effect n.s., sprint-time interaction effect n.s., trial-time interaction effect P<O.OS, 
sprint-trial-time interaction effect n.s. 
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Hormone responses to cycle ergometer sprinting 
Figure 5.4 shows the mean serum hGH response to repeated maximal 30-s cycle 
ergometer sprints. The first sprint resulted in a distinct hGH pulse with highest 
measured mean concentrations of 40.8 ± 8.2 and 20.8 ± 6.1 mU.r1 30 min after the 
sprint in the FAST and SLOW trials respectively. Serum hGH was still elevated 60 
min after the first sprint whereas there was no hGH pulse after the second sprint. 
Serum hGH did not show a trial effect (P = 0.08), but there was a sprint effect (P 
<0.05), a time effect (P <0.05) and a sprint-time interaction (P <0.05). The peak hGH 
response for sprint 1 (mean of individual peaks) during the FAST trial was more than 
twice that during the SLOW trial (mean peak hGH, FAST 37.7 ± 6.0 compared with 
SLOW 17.6 ± 3.7 mU.r1, P <0.05). 
Mean integrated hGH concentrations (AUC) for the 1 h period following each sprint 
demonstrated a difference between sprints (mean hGH AUC, sprint 1 1315 ± 243 
compared with sprint 2 729 ± 146 min.mU-1.r\ P <0.01). There was also a trend for 
a lower hGH AUC in the SLOW trial, with nine of the ten subjects following this 
pattern (mean hGH AUC, FAST 1381 ± 231 compared with SLOW 663 ± 162 
min.mu-1.r1, P = 0.06). The insulin (Figure 5.6) and cortisol (Figure 5.7) responses 
were similar in the two trials, although the cortisol response to the first sprint was 
different to that of the second (P <0.05). 
Correlation analysis showed a significant correlation between MPR and hGH AUC in 
both sprints (sprint 1, r = 0.59, P<O.Ol; sprint 2, r = 0.61, P<O.Ol). A significant 
correlation was also found between PPR and hGH AUC (sprint 1, r = 0.48, P <0.05; 
sprint 2, r = 0.58, P <0.01), but not between MPO and hGH AUC (sprint 1, r = 0.31, 
n.s.; sprint 2, r = 0.12, n.s.). PPO and hGH AUC showed a significant correlation 
during the second sprint, but not the first (sprint 1, r = 0.41, n.s.; sprint 2, r = 0.47, P 
<0.05). When considering metabolites, integrated lactate and ammonia 
concentrations showed little correlation with hGH AUC (Lactate, sprint 1, r = 0.08, 
n.s.; sprint 2, r = 0.08, n.s.; Ammonia, sprint 1, r =- 0.04, n.s.; sprint 2, r = 0.08, n.s.) 
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Figure 5.4. Mean serum growth hormone concentrations at rest and during 1 h of 
recovery after two 30 s maximal cycle ergometer sprints for the FAST and SLOW 
trials. Sprint main effect P<O.OS, trial main effect P=O.OB (n.s.), time main effect 
P<O.Ol, sprint-trial interaction effect n.s., sprint-time interaction effect P<O.Ol, trial-
time interaction effect n.s., sprint-trial-time interaction effect n.s. 
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Figure 5.5. Mean serum insulin concentrations at rest and during 1 h of recovery after 
two 30 s maximal cycle ergometer sprints for the FAST and SLOW trials. Sprint 
main effect n.s., trial main effect n.s., time main effect n.s., sprint-trial interaction 
effect n.s., sprint-time interaction effect n.s., trial-time interaction effect n.s., sprint-
trial-time interaction effect n.s. 
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Figure 5.6. Mean serum cortisol concentrations at rest and during 1 h of recovery after 
two 30 s maximal cycle ergometer sprints for the FAST and SLOW trials. Sprint 
main effect P <0.05, trial main effect n.s., time main effect n.s., sprint-trial interaction 
effect n.s., sprint-time interaction effect n.s., trial-time interaction effect n.s., sprint-
trial-time interaction effect n.s. 
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Changes in plasma volume 
The estimated changes in mean plasma volume at 2 min post-exercise were -17.0 ± 
0.6% and -13.7 ± 0.8 %for sprint 1 and sprint 2 and -15.2 ± 0.9% and -15.4 ± 0.7% 
for FAST and SLOW trials (sprint 1 compared to sprint 2, n.s.; FAST compared to 
SLOW, n.s.). All values had returned to baseline by 30 min post-exercise. 
Discussion 
This study demonstrates that a single 30 s sprint is a potent stimulus for hGH release. 
However, if a similar sprint is completed 1 h later there is no hGH response. 
Furthermore, cycling at fast pedal speeds results in greater hGH release than cycling 
at slow pedal speeds (P = 0.06). 
A single 30 s treadmill sprint has been shown to stimulate a near maximal hGH 
response (Nevill et al., 1996b ). The results of the present study show that 30 s of 
maximal cycle ergometer exercise elicits a marked hGH response, although hGH 
responses in this study were not as large as those found by Nevill et al. (1996b ). This 
may reflect the fact that sprint cycling, with movement concentrated in the lower 
limbs, elicits a different hGH response when compared with the treadmill sprinting 
employed in the study by Nevill et al. (1996b). This is supported by Gordon et al. 
(1994) who showed that a 90 s all-out effort on a cycle ergometer elicited a similar 
hGH response to that seen in the present study. 
One hour after the first sprint in each trial blood metabolites had returned to near 
baseline. A second sprint completed at this time resulted in a metabolic response over 
60 min similar to that after the first sprint. In contrast, after 60 min of recovery from 
a single sprint, hGH had not returned to baseline and, furthermore, a second sprint 
completed at this time point did not elicit a hGH response. This finding is in 
agreement with studies demonstrating attenuation of spontaneous and GHRH-
stimulated GH secretion after exogenous GH administration in rats (Lanzi and 
Tannenbaum, 1992a and 1992b). Studies in humans have also demonstrated a 
progressively decreasing hGH response with repeated GHRH administration (Ghigo 
et al., 1991). 
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Kanaley et al. (1997) demonstrated an augmented hGH response to repeated bouts of 
30 min exercise at 70% V02max separated by 60 min of recovery suggesting that 
exercise provides sufficient stimulus to overcome the attenuation of the hGH response 
shown using pharmacological interventions. However, Cappon et al. (1994) found 
that the hGH response to exercise is attenuated by prior exercise. These findings are 
in agreement with those of the present study where a second bout of exercise did not 
elicit a hGH response, demonstrating that the suppression of the hGH response with 
repeated stimuli is not limited to studies employing pharmacological stimuli, but that 
it is also a physiological response. The discrepancy between the findings of the 
present study and those of Kanaley et al. (1997) may be explained by the nature of the 
stimulus for hGH release, since submaximal exercise is known to induce a lesser hGH 
response than that induced by sprint exercise. However, Ghigo et al. (1991), using 
GHRH as a stimulus, induced an initial hGH response similar to that found by 
Kanaley et al. (1997), and yet demonstrated an attenuated hGH response to a second 
stimulus. 
The mechanism by which the hGH response is attenuated is unclear. The depletion of 
pituitary stores as a result of the first bout is unlikely since Kanaley et al. (1997) 
found an augmented hGH response with repeated submaximal exercise. Furthermore, 
Jaffe et al. (1993) suggested that pituitary hGH content far exceeds the amount of 
hGH released in their study and yet they demonstrated a suppression of the hGH 
response to repeated GHRH administration. 
Inhibition of hGH by elevated levels of insulin-like growth factor (IGF-I) is a possible 
explanation for the lack of a hGH response to the second sprint. Jaffe et al. (1998) 
demonstrated that infusion of rhiGF-I suppressed pulsatile and GHRH-stimulated 
hGH secretion in male subjects. However, IGF-I concentration was not measured in 
the present study, and it is not known, therefore, whether IGF-I was elevated at the 
onset of the second sprint. Cappon et al. (1994) found that acute, exercise stimulated 
IGF-I levels had returned to pre-exercise levels within 60 min of recovery. If this 
occurred in the present study, elevated IGF-I was unlikely to be responsible for the 
suppression of the hGH response. 
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Growth hormone can directly inhibit its own release, possibly at the pituitary gland 
(Pontiroli et al., 1991). Since, in the present study, hGH was still elevated at the start 
of the second sprint, hGH autoinhibition may be responsible for preventing a hGH 
response to the second sprint. 
Alternatively, it has been suggested that this auto-negative feedback occurs at the 
level of the hypothalamus, mediated by an increase in somatostatin release and/or a 
decrease in the release of GHRH. Lanzi and Tannenbaum (1992a) demonstrated that 
the irnmunoneutralization of somatostatin prevented the attenuation of spontaneous 
GH release after GH pre-treatment in rats, thus obtaining strong support for a role for 
somatostatin in GH autoregulation. In a further study Lanzi and Tannenbaum (1992b) 
also demonstrated a role for somatostatin in the attenuation of exogenous GHRH 
induced GH release. The understanding that GH receptor mRNA is colocalized in 
somatostatin neurons in the rat hypothalamus (Burton et al., 1991) further supports 
these findings. Peripheral measurements of GHRH and somatostatin would probably 
not reflect hypothalamic secretion but studies employing direct hypophysial-portal 
sampling in nonhuman species suggest that hypothalamic discharges of GHRH 
regulate GH pulses (Frohman et al., 1990) whilst somatostatin may modulate the 
action of GHRH (Thomas et al., 1991). 
It has been suggested that the metabolic response to a 30 s sprint has a part to play in 
hGH release (Nevill et al. 1996b ). However, the results of the present study do not 
support this contention since there was a poor correlation between plasma ammonia 
and serum hGH concentration and blood lactate and serum hGH concentration. When 
comparing FAST and SLOW trials the pH and lactate responses were similar between 
trials and between sprints although the highest measured ammonia concentrations 
were greater in the FAST than the SLOW trial. Jones et al. (1985) demonstrated that 
high and low pedalling rates on an isokinetic ergometer induced similar metabolic 
responses in mixed muscle. Previous work in this laboratory (Cherry et al. 1998) also 
showed that pedalling rate during sprinting on a friction loaded cycle ergometer has 
little effect on the magnitude of the subsequent metabolic response in muscle and 
blood. The results of the present study suggest that the hGH response to a single 30 s 
cycle ergometer sprint might be greater when pedalling at faster speeds (Figure 5.4), 
although this trend was not found to be significant (P = 0.06). This observation 
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indicates that metabolic conditions in muscle and blood might not determine the 
magnitude of the hGH response to all-out sprinting, but that there is another 
mechanism for hGH release. 
Kozlowski et al. (1983) found no causal relationship between blood metabolites and 
hGH but suggested that muscle metabolic receptors may play a role in hGH release. 
The results of the present study do not support this view. However, activity in motor 
centres may directly stimulate pituitary hormone secretion, including hGH, during 
exercise (Kozlowski et al., 1983; Kjaer et al., 1987; Kjaer et al., 1989; Kjaer et al., 
1996a). It is possible that in the present study there was greater central motor activity 
when sprinting at faster pedal speeds, resulting in a greater hGH response. However, 
due to the maximal nature of the exercise it is unlikely that there was any difference in 
motor centre activity in the FAST and SLOW trials. 
Other work by Kjaer et al. (1996b) suggested that humoral feedback mechanisms and 
autonomic nervous reflexes, without efferent motor centre activity, may exert 
redundant control of pituitary hormonal responses. Gosselink et al. (1998) found 
evidence of a proprioceptive mechanism for the regulation of bioassayable hGH but 
not of immunoassayable hGH in rats. However, they also showed that stimulation of 
a large muscle mass resulted in elevated immunoassayable hGH. It was suggested 
that this might be due to metabolic perturbations although metabolites were not 
measured. In the present study there was a poor correlation between metabolites and 
hormones but a significant correlation between PPR and serum hGH and MPR and 
serum hGH, with smaller hGH responses elicited by pedalling at slower speeds. It is 
possible, therefore, that proprioceptive feedback plays an important role in the 
regulation of hGH during sprint exercise. 
In conclusion, this study has demonstrated that a single 30 s cycle ergometer sprint 
elicits a marked hGH response, but that a similar sprint completed 60 min later does 
not result in an increase in hGH concentrations. Human GH autoinhibition may be 
responsible for the suppression of the hGH response to the second sprint, possibly 
mediated by an increase in somatostatin. The present study has also shown that cycle 
ergometer sprinting at faster pedal speeds elicits a greater hGH response than 
pedalling at slower pedal speeds, despite a similar metabolic response. This 
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highlights the potential importance of a proprioceptive mechanism for the regulation 
of hGH release during sprint exercise. 
CHAPTER6 
THE EFFECT OF SIX WEEKS OF SPRINT TRAINING ON THE GROWTH 
HORMONE RESPONSE TO REPEATED MAXIMAL CYCLE ERGOMETER 
EXERCISE 
Introduction 
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A number of studies have identified an increase in human growth hormone (hGH) 
concentration in response to acute exercise, although only a few have considered high 
intensity or sprint exercise (Gordon et al., 1994; Nevill et al., 1996b). The 
mechanisms controlling the magnitude of the GH response to exercise are not well 
understood but it has been suggested that intensity and duration of exercise (Sutton et 
al., 1976), metabolic responses to the exercise bout (Karagiorgos et al., 1979; Gordon 
et al., 1994; Chwalbinska-Moneta et al., 1996) and training state may have a role to 
play. 
The results of Chapters 4 and 5 show that a single 30 s cycle ergometer sprint elicits a 
distinct increase in serum hGH concentration in healthy young men with levels 
remaining elevated for at least 60 min post-exercise. These results support the 
findings of Nevill et al. (1996b) who demonstrated a near maximal GH response to a 
single 30 s treadmill sprint when compared with the results from pharmacological 
intervention studies, although the hGH response to sprint cycling was smaller than the 
response to treadmill sprinting. 
Some studies have considered the effect of training state on the hGH response to an 
acute bout of exercise. There is little agreement between these studies as to whether 
exercise training increases (Bunt et al., 1986; Bonifazi et al., 1998; McCall et al., 
1999), decreases (Bloom et al., 1976; Weltman et al., 1997) or has no effect on 
(Kraemer et al., 1998) the hGH response to a single exercise bout. However only 
three of these studies (Bloom et al., 1976; Bunt et al., 1986; McCall et al., 1999) 
compared the response of trained individuals with untrained control subjects and no 
study has considered the effect of a supervised sprint training regimen on the hGH 
response to a single bout of sprint exercise. In addition, Nevill et al. (1996b) found 
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that sprint-trained individuals had a larger hGH response to a single 30 s sprint than 
endurance-trained individuals. It was suggested that these results could be attributed 
to changes in the metabolic responses to, and the power output achieved during, a 
sprint. Both of these factors may be expected to be altered by a short period of sprint 
training (Nevill et al., 1989), and it is likely, therefore, that hGH secretion will be 
augmented following six weeks of sprint training. 
Cappon et al. (1994) found that, in humans, repeated heavy 10 min exercise bouts 
resulted in progressive attenuation of the hGH response to the exercise. The results of 
Chapter 5 also demonstrate an attenuated hGH response to repeated 30 s cycle 
ergometer sprinting, however, the effect of a period of sprint training on the hGH 
response to repeated sprint exercise has not yet been considered. 
It has been demonstrated that hGH can directly inhibit its own release either at the 
level of the pituitary gland (Pontiroli et al., 1991) or the hypothalamus (Lanzi and 
Tannenbaum, 1992a; Lanzi and Tannenbaum, 1992b). These findings, and the 
understanding that hGH concentrations remain elevated for at least 60 min following 
a single 30 s sprint (Nevill et al., 1996b; Chapters 4 and 5) suggest that, if hGH 
autoregulation is the dominant mechanism for the attenuation of the hGH response to 
repeated exercise, the proposed increases in exercise-induced hGH secretion 
following training will ensure that attenuation of the hGH response will persist. 
Therefore, the purpose of the present study was to test two hypotheses. First, that six 
weeks of participation in a prescribed sprint training programme will improve sprint 
performance and modify the metabolic response to exercise, and that these changes 
will contribute to greater exercise-induced hGH secretion. Second, that training will 
not modify the attenuation of the hGH response to repeated bouts of cycle ergometer 
sprinting. 
Methods 
Subjects 
Sixteen healthy male volunteers gave their written informed consent for this study 
which had the approval of the Loughborough University Ethical Committee. 
Volunteers were randomly assigned to either a training group (n=8), who were 
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prescribed a sprint training program, or a control group (n=8), who continued with 
regular daily activities. Table 6.1 summarises the physical characteristics of the 
subjects in each of the groups. 
Table 6.1. Physical characteristics of the subjects in the training and control groups. 
Age (years) Height (cm) Mass (kg) 
Pre- Post-
mean SEM mean SEM mean SEM mean SEM 
Training 24.0 1.1 179.2 2.6 78.5 2.6 77.7 2.5 
Control 25.4 1.4 178.3 1.2 80.3 2.0 80.2 1.9 
Equipment 
The exercise tests were carried out on a modified friction-loaded cycle ergometer 
(Monark 864), which was interfaced to a microcomputer (BBC). This allowed 
instantaneous power output, corrected for flywheel acceleration, to be monitored and 
recorded accurately. Performance data were averaged over 1 s intervals. Lakomy 
(1986) has described the equipment used in detail. A restraining harness was also 
placed around the subjects' waists in order to prevent them from rising out of the 
saddle, thereby concentrating movement in the lower limbs. The same harness setting 
and saddle height were used for each trial. Toe-clips and tape held the subjects' feet 
securely in the pedals. 
Protocol 
Before any main trials were completed subjects carried out at least three 
familiarisation sessions where they practised sprint starts and became accustomed 
with all-out sprinting on the cycle ergometer. 
Each subject completed two main trials, one before the training period and one 
following the training period. The protocol for these trials was identical. Subjects 
were asked to arrive at the laboratory in a post-absorptive state having refrained from 
heavy exercise for a day prior to each trial. 
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The subjects then completed a standardised sub-maximal warm-up consisting of 4 
min pedalling at 60W, 30 s pedalling at SOW and 30 s pedalling at lOOW. Subjects 
then rested on the ergometer for 5 min before completing an all-out 30 s sprint from a 
stationary start against an applied resistance equivalent to 7.5% (75N.kN-1) of their 
body weight. Subjects then rested whilst seated on a couch (maintaining 
approximately the same body position as on the ergometer) for 60 min before 
repeating the same warm-up routine followed by a second all-out 30 s sprint, against 
the same applied resistance, 5 min later. Subjects then rested on a couch for a further 
60 min. Subjects were instructed to sprint maximally for the duration of each sprint 
and were encouraged verbally whilst sprinting. 
Blood sampling and analysis 
Venous blood samples were taken via a cannula inserted into an antecubital forearm 
vein under local anaesthetic (1% lignocaine). Blood samples were taken in a seated 
position at rest (-10 min) and post warm-up (-4 min) prior to the first sprint and 5, 10, 
20, 30, 40 and 60 min after each sprint. The first blood sample was taken at least 15 
min after the cannula was inserted. Patency was maintained by displacing the blood 
contained in the cannula with isotonic saline. Samples were dispensed into three 
tubes: (i) One portion ( 4/5 ml) was placed into a lithium heparinised tube (Sarstedt 
LH/5ml). Blood pH was measured immediately (Radiometer ABL5 pH/blood gas 
monitor) and thereafter, 20 1-11 aliquots of blood were removed, deproteinized in 2.5% 
perchloric acid and stored at -20°C for later determination of blood lactate 
concentrations (Maughan, 1982). Further aliquots were removed for the measurement 
of haematocrit by microcentrifugation (Hawksley Ltd.) and haemoglobin 
concentration (by the cyanmethaemoglobin method) for the calculation of percentage 
change in plasma volume (Dill and Costill, 1974). (ii) A further 1.5 ml was placed in 
a calcium heparinised eppendorf tube. This was immediately centrifuged and the 
plasma removed and stored at -70°C for the determination of ammonia concentration 
within 48 h (Sigma Diagnostics, kit 171 - C). (iii) The remaining blood ( 4/5 ml) was 
allowed to clot for 1 h in a plain tube (Sarstedt Serum Z/5 ml). This was then 
centrifuged at 3°C for 15 min at a speed of 6000 rev.min-1 (Burkard Koolspin) and the 
serum was removed and stored at -70°C for the determination of GH, insulin and 
cortisol concentrations. Serum GH and cortisol were measured by routine ELISA. 
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The GH assay (Medigenix HGH-Biosource) had a sensitivity of 0.11 mU.r1, an intra-
assay coefficient of variation (cv) of 2.1-3.6% and an inter-assay cv of 6.8-7.1 %. 
The sensitivity of the cortisol assay (Milenia, DPC cortisol) was 8.3 nmol.r1 with an 
intra-assay cv of 5.9-8.0% and an inter-assay cv of 8.3-9.0%. 
Training 
Mter the first main trial had been completed subjects completed a six week training 
period. During this time 9 subjects completed three supervised speed/speed-
endurance sessions per week in the laboratory (Training group) whilst 9 subjects did 
not have to report to the laboratory. Both groups were asked to continue with normal 
activity and training levels throughout the training period so that the training group 
completed the sprint-cycling training in addition to normal activity whilst the control 
group simply maintained normal activity levels. Table 6.2 summarises the training 
sessions completed by the training group. Subjects in the training group completed 
three supervised sessions per week for the six week training period. In most cases 
supervised sessions were separated by at least one day. The first and third session of 
each week was prescribed as a "speed session" and the second session was a "speed 
endurance session". Every session started with a standard warm-up consisting of a 5 
min period of cycling against an applied resistance of 1 kg, 2 min cycling at 60 W and 
30 s at 90 W followed by 5 min of stretching. 
Speed sessions were designed to improve speed and strength particularly over the 
early part of a 30 s sprint. The early sessions (Weeks 1 and 2) were intended to 
facilitate the development of good technique and start to develop strength. Sessions 
against the lighter resistance of 4% ( 40 N.kN-1) body weight were designed for the 
development of pure speed whilst those against the heavier resistance of 11% 
(llON.kN-1) body weight were designed to develop strength. The middle sessions 
(Weeks 3 and 4) were designed to build on speed and strength improvements and 
increase the intensity of the training sessions by increasing the number of sprints 
completed and reducing recovery time between sprints. The final sessions (Weeks 5 
and 6) used the same resistance of 7.5% (75N.kN-1) as that of the main trial. During 
these sessions the number of sprints completed per session were reduced and recovery 
between sprints increased. 
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The training group completed one speed endurance session per week. The purpose of 
these sessions was to facilitate the maintenance of a high pedal speed throughout a 30 
s sprint, thereby increasing the total amount of work performed. During these 
sessions subjects were asked to perform paced efforts rather than maximal sprints. In 
each session subjects were asked to perform two sets of 4 paced efforts achieving 60-
70-70-60% of the work done in their 30 s sprint. Pedal speed was set at 110% of 
mean pedal rate achieved during the subjects' 30 s sprints. Applied resistance was 
then calculated at that pedal speed in order to achieve 60% and 70% of work done in 
their sprints. In weeks 3 and 5 subjects completed a maximal 30 s sprint in place of 
the first set of 4 paced efforts. If any improvement in work done compared with the 
pre-training trial, the 60% and 70% values were recalculated in order that absolute 
work done during the training sessions was increased. 
Table 6.2. Summary of the 18 sessions completed by the training group over the 6 
week period of training. 
SPEED SESSIONS 
WEEK 1 2 3 4 5 6 
SESSION 1 3 4 6 7 9 10 12 13 15 16 18 
WAD 4% 11% 4% 11% 4% 11% 4% 11% 4% 11% 4% 11% 
SPRINTS 2 sets of 8 2setsof8 2 sets of8 2 sets of8 2 sets of 2 sets of 2 sets of 2 sets of 2 sets of 2 sets of 2sets of8 2 sets of8 X6s X6s X6s X6s 10X6s 10X6s 10X6s 10X6s 10X6s 10X6s X6s X6s 
RECOVERY 
Between sprints! 60s I 60s I 50s I 50s I 45s I 45 s I 30s I 30s I 60s I 60s I 90s I 90s 
Between sets 120 s 1 120 s I 90s I 90s I 120s I 120s I 90s I 90s 120 s I 120 s I 180 s I 18o s 
SPEED ENDURANCE SESSIONS 
WEEK 1 2 3 4 5 6 
SESSION 2 5 8* 11 14* 17 
EFFORTS 2sets of4X 30 s 2sets of4 X 30s 1setof4X30s 2sets of 4X 30 s 1 setof4X30s 2sets of4X 30s 
RECOVERY 
Between efforts 120s 90s 75 s 60s I 75 s 120s 
Between sets 300s 300s 
-
300s 
-
300s 
Statistical analysis 
A three-way analysis of variance with repeated measures was used to ascertain 
whether there were any differences in performance between Training and Control 
groups (main effect - group), between pre- and post-training (main effect - training) 
and between the first and second sprints in each trial (main effect- sprint). A four-
way analysis of variance with repeated measures was also used to discover any 
differences in biochemical responses between Training and Control groups (main 
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effect- group), between pre- and post-training (main effect- training), between the 
first and second sprints in each trial (main effect- sprint) and the response of each 
subject with respect to time (main effect- time). Statistical significance was accepted 
at the P < 0.05 level. All results are expressed as mean ±SEM. 
Results 
Performance 
A summary of the performance variables pre- and post-training in the TR and CON 
groups is shown in Table 6.3. Peak power output (PPO) and peak power output 
corrected to the subjects' body mass (PPO-corr) displayed no significant differences 
between Sprint 1 and Sprint 2. A group-training interaction effect was found in PPO 
(P<0.05) and PPO-corr (P<0.05) with a 6% improvement in PPO (1385±56 W to 
1468±51 W) in the TR group after training and a 7% improvement in PPO-corr 
(17.9±0.5 W.kg-1 to 19.1±0.5 W.kg-1), while in the CON group PPO and PPO-corr fell 
by 6% over the training period. 
Mean power output (MPO) and mean power output corrected to the subjects' body 
mass (MPO-corr) were greater in Sprint 2 than Sprint 1 (P<0.05). A group-training 
interaction effect was also found in MPO (P<0.05) and MPO-corr (P<0.05) with a 5% 
improvement in MPO (665±27 W to 696±21 W) in the TR group after training and a 
6% improvement in MPO-corr (8.6±0.2 W.kg-1 to 9.1±0.1 W.kg-1). In the CON group 
MPO and MPO-corr fell by 6% over the training period. 
Peak pedal rate (PPR) demonstrated a group-training interaction effect (P<0.05) and a 
group-training-sprint interaction effect (P<0.05). PPR was 2% faster in the TR group 
after training (161±4 rev.min-1 to 165±2 rev.min-1) whereas PPR in the CON group 
was 3% slower after the training period. 
Mean pedal rate (MPR) was faster in Sprint 2 than Sprint 1 (P<0.05). There was also 
a group-training interaction effect (P<0.05) with a 5% increase in MPR in the TR 
group (118±3 rev.min-1 to 125±1 rev.min-1) after training and a 5% decline in MPR in 
the CON group after the training period. Fatigue index showed no significant changes 
in either the TR or the Con group over the training period. 
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Table 6.3. Peak power output (PPO), PPO corrected for each subject's body mass 
(PPO-corr), mean power output (MPO), MPO corrected for each subject's body mass 
(MPO-corr), peak (PPR) and mean (MPR) pedal revolutions and fatigue index for the 
training and control groups before and after the 6 week training period. a P<O.OS 
group-training interaction effect, b P<O.OS group-training-sprint interaction effect. 
PRE- POST-
Training Control Training Control 
Sprintl Sprint2 Sprint! Sprint2 Sprint! Sprint2 Sprint 1 Sprint2 
PPOCW) 1395(83) 1376(81) 1398(91) 1390(96) 1470(73) 1465(76) 1287(68) 1322(81) a 
PPO-corr (W) 18.0(0.8) 17.8(0.7) 17.5(1.0) 17.4(1.0) 19.2(0.6) 19.1(0.7) 16.2(0.9) 16.6(0.9) a 
MPO(W) 656(40) 674(38) 715(39) 727(44) 692(29) 700(31) 670(31) 687(31) a 
MPO-corr CW) 8.5(0.3) 8.7(0.2) 8.9(0.3) 9.1(0.4) 9.0(0.1) 9.1(0.2) 8.4(0.3) 8.6(0.3) a 
PPR (rev.min"1) 160(6) 163(5) 158(6) 158(6) 165(3) 165(3) 151(5) 153(6) a,b 
MPR (rev.min"1) 117(5) 120(3) 122(5) 124(5) 124(2) 126(2) 115(4) 118(4) a 
Fatigue Index (%) 69(2) 67(1) 62(3) 62(2) 69(1) 68(1) 62(3) 63(3) 
Metabolic responses to cycle ergometer sprinting 
Figure 6.1 shows the blood pH response to Sprint 1 and Sprint 2 in the TR and CON 
groups before and after training. Blood pH was lower in the TR group than the CON 
group (mean lowest measured pH 7.12±0.01 compared with 7.17±0.01, P<O.OS) and 
lower after Sprint 1 than Sprint 2 (mean lowest measured pH 7.13±0.01 compared 
with 7.16±0.01, P<O.OS). The training period did not result in any significant changes 
in pH levels following sprinting although there was a trend for higher pH levels 
during recovery in the training group (group-training interaction effect, P=0.07). 
The blood lactate response is shown in Figure 6.2. Blood lactate concentrations were 
higher in the TR group than the CON group (mean highest measured blood lactate 
13.8±0.5 compared with 10.4±0.4 mmol.r1, P<O.OS) and the blood lactate response 
also showed a group-time interaction effect (P<O.OS). Training resulted in a change 
in the blood lactate response with regard to time, with an increase in highest measured 
mean blood lactate concentrations following the first sprint, but lower blood lactate 
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concentrations for the remainder of recovery from the first sprint and following sprint 
2 (group-training-time interaction effect, P<0.05). 
Figure 6.3 shows the plasma ammonia response to Sprint 1 and Sprint 2 in the TR and 
CON groups before and after the training period. Plasma ammonia concentrations 
were higher after Sprint 1 than after Sprint 2 (mean highest measured plasma 
ammonia 182.2±12.5 !-lmol.r1 compared with 139.0±9.2 !-lmol.r1, P<0.05). Plasma 
ammonia was also lower in the TR group after training (mean highest measured 
plasma ammonia 184.1±9.8 !-lmol.r1 compared with 137.0±11.7 1-lmol.r\ P<0.05) 
whilst plasma ammonia concentrations in the CON group did not change over the 
training period. Plasma ammonia concentration also demonstrated a group-training-
time interaction effect (P<0.05) and a group-training-sprint-time interaction effect 
(P<0.05). 
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Figure 6.1. Mean blood pH at rest and during 1 h of recovery after two 30 s maximal 
cycle ergometer sprints (Sprint 1 and Sprint 2) for the TR (top) and CON (bottom) 
groups pre- and post-training. Main effect group P<0.05, main effect sprint P<0.05, 
training-sprint interaction effect P<0.05. 
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Figure 6.2. Mean blood lactate concentrations at rest and during 1 h of recovery after 
two 30 s maximal cycle ergometer sprints (Sprint 1 and Sprint 2) for the TR (top) and 
CON (bottom) groups pre- and post-training. Main effect group P<O.OS. 
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Figure 6.3. Mean plasma ammonia concentrations at rest and during 1 h of recovery 
after two 30 s maximal cycle ergometer sprints (Sprint 1 and Sprint 2) for the TR 
(top) and CON (bottom) groups pre- and post-training. Main effect sprint P<O.OS, 
group-training interaction effect P<O.OS. 
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Hormone responses to cycle ergometer sprinting 
Figure 6.4 shows the mean serum hGH response to Sprint 1 and Sprint 2 before and 
after the training period in both the TR and CON groups. There were no differences 
in resting hGH concentrations between groups or before and after the training period. 
In all trials Sprint 1 resulted in a distinct hGH pulse with highest measured mean 
concentrations of 20.5±6.2 mU.r1 in the TR group and 11.9±4.7 mU.r1 in the CON 
group between 20 and 40 min after the sprint before the training period. In each case 
hGH was still elevated 60 min after Sprint 1. In contrast, there was no hGH pulse 
following Sprint 2 in any of the trials and there was a significant difference between 
the response to Sprint 1 and Sprint 2 with highest measured mean concentrations of 
13.4±2.4 mU.r1 and 4.6±1.0 mU.r1 respectively (P<0.05). 
There was also a group-training interaction effect for hGH (P<0.05) with highest 
measured mean concentrations lower in all subjects in the TR group after the training 
period resulting in a mean decrease in highest measured mean concentration of over 
40% over the 6 weeks of training (20.5±6.2 mU.r1 vs. 11.6±5.0 mu.rt, P<0.05) with 
no change in the control group (11.9±4.7 mU.r1 vs. 13.0±5.1 mU.r\ n.s.). hGH also 
demonstrated a training-time interaction effect (P<0.05). Mean integrated serum hGH 
concentrations (Area under the curve - AUC) are shown in Figure 6.5. These were 
55% lower in the TR group after the training period with no differences in the CON 
group (TR, 1133±316 vs. 512±241; CON, 741±298 vs. 896±297, P<0.05). 
Figure 6.6 shows the mean serum concentration of cortisol following Sprint 1 and 
Sprint 2 before and after the training period in both the TR and CON groups (n=8). 
There were no differences in the serum cortisol response between groups and no 
differences were seen between pre- and post-training serum cortisol concentrations. 
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Figure 6.4. Mean serum hGH concentrations at rest and during 1 h of recovery after 
two 30 s maximal cycle ergometer sprints (Sprint 1 and Sprint 2) for the TR (top) and 
CON (bottom) groups pre- and post-training. Main effect sprint P<O.OS, group-
training interaction effect P<0.05, training-time interaction effect P<O.OS. 
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Figure 6.5. Mean integrated 2 h serum hGH concentrations (AUC) for the TR and 
CON groups pre- and post-training. Group-training interaction effect P<0.05. 
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Figure 6.6. Mean serum cortisol concentrations (n=8) at rest and during 1 h of 
recovery after two 30 s maximal cycle ergometer sprints (Sprint 1 and Sprint 2) for 
the TR (top) and CON (bottom) groups pre- and post-training. 
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Changes in plasma volume 
The estimated changes in mean plasma volume were greater in Sprint 1 than Sprint 2 
(-5.7±0.5% and -3.9±0.5%, P<0.05). At 5 min postexercise mean estimated changes 
in plasma volume were -17.2±1.4% and -13.9±1.7% for Sprint 1 and Sprint 2 for the 
TR group before training and -16.7±1.1% and -13.8±1.2% for the TR group after 
training with similar changes in the control group (group main effect n.s., group-
training interaction effect n.s). All values had returned to baseline by 40-min 
postexercise. 
Discussion 
The results of the present study have demonstrated that a short period of sprint 
training results in a blunted hGH response to repeated maximal cycle ergometer 
sprinting despite an improvement in sprint performance. In addition, following 
training, the hGH response to a second sprint, completed 60 min after the first, was 
still attenuated indicating that sprint training did not have any effect on hGH 
autonegative feedback. 
In the present study the TR group demonstrated small, but significant, improvements 
in performance, which is in agreement with other studies employing short-term sprint 
or interval training (Boobis et al., 1983; Sharp et al., 1986; Cheetham and Williams, 
1987; Nevill et al., 1989; Stathis et al., 1994). The fact that an improvement in 
performance was seen in the present study demonstrates that a 30 s cycle ergometer 
sprint is sensitive enough to demonstrate a training effect after a short period of sprint 
training despite the concerns of Jacobs et al. (1987). 
It is possible that the mechanism for improved power output was that the number of 
contractions during the 30 s sprint increased following training. Indeed the TR group 
demonstrated an increase in both PPR and MPR after the training period. An increase 
in the number of contractions during the sprint could be facilitated by a decrease in 
the time to peak tension of fibres after training (Nevill et al., 1989). Sprint training 
has been found to reduce time to peak tension of rat soleus muscle by 14% (Staudte 
et al., 1973), whilst high intensity training reduced contraction time in rat soleus 
muscle from 111 to 92 ms (Troup et al., 1986). In addition, Troup et al. (1986) 
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identified an increase in the activity of phosphofructokinase (PFK) following training, 
which has been correlated with actomyosin ATPase activity in rats (Baldwin et al., 
1975), suggesting that the glycogenolytic pathway and actomyosin ATPase activity 
are regulated in parallel. Furthermore a correlation between actomyosin ATPase 
activity and speed of shortening (Barany, 1967) makes it possible that, in the present 
study, sprint training elicited an increase in glycogenolytic rate in parallel with 
increased actomyosin ATPase activity, resulting in the greater PPR and MPR. 
In the present study, training resulted in an increase in highest measured mean post-
exercise blood lactate concentrations in association with an improvement in sprint 
performance, suggesting that, if blood lactate concentrations reflect the accumulation 
of lactate in the muscle, there was an increase in anaerobic energy provision. Boobis 
et al. (1983) identified an improvement in sprint performance following 8 weeks of 
sprint training but did not find a concomitant increase in energy provision from 
glycogenolysis, whilst it has also been suggested that sprint training decreases 
glycolytic rate in rats (Troup et al., 1986) and humans (Harmer et al., 2000) and 
increases the aerobic contribution to sprinting (MacDougall et al., 1998; Harmer et al., 
2000). However, studies employing training protocols utilising very short sprints 
(Linossier et al., 1993), longer sprints (Jacobs et al., 1987), speed-endurance training 
(Stathis et al., 1994; MacDougall et al., 1998) and combined speed and speed 
endurance training (Nevill et al., 1989), have all reported an increase in glycolytic 
rate. Therefore, in the present study, if measurements of blood lactate concentration 
can be extrapolated to muscle lactate accumulation, it is likely that glycolytic rate was 
enhanced following training resulting in an improvement in sprint performance. 
Another possible mechanism for the improved performance and increase in both PPR 
and MPR identified in the present study is an increase in the activity of myofibrillar 
ATPase, since the activity of this enzyme is a very important factor in determining 
this contractile speed (Belcastro et al., 1981). Furthermore, Belcastro et al. (1981) 
observed a 34% increase in myofibrillar ATPase following training. Myofibrillar 
ATPase activity could be enhanced by an increase in the activity of adenylate kinase, 
which has been demonstrated to be higher after strength training in humans (Costill et 
al., 1979). If adenylate kinase activity also increased following sprint training, the 
removal of ADP from the contraction site would be enhanced, via deamination of 
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ADP to IMP, thus reducing the inhibition of ATP utilisation by product inhibition 
(Nevill et al., 1989). 
However, increases in adenylate kinase activity following training might be expected 
to result in greater plasma NH3 concentrations, yet in the present study plasma 
ammonia concentrations were lower in the TR group following training with no 
change in the CON group. Stathis et al. (1994) found sprint training to result in lower 
post-exercise muscle IMP and ammonia concentrations after a 30 s sprint reflecting a 
reduction in the magnitude of ATP depletion, and observed a tendency for plasma 
ammonia concentrations to be lower after 20 min of recovery (P = 0.06) despite being 
higher 2 min after exercise. Snow et al. (1992) also found sprint training to reduce 
exercise-induced increases in plasma ammonia concentrations. A decrease in the 
plasma ammonia response to exercise might reflect reduced muscle ammonia 
concentrations due to an improved balance between ATP hydrolysis and resynthesis 
following training, and this is most likely to be due to increased glycolytic rate (Sharp 
et al., 1986; Jacobs et al., 1987; Nevill et al., 1989). 
In the present study the blood lactate response to exercise was observed to be greater 
following training, suggesting an increase in glycolysis. It is also possible that the 
decrease in the plasma ammonia response to exercise following training might reflect 
an attenuation of the net efflux of ammonia from exercising muscles (Snow et al., 
1992) rather than reduced muscle ammonia accumulation. However, evidence from 
the present study, and other studies, of increased glycolytic flux following sprint 
training (Jacobs et al., 1987; Nevill et al., 1989; Linossier et al., 1993; Stathis et al., 
1994; MacDougall et al., 1998) suggest that the lower exercise-induced plasma 
ammonia concentrations actually reflect reduced muscle ammonia concentrations. 
Sprint training might not, therefore, result in an increase in adenylate kinase activity 
in the present study, and, furthermore, another training adaptation might be 
responsible for any reduction in the time to peak tension of the fibres. 
Sprint training has been reported to improve buffering capacity following 8 wk of 
sprint training (Sharp et al., 1986). In addition, Nevill et al. (1989) reported that 
buffering capacity calculated from changes in lactate concentration and pH during a 
30 s treadmill sprint, showed a tendency to increase following training, and it was 
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suggested that training might result in enhanced efflux from exercising muscles. The 
results of the present study, however, show a trend for a higher blood pH levels 
following training, that is a decrease in the magnitude of the changes in blood pH, and 
do not, therefore, support this suggestion. It is possible, however, that intracellular 
buffering might have improved following training through increases in the major 
buffering components; the bicarbonate buffer system, PCr, Ph protein-bound histidine 
residues and carnosine (Parkhouse and McKenzie, 1984). Improvements in 
intramuscular pH and nonbicarbonate buffering capacity have been shown to occur in 
association with improvements in performance in one-legged sprint exercise 
following training (Bell et al., 1988), and may account for the improvements in sprint 
performance identified in the present study. However, it is likely that the 
improvements in both peak and mean power output are attributable to the recruitment 
of a larger muscle mass (Boobis et al., 1983) in addition to neural adaptations 
(Harridge et al., 1998) as a result of cycle ergometer sprint training. 
In the present study sprint training did not result in any changes in resting hGH 
concentrations. This has previously been identified when comparing sedentary 
individuals and athletes (Bloom et al., 1976; Mikines et al., 1985; Bunt et al., 1986; 
Barreca et al., 1988), sprint-trained and endurance-trained athletes (Nevill et al., 
1996b) and following endurance (Bonifazi et al., 1998) or resistance (Kraemer et al., 
1998; McCall et al., 1999) training. In all of these studies resting hGH concentrations 
are very low, probably accounting for the lack of any differences between groups. In 
contrast, 14 days of detraining of power athletes has been shown to increase resting 
hGH concentrations (Hortobagyi et al., 1993) whereas one year of endurance run 
training has been observed to increase resting hGH concentrations in women 
(Weltman et al., 1992). It is, therefore, unclear what effect training has on resting 
hGH concentrations but the results of the present study suggest that they are not 
significantly affected by sprint training. 
However, in the present study, the hGH response to cycle ergometer sprinting is 
attenuated as a result of sprint training. This is in agreement with Bloom et al. (1976) 
and Weltman et al. (1997) who suggested that the reduced exercise-induced hGH 
concentrations following training may be a result of a combination of reduced hGH 
secretion and enhanced hGH clearance. In support of this contention is the suggestion 
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that the half-life of endogenous hGH is shorter in exercising than resting individuals 
(Thompson et al., 1993). On the other hand, Kraemer et al. (1998) did not find any 
change in the exercise-induced hGH response following resistance training, although 
it was postulated that other hGH variants might adapt differently to training and that 
different variants are different in their biological activity. 
Other studies have demonstrated an increase in the hGH response to endurance (Bunt 
et al., 1986; Bonifazi et al., 1998) and resistance (McCall et al., 1999) exercise and 
insulin-induced hypoglycaemia (Mikines et al., 1985) following training. McCall et 
al. (1999) carried out the only study employing a similar design as the present study, 
that is a short term, longitudinal study with a control group. The increases in post-
exercise hGH concentrations observed by McCall et al. (1999) following training are 
at odds with the result of the present study. It is possible that the reason for this 
difference might be the different types of exercise employed, both during training and 
in performance tests. The present study is the first to consider the exercise-induced 
hGH response following sprint training and it would appear that sprint training results 
in an attenuated hGH response to exercise. This is supported by the fact that 
detrained power athletes have increased resting hGH concentrations (Hortobagyi et 
al., 1993). However, further study of all types of exercise training is required in order 
to improve the understanding of the resulting hGH adaptation. 
It is possible that the decrease in post-exercise hGH concentrations in the present 
study are a result of a sudden increase in training volume for the subjects. Although 
all of the subjects were previously involved in athletic training, an extra three sessions 
per week of the intensity employed in the present study may have resulted in 
overtraining and the changes in exercise-induced hGH concentrations may reflect this. 
Urhausen et al. (1998) observed that pituitary function was impaired in overtrained 
endurance cyclists, including lower exercise-induced hGH concentrations. Resting 
hGH concentrations were unchanged in the overtrained state and there was no change 
in the performance of a 30 s cycle ergometer sprint, although exercise duration to 
exhaustion in a stress test was decreased. In contrast, Fry et al. (1998) measured a 
12% decrement in 1-RM strength performance, but no concomitant decrease in 
exercise-induced hGH concentrations as a result of high intensity resistance 
overtraining. It is, therefore, possible that resistance over-training does not influence 
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resting or exercise-induced hGH concentrations. However, Fry et al. (1998) only 
measured hormone concentrations for 5 min after the exercise bout whereas a longer 
period of measurement might identify changes in the hGH response to exercise. 
There are no data currently available on endocrine responses to sprint overtraining 
and it is therefore difficult to assess whether the results in the present study are a 
manifestation of overtraining. However, other studies have shown a decreased 
exercise-induced hGH response as a result of training and it is unlikely that in all of 
these cases this response was due to overtraining. 
Although there is an attenuated hGH response to exercise after training in the present 
study, it is possible that 24 h secretion of hGH is increased after training. Weltman et 
al. (1992) observed an increase in 24 h integrated hGH concentrations following one 
year of run training in women. It has also been reported that serum IGF-I 
concentrations, taken as a measure of integrated hGH secretion because it is hGH 
dependent, increase following two weeks of endurance training (Roelen et al., 1997). 
A similar trend was described by Weltman et al. (1997) although this increase was not 
found to be significant. It is, therefore, possible that 24 h hGH concentrations are 
elevated following training despite the blunted acute hGH response to exercise. 
The mechanism for hGH release in response to exercise is not fully understood. It has 
been suggested that hGH release is, at least in part, regulated by blood lactate 
concentration (Sutton et al., 1969). However, artificial manipulation of lactate levels 
using sodium lactate (Vigas et al., 1974) and lactic acid (Sutton et al., 1976) have 
shown blood lactate concentrations to have no consistent effect on hGH 
concentration. In addition the hGH response to intermittent exercise has been shown 
to be similar to the response to continuous exercise, despite a greater blood lactate 
response to the intermittent exercise (Karagiorgos et al., 1979). Weltman et al. (1997) 
found that 6 weeks of endurance training resulted in a continuous decrease in blood 
lactate concentration, but observed a different time course for the alteration of hGH 
concentration which appeared to be complete by the third week of training. In the 
present study highest measured blood lactate concentrations following exercise 
increased as a result of training in contrast to the serum hGH response which was 
attenuated. It is possible that training altered the relationship between blood lactate 
and hGH concentrations. However, it is more likely to be further evidence that blood 
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lactate concentration, whilst it may play a part, is not the prime regulator of the hGH 
response to sprint exercise. 
It has been suggested that there is a close link between sympathetic activity and hGH 
secretion (Weltman et al., 1997). Kozlowski et al. (1983) observed serum hGH and 
plasma noradrenaline to be positively correlated at the end of exercise whilst Kjaer et 
al. (1997) suggested that impulses from motor centres directly stimulate both 
sympathoadrenal and pituitary secretion. The relationship between peripheral 
catecholamine concentrations and hGH concentrations are not entirely clear, however, 
since only noradrenaline released in the brain is effective in control of hGH secreton. 
Participation of blood noradrenaline in neuroendocrine control is, therefore, unlikely 
because of the poor permeability of the blood-brain barrier to catecholamines. Brooks 
et al. (1985) observed that the plasma catecholamine response to a 30 s sprint is 
reduced following endurance training whilst Nevill et al. (1989) found the plasma 
catecholamine response to a 30 s sprint to increase following sprint training. In 
addition, higher post-exercise catecholamine concentrations have been identified in 
sprint-trained athletes when compared with endurance-trained athletes (Nevill et al., 
1996b ). Although plasma catecholamines were not measured in the present study it is 
reasonable to assume that the response to sprint training would be similar to that 
observed in the study by Nevill et al. (1989), that is they would increase. The hGH 
response to sprint exercise was, however, attenuated in the present study suggesting 
that peripheral catecholamines might not regulate hGH secretion. 
Central sympathetic tone may, however, be an important regulator of hGH release 
since a-adrenergic blockade has been shown to suppress the hGH response to 
exercise (Sutton & Lazarus, 1974). In addition, clonidine is a specific activator of 
central adrenergic receptors and it's oral administration results in hGH release in 
humans (Casanueva et al., 1984). However the administration of both clonidine and 
atropine, a muscarinic cholinergic receptor blocker which easily crosses the blood-
brain barrier, resulted in complete hGH secretory blockade (Casanueva et al., 1984). 
Administration of atropine in conjunction with physical exercise also resulted in 
complete hGH sectretory blockade suggesting that cholinergic tone is very important 
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in regulating hGH secretion and that a cholinergic synapse is a final common pathway 
of a variety of different stimuli to hGH release (Casanueva et al., 1984). 
Thompson et al. (1993) demonstrated that administration of a cholinergic agonist, 
pyridostigmine, potentiated the increase in hGH concentration following exercise 
probably through the suppression of somatostatin release from the hypothalamus. 
However, it is also possible that cholinergic tone may modulate a2-adrenergic 
neurons. Therefore links seen between sympathetic activity, as measured by 
peripheral catecholamine concentrations, and hGH release may have some relevance 
and it may be that increased cholinergic tone potentiates the hGH response to 
norepinephrine (Thompson et al., 1993) released in response to motor center activity 
(Kjaer et al., 1987). 
At low exercise intensities, however, it is thought that hGH increased central 
cholinergic tone results in suppression of somatostatin release from the hypothalamus, 
producing a weak stimulus for hGH release (Casanueva et al., 1984; Maas et al., 
2000; Thompson et al., 1993). However, Maas et al. (2000) suggest that there is 
complete suppression of somatostatin release at relatively low exercise intensities and 
that when exercise intensity is increased another mechanism must contribute to the 
stimulation of hGH secretion. This mechanism might be an increase in GHRH, 
possibly with the help of a secondary releasing factor which either stimulates different 
receptors to either somatostatin or GHRH or works as an activator for an unknown 
hypothalamic factor (Maas et al., 2000). 
In the present study the subjects performed sprint exercise and therefore, by 
definition, exercise intensity was maximal. Post-exercise highest measured mean 
concentrations of hGH were much lower (11.9±4.7 - 20.5±6.2 mU.r1) than those 
observed at the end of an incremental exhaustive exercise test performed on a cycle 
ergometer (116.8±18.6 mU.r1 ) (Maas et al., 2000) and were more similar to those 
measured after a 20 min constant load cycle ergometer test carried out at an intensity 
above the lactate threshold (-10 mU.r\ one subject reported) (Weltman et al., 1997). 
However, in Chapter 4, the same exercise protocol as that in the present study elicited 
hGH responses twice as great (46±10 mU.r1) as those reported here, indicating that 
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there is a need for further study to elucidate the mechanisms regulating the magnitude 
of the hGH response to sprint exercise. 
Repeated GHRH administration (Ghigo et al., 1991) and repeated exercise bouts 
(Cappon et al., 1994; Chapter 4) have been demonstrated to result in an attenuated 
hGH response. The results of the present study support these earlier findings since, 
before the training period, 60 min after a single sprint, GH had not returned to 
baseline and, furthermore, a second sprint completed at this time point did not elicit a 
GH response. Since, in the present study, hGH was still elevated at the start of the 
second sprint, hGH autoinhibition may be responsible for preventing a GH response 
to the second sprint. hGH can directly inhibit its own release, possibly at the pituitary 
gland (Pontiroli et al., 1991) or at the hypothalamus, mediated by an increase in 
somatostatin and/or a decrease in GHRH (Lanzi and Tannenbaum, 1992a; Lanzi and 
Tannenbaum, 1992b ). In the presnt study the attenuated hGH response to the second 
sprint was still in evidence following the six week training period suggesting that 
hGH autonegative feedback is not affected by training. 
In summary, this study is the first to consider the effect of sprint training on the 
exercise-induced hGH response. A six week period of combined speed and speed-
endurance training resulted in a blunted hGH response to a 30 s maximal cycle 
ergometer sprint despite an improvement in sprint performance. In addition, sprint 
training did not alter the regulation of hGH in response to repeated sprinting, probably 
mediated by hGH autonegative feedback. 
CHAPTER7 
HUMAN GROWTH HORMONE RESPONSES TO REPEATED BOUTS OF 
MAXIMAL SPRINT CYCLING WITH DIFFERENT RECOVERY PERIODS 
BETWEEN BOUTS 
Introduction 
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Exercise has been shown to be a potent stimulus for hGH secretion and the previous 
studies in this thesis have demonstrated that a single 30 s cycle ergometer sprint elicits 
a marked hGH response. Furthermore, hGH release is under the control of a number 
of feedback pathways and Chapters 5 and 6 have shown that repeated bouts of 
sprinting separated by 60 min of recovery result in an attenuated hGH response. It is 
likely that this inhibition of hGH secretion is a result of hGH autoinhibition, possibly 
at the level of the pituitary since hGH levels are still elevated 60 min after a single 30 
s sprint, and it has been shown that inhibition of the GH response to GHRH can occur 
independently of circulating plasma FFA and somatostatin release (Pontiroli et al., 
1991). 
However, it is not known whether the attenuation of the hGH response to sprint 
exercise continues beyond the return of hGH concentrations to resting levels. In 
contrast to the results of the previous studies in this thesis, Kanaley et al. (1997) 
demonstrated an augmentation of the hGH response with repeated bouts of 
submaximal exercise, and gave evidence for greater augmentation of hGH release 
with an increased recovery period. Chapter 4 shows that serum hGH concentrations 
remain elevated for between 90 and 120 min after a single 30 s cycle ergometer sprint. 
The magnitude of the hGH response to a second 30 s sprint performed more than 120 
min after the first sprint has not been studied. 
In addition, it has been suggested that both acute hGH dependent IGF-I release and 
hGH independent IGF-I release with a longer time course can occur following high 
intensity exercise (Cappon et al., 1994). However, increases in IGF-I immediately 
after exercise have not been found in all studies (Wilson and Horowitz, 1987; 
Hagberg et al., 1988) or following different types of exercise (Nguyen et al., 1998). 
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Marcus et al. (1990) demonstrated an acute increase in IGF-1 several hours after rhGH 
administration and it is expected that an exercise-induced increase in circulating hGH 
concentrations will have a similar effect. IGF-1 is known to participate in the GH 
negative feedback system (Tannenbaum et al., 1983), and highly purified IGF-1 has 
been shown to stimulate somatostatin secretion from rat hypothalamus cells in culture 
(Berelowitz et al., 1981). However, the role of both direct and indirect exercise-
induced IGF-1 synthesis and secretion in the regulation of the hGH response to 
repeated sprints is unclear. 
It has been suggested that circulating IGF-1 levels might remain elevated for more 
than 24 h after exercise and Yan et al. (1993) found that IGF-1 immunoreactivity did 
not increase significantly until 4 days after 192 eccentric muscle contractions in rats. 
There is no information available regarding IGF-1 concentrations the day after sprint 
exercise. In addition, the potential influence that variations in resting serum IGF-1 
concentrations might have on the hGH response to exercise performed on consecutive 
days has not been studied. 
Therefore, the aim of the present study was to test three hypotheses. First, that a 
single 30 s cycle ergometer sprint will result in an increase in serum concentrations of 
both hGH and IGF-1, and that IGF-1 will have returned to resting levels within 60 min 
of recovery, whereas hGH levels will remain elevated. The elevated hGH 
concentration will result in an attenuation of the hGH response to the second sprint. 
Second, that by 240 min of recovery hGH levels will have returned to baseline, and 
will not, therefore, moderate the hGH response to a second sprint. However, at this 
time there might be a hGH-induced increase in serum IGF-1 concentrations, which 
will attenuate the hGH response to the second sprint. Third, that IGF-1 concentrations 
might be elevated the day after sprint exercise, which would attenuate the hGH 
response to a 30 s sprint under these conditions. Should IGF-1 levels not be elevated, 
the exercise-induced hGH response will be the same as that observed on the previous 
day. 
Methods 
Subjects 
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Eight healthy male volunteers aged 19 to 26 years (23±1 year) gave their written 
informed consent for this study which had the approval of the Loughborough 
University Ethical Committee. Body mass ranged from 66.3 to 97.4 kg (82.7±4.1 kg) 
and height ranged from 170.1 to 189.1 cm (180.2±2.4 cm). 
Equipment 
The exercise tests were carried out on a modified friction-loaded cycle ergometer 
(Monark 864), which was interfaced to a microcomputer (BBC). This allowed 
instantaneous power output, corrected for flywheel acceleration, to be monitored and 
recorded accurately. Performance data were averaged over 1 s intervals. Lakomy 
(1986) has described the equipment used in detail. A restraining harness was also 
placed around the subjects' waists in order to prevent them from rising out of the 
saddle, thereby concentrating movement in the lower limbs. The same harness setting 
and saddle height were used for each trial. Toe-clips and tape held the subjects' feet 
securely in the pedals. 
Protocol 
Mter familiarisation, the subjects arrived in the laboratory after a 4 h fast on three 
separate occasions, completing one trial on each visit. The subjects then completed a 
standardised sub-maximal warm-up consisting of 4 min pedalling at 60W, 30 s 
pedalling at SOW and 30 s pedalling at lOOW. Subjects then rested on the ergometer 
for 5 min before completing an all-out 30 s sprint from a standing start against an 
applied resistance equivalent to 7.5% (75N.kN-1) of their body weight. Subjects then 
rested whilst seated on a couch (maintaining approximately the same body position as 
on the ergometer) whilst venous blood samples were collected. In Trial A, subjects 
rested on the couch for 60 min before repeating the same warm-up routine followed 
by a second all-out 30 s sprint, against the same applied resistance. Subjects then 
rested on a couch for a further 60 min. In Trial B, subjects rested on the couch for 
240 min following the first sprint, before repeating the same warm-up routine 
followed by a second all-out 30 s sprint, against the same applied resistance. They 
then rested on the couch for a further 90 min whilst further blood samples were taken. 
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Trial C was carried out the day after Trial B and followed the same procedure as the 
other two trials. However, in Trial C, subjects only completed one cycle ergometer 
sprint before resting on the couch for 120 min whilst blood samples were taken. 
Subjects were instructed to sprint maximally for the duration of each sprint and were 
encouraged verbally whilst sprinting. 
Blood sampling and analysis 
Venous blood samples were taken via a cannula inserted into an antecubital forearm 
vein under local anaesthetic (1% lignocaine). The first blood sample was taken at 
least 15 min after the cannula was inserted. Patency was maintained by displacing the 
blood contained in the cannula with isotonic saline. In Trial A blood samples were 
taken in a seated position at rest (-10 min) and then post warm-up (-4 min), prior to, 
and 5, 10, 20, 30, 40 and 60 min after each sprint. In trial B, blood samples were 
taken at rest and then post warm-up, prior to, and 5, 10, 20, 30, 40, 60, 90, 120, 180 
and 240 min after the first sprint and post warm-up, prior to, and 5, 10, 20, 30, 40, 60 
and 90 min after the second sprint. In Trial C, blood samples were taken at rest and 
then post warm-up, prior to, and 5, 10, 20, 30, 40, 60, 90 and 120 after the single 
sprint. 
Samples were dispensed into three tubes: (i) One portion ( 4 to 5 ml) was placed into a 
lithium heparinised tube (Sarstedt LH/5ml). Blood pH was measured immediately 
(Radiometer ABL5 pH/blood gas monitor) and thereafter, 20111 aliquots of blood were 
removed, deproteinized in 2.5% perchloric acid and stored at -20°C for later 
determination of blood lactate concentrations (Maughan, 1982). Further aliquots were 
removed for the measurement of haematocrit by microcentrifugation (Hawksley Ltd.) 
and haemoglobin concentration (by the cyanmethaemoglobin method) for the 
calculation of percentage change in plasma volume (Dill and Costill 1974). (ii) A 
further 1.5 ml was placed in a calcium heparinised eppendorf tube. This was 
immediately centrifuged and the plasma removed and stored at -70°C for the 
determination of ammonia concentration within 48 h (Sigma Diagnostics, kit 171 - C). 
(iii) The remaining blood ( 4 to 5 ml) was allowed to clot for 1 h in a plain tube 
(Sarstedt Serum Z/5ml). This was then centrifuged at 3°C for 15 min at a speed of 
6000 rev.min-1 (Burkard Koolspin) and the serum was removed and stored at -70°C 
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for the determination of hGH, cortisol IGF-1 and FFA concentrations. Serum GH, 
serum cortisol and serum IGF-1 were measured by routine ELISA. The GH assay 
(Medigenix HGH-Biosource) had a sensitivity of 0.11 mU.r1, an intra-assay 
coefficient of variation (cv) of 2.1-3.6% and an inter-assay cv of 6.8-7.1 %. The 
sensitivity of the cortisol assay (Milenia, DPC cortisol) was 8.3 nmol.r1 with an intra-
assay cv of 5.9-8.0% and an inter-assay cv of 8.3-9.0%. The IGF-1 assay (R&D 
Systems Europe) had a sensitivity of 0.026 ng.mr1, and intra-assay cv of 3.5-4.3% 
and an inter-assay cv of 7.5-8.3%. 
Statistical analysis 
One-way analysis of variance with repeated measures was used to discover any 
differences in sprint performance. Two-way analysis of variance with repeated 
measures was used to discover any differences in the blood lactate (n=7), blood pH, 
plasma ammonia (n=7) and serum hGH and cortisol responses for 60 min following 
sprint 1 and sprint 2 in Trial A and in Trial B as well as when comparing the first 
sprint in Trial B (day 1) with the sprint in Trial C (day 2). One-way analysis of 
variance was also used to discover any differences in the serum IGF-1 concentrations 
pre-exercise and 5 min after sprints 1 and 2 in Trial A and in Trial B, and the sprints 
performed on day 1 and day 2. A paired t test was used to discover any differences 
between serum FFA concentrations prior to sprints 1 and 2 in Trial A and in Trial B, 
and the sprints performed on day 1 and day 2. Statistical significance was accepted at 
the P < 0.05 level. All results are expressed as mean ±SEM. 
Results 
Performance 
Table 7.1 is a summary of the performance variables in all of the trials. Peak power 
output (PPO) was similar in both sprints in trial in Trial A and in both sprints in Trial 
B. However, PPO was significantly greater in Trial B sprint 1 compared with a sprint 
completed 24 h later (Trial C). There were no other differences in sprint performance 
variables either between sprints in Trial A and Trial B, or between the first sprint in 
Trial B (day 1) and the sprint in Trial C (day 2). 
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Table 7.1. Peak (PPO) and mean (MPO) power output, peak (PPR) and mean (MPR) 
pedal revolutions, total work done and fatigue index in sprints 1 and 2 in Trial A and 
Trial B and the sprint completed in Trial C (n=8). 
Trial A 
Sprint1 
PPO (W) 1538±65 
MPO(W) 719±30 
PPR (rev.min-1) 165±4 
MPR (rev.min-1) 122±3 
Work Done (J) 21488±944 
Fatigue Index (%) 70±2 
a P<0.05 vs. Trial B sprint 1 
Trial A (60 min recovery) 
Metabolic responses to sprinting 
Sprint 2 
1494±70 
725±32 
164±4 
123±3 
21757±959 
68±2 
Trial B Trial C 
Sprint 1 Sprint2 
1528±85 1487±75 1464±67a 
711±32 699±31 709±32 
163±5 162±5 162±4 
120±3 119±3 120±3 
21311±959 20980±940 21265±953 
70±2 70±1 68±2 
Figure 7.1a shows the blood lactate responses to sprint 1 and sprint 2 in Trial A (n=7). 
There were no differences in the blood lactate responses to the sprints, with highest 
measured mean blood lactate concentrations of 11.8±0.6 mmol.r1 following sprint 1 
and 11.5±0.8 mmol.r1 following sprint 2 (n.s.). There was, however, a sprint-time 
interaction effect (P<0.05) reflecting faster recovery of blood lactate concentrations 
towards pre-exercise values following sprint 2. There were no differences in the 
blood pH responses to sprint 1 and sprint 2 in Trial A (Figure 7.1b). Similarly, there 
were no significant differences in the plasma ammonia responses to the sprints in 
Trial A (Figure 7.1c, n=7), although there was a trend for a reduced highest measured 
mean plasma ammonia concentration, and for a slower recovery towards pre-exercise 
concentrations following the second sprint (sprint-time interaction effect, P=0.06, 
n.s.). Pre-exercise serum FFA concentrations (Table 7.2, n=7) were not significantly 
different prior to sprint 1 and sprint 2. 
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Hormone and growth factor responses to sprinting 
Figure 7 .2a shows the serum hGH responses to sprint 1 and sprint 2 in Trial A. Sprint 
1 resulted in a significant elevation of serum hGH concentrations with highest 
measured mean hGH concentrations of 27.3±6.9 mU.r1 40 min after the sprint. 
Serum hGH concentrations were still elevated above pre-exercise levels after 60 min 
of recovery. Sprint 2 did not induce a further increase in serum hGH concentrations. 
Human GH demonstrated a sprint-time interaction effect (P<0.05), whilst the area 
under the curve for hGH (hGH AUC- 919±246 vs. 451±129) and mean highest 
measured hGH concentrations (hGH peak- 28.8±6.8 vs. 14.1±3.4 mU.r1) were both 
significantly higher in recovery from sprint 1 compared with sprint 2 (both P<0.05). 
Serum IGF-1 responses to sprint 1 and sprint 2 in Trial A are shown in Figure 7.2b 
(n=3). Both sprints resulted in an acute increase in circulating IGF-1 level, although 
serum IGF-1 concentrations did not remain elevated for longer than 10 min. Table 7.3 
(n=7) shows that serum IGF-1 concentrations were significantly elevated above pre-
exercise concentrations 5 min after both sprint 1 and sprint 2 (sprint 1, 199±16 vs. 
238±22 mg.mr1, sprint 2, 191±13 vs. 227±23 mg.mr1, time main effect, P<0.05) and 
there was no difference in the responses between sprints. Serum cortisol 
concentrations (Figure 7.2c) increased following sprint 1 with highest measured mean 
levels of 656.6±63.5 nmol.r1 20 min into recovery. After this point serum cortisol 
concentrations fell and there was no further increase following the second sprint 
(sprint main effect, P<0.05). 
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Figure 7.1. Mean blood lactate concentrations (a, n=8), mean blood pH (b, n=8) and 
mean plasma ammonia concentrations (c, n=7) at rest and during 60 min of recovery 
from sprint 1 and sprint 2 in Trial A. 
(a) time main effect (P<O.OS), sprint-time interaction effect (P<O.OS). 
(b) time main effect (P<O.OS). 
(c) time main effect (P<O.OS), sprint-time interaction effect (P=0.06, n.s.) 
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Figure 7.2. Mean serum hGH concentrations (a, n=8), mean serum IGF-1 
concentrations (b, n=3) and mean serum cortisol concentrations ( c, n=8) at rest and 
during 60 min of recovery from sprint 1 and sprint 2 in Trial A. 
(a) time main effect (P<O.OS), sprint-time interaction effect (P<O.OS). 
(c) sprint main effect (P<O.OS), time main effect (P<O.OS 
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Metabolic responses to sprinting 
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Figure 7.3a shows the blood lactate responses to sprint 1 and sprint 2 in Trial B (n=7). 
Both sprints resulted in an increase in blood lactate concentrations, but the blood 
lactate response to the first sprint was greater than that following the second sprint, 
with highest measured mean blood lactate concentrations of 10.9±0.9 mmol.r1 and 
10.1±0.8 mmol.r1 following sprint 1 and sprint 2, respectively (main effect sprint, 
P<0.05). There was also a statistically significant difference between the blood pH 
responses following the two sprints with lowest measured mean pH of 7.20±0.01 
following sprint 1 and 7.21±0.02 following sprint 2 (main effect sprint, P<0.05). 
Plasma ammonia demonstrated a difference between sprints as well as a sprint-time 
interaction effect (Figure 7.3c, n=7). The response to the second sprint was lower 
than that to the first sprint with highest measured mean plasma ammonia 
concentrations of 182.3±25.9 and 143.8±24.0 f .. tmol.r1 after sprint 1 and sprint 2, 
respectively (main effect sprint, P<0.05). Table 7.2 (n=7) shows that pre-exercise 
serum FFA concentrations were higher before sprint 2 than before sprint 1 (P<0.05). 
Hormone and growth factor responses to sprinting 
The serum hGH responses to sprint 1 and sprint 2 in Trial Bare shown in Figure 7.4a. 
Sprint 1 resulted in a marked hGH response with highest measured mean serum hGH 
concentrations of 25.3±7.4 mU.r1 40 min into recovery. Serum hGH levels returned 
to pre-exercise concentrations within 120 min following sprint 1 and remained low for 
the rest of the 240 min recovery period. Sprint 2 resulted in a further hGH response, 
although there was a tendency for the exercise-induced increases in hGH levels to be 
smaller than those seen after sprint 1 with highest measured mean hGH concentrations 
of 13.2±3.9 mU.r1 40 min after sprint 2 (sprint main effect, P=0.10, n.s.). There was 
also a trend for lower hGH AUC (10223±280 vs. 483±134, P=0.09, n.s.) and hGH 
peak (34.1±10.0 vs. 16.8±5.0 mU.r1, P=0.09, n.s.) following sprint 2. 
Figure 7.4b shows the serum IGF-1 responses to sprint 1 and sprint 2 for 3 subjects. 
Serum IGF-1 concentrations did not increase following sprint 1, and although serum 
IGF-1 appeared to be elevated above pre-exercise levels 180 min after sprint 1, this 
elevation did not extend to 240 min of recovery. Table 7.3 (n=7) shows that serum 
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IGF-1 concentrations were not elevated 5 min after sprint 1 (208±21 vs. 208±23 
mg.mr1) and that IGF-1 concentrations were not elevated 240 min after sprint 1. In 
addition, despite a small acute increase in serum IGF-1 concentrations following sprint 
2, there were no significant differences between the IGF-1 responses to sprint 1 and 
sprint 2. There was no acute increase in serum cortisol concentrations following 
sprint 1 and from 40 min of recovery serum cortisol levels decreased to 331.1±24.8 
nmol.r1 immediately prior to the second sprint (240 min of recovery). Sprint 2 
resulted in an acute increase in serum cortisol concentrations to 427.6±52.4 nmoi.rl, 
and there was a difference in the cortisol response compared to sprint 1 (main effect 
sprint, P<0.05). 
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Figure 7.3. Mean blood lactate concentrations (a, n=8), mean blood pH (b, n=8) and 
mean plasma ammonia concentrations (c, n=7) at rest and during 240 min and 90 min 
of recovery from sprint 1 and sprint 2, respectively, in Trial B. 
(a) sprint main effect (P<0.05), time main effect (P<0.05). 
(b) sprint main effect (P<0.05), time main effect (P<0.05). 
(c) sprint main effect (P<0.05), time main effect (P<0.05), sprint-time interaction 
effect (P<0.05). 
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Figure 7.4. Mean serum hGH concentrations (a, n=8), mean serum IGF-1 
concentrations (b, n=3) and mean serum cortisol concentrations ( c, n=8) at rest and 
during 240 min and 90 min of recovery from sprint 1 and sprint 2, respectively, in 
Trial B. 
(a) sprint main effect (P=O.lO, n.s.), time main effect (P<0.05). 
(c) sprint main effect (P<0.05), time main effect (P<0.05). 
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Trial C (24 h recovery) 
Metabolic responses to sprinting 
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There were no significant differences in the blood lactate (Figure 7.5a, n=7) and blood 
pH (Figure 7.5b) responses to sprint 1 in Trial B (day 1) and the sprint completed 24 h 
later, in Trial C (day 2). However, plasma ammonia responses to the sprint on day 2 
were smaller than those observed following the first sprint on day 1 (Figure 7.5c, n=7) 
with highest measured mean plasma ammonia concentrations of 182.3±25.9 11mol.r1 
5 min after the sprint on day 1 and 143.9±12.7 11mol.r1 5 min after the sprint on day 2 
(main effect sprint, P<0.05). Table 7.2 shows that pre-exercise serum FFA 
concentrations were higher on day 2 than on day 1 (P<0.05). 
Hormone and growth factor responses to sprinting 
Figure 7.6a shows the hGH responses to sprint 1 in Trial B (day 1) and the sprint in 
Trial C (day 2). As described above, the sprint on day 1 induced a marked increase in 
serum hGH concentrations with highest measured mean hGH concentrations of 
25.3±7.4 mU.r1. There was no difference between the hGH responses to this sprint 
and the sprint on day 2, although highest measured mean serum hGH concentrations 
were 27.1±9.7 mU.r1 20 min after the sprint on day 2, 20 min earlier than the highest 
measured mean serum hGH concentrations following the sprint on day 1. Serum IGF-
1 concentrations following the sprints on day 1 and day 2 are shown in Figure 7.6b 
(n=3). Table 7.3 (n=7) shows that pre-exercise serum IGF-1 concentrations were 
higher on day 1 than on day 2 (208±21 vs. 186±21 mg.ml-1, sprint-time interaction 
effect, P<0.05). In addition, there was an acute increase in serum IGF-1 levels 
following the sprint on day 2, which was not evident following the sprint on day 1, 
although this only resulted in serum IGF-1 concentrations similar to those found on 
day 1 (208±23 vs. 211±25 mg.mr1). There were no differences in the serum cortisol 
responses to the sprints on day 1 and day 2. 
181 
Figure 7.5. Mean blood lactate concentrations (a, n=8), mean blood pH (b, n=8) and 
mean plasma ammonia concentrations (c, n=7) at rest and during 120 min of recovery 
from sprint 1 in Trial B (day 1) and the sprint in Trial C (day 2). 
(a) time main effect (P<O.OS). 
(b) time main effect (P<0.05). 
(c) sprint main effect (P<0.05), time main effect (P<O.OS). 
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Figure 7.6. Mean serum hGH concentrations (a, n=8), mean serum IGF-1 
concentrations {b, n=3) and mean serum cortisol concentrations ( c, n=8) at rest and 
during 120 min of recovery from sprint 1 in Trial B (day 1) and the sprint in Trial C 
(day 2). 
(a) time main effect (P<O.OS). 
(c) time main effect (P<O.OS). 
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Table 7.2. Mean serum FFA concentrations (mol.r1) before sprint 1 and sprint 2 in 
trals A, B and C (n=7) 
Trial 
A 
B 
c 
Sprint 1 
0.29±0.07 
0.33±0.09 
0.33±0.09 
a, sprint 1 vs. sprint 2, P<0.05 
Changes in plasma volume 
Sprint 2 
0.15±0.02 
0.76±0.11 
0.46±0.11 
a 
a 
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All of the sprints in Trials A, B and C resulted in a change in plasma volume with 
mean estimated changes in plasma volume of -17.3±1.2, -14.1±1.1, -13.4±1.2, -
10.0±1.7 and -14.8±0.8% 5 min post-exercise in Trial A, sprint 1 and sprint 2, Trial 
B, sprint 1 and sprint 2, and Trial C respectively. There were no differences in 
estimated change in plasma volume following the two sprints in Trial A, or between 
Trial B sprint 1 and the sprint in trial C. However, the mean estimated changes in 
plasma volume were greater in the first sprint than the second sprint in Trial B (-
3.9±1.0 vs. 0.2±1.1 %, main effect sprint, P<0.05). 
Table 7.3. Mean serum IGF-1 concentrations (ng.mr1) at rest and 5 min after sprint 1 
and sprint 2 in trials A, Band C (n=7). 
Sprint1 Sprint2 
Trial Pre-ex Post-ex Pre-ex Post-ex 
A 199±16 238±22 191±13 227±23 a 
B 208±21 208±23 190±20 210±31 
c 208±21 208±23 186±21 211±25 b 
a, time main effect, P<0.05 
b, sprint-time interaction effect, P<0.05 
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Discussion 
The results of the present study demonstrate an attenuation of the hGH response to 
repeated bouts of cycle ergometer sprinting separated by 1 h of passive recovery. The 
hGH response to exercise was not fully restored within 4 h of recovery. However, the 
hGH responses to sprints completed at the same time on consecutive days were 
similar. A single 30 s cycle ergometer sprint has also been shown to induce an acute 
increase in IGF-1. 
As shown in previous chapters, this study demonstrates that a single 30 s cycle 
ergometer sprint elicits a marked hGH response, and serum hGH concentrations were 
still elevated 60 min after the sprint. Furthermore, the results show once again that a 
second sprint, completed 60 min after the first, does not stimulate further hGH 
secretion since both mean highest measured hGH concentrations and hGH AUC were 
significantly lower following the second sprint. These results add further support for 
a role of hGH autofeedback, possibly at the level of the pituitary. 
The results of the present study also demonstrate an acute increase in serum IGF-1 
concentrations following both sprints in Trial A. Highest measured serum IGF-1 
concentrations were identified 5 min after each sprint and were significantly different 
from resting concentrations, however, they had returned to close to pre-exercise levels 
within 10 min of recovery. Previously, conflicting results have been reported 
regarding the effect of exercise on IGF-1. Neither Wilson and Horowitz (1987) nor 
Hagberg et al. (1988) identified an increase in IGF-1 following exercise. However, 
Bang et al. (1990) reported a 26% increase in IGF-1 10 min into a 30 min exercise 
bout and suggested a rapid time course for the exercise-induced hGH response. In 
agreement with these findings, Cappon et al. (1994) identified an increase m 
circulating IGF-1 of -14% after high intensity submaximal exercise, whilst Weller et 
al. (1999) observed increased levels of circulating IGF-1 immediately, but not 1 h, 
after an incremental exercise test to exhaustion. The results of the present study 
support these findings, demonstrating a rapid time course for the acute IGF-1 response 
to sprint exercise. 
This acute increase in serum IGF-1 concentrations appears to be independent of serum 
hGH concentrations, since, in the present study, highest measured mean IGF-1 
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concentrations occurred -35 mm before the highest measured mean hGH 
concentrations following the first sprint in Trial A. Cappon et al. (1994) came to the 
same conclusion since they demonstrated that the time courses of the IGF-1 and hGH 
responses to 10 min of exercise at -70% V02max were similar. In contrast, it took 
several hours before an increase in IGF-1 concentrations was detected following rhGH 
administration in healthy elderly individuals (Marcus et al., 1990). Further evidence 
for a hGH independent increase in IGF-1 levels following exercise in humans is the 
finding that the magnitude of the IGF-1 response to high intensity submaximal 
exercise was not altered despite the attenuation of the exercise-induced hGH response 
by a high fat meal (Cappon et al., 1994). 
However, the mechanism for the acute exercise-induced increase in circulating IGF-1 
levels is unclear. Most current evidence suggests that circulating IGF-1 is of hepatic 
origin (Maiter et al., 1988) but as explained in the previous paragraph, hepatic IGF-1 
synthesis and secretion takes longer than 5 min (the time taken to reach mean highest 
measured IGF-1 in the present study). It has been shown that IGF-1 peptide 
concentrations are elevated in muscles undergoing hypertrophy (Adams and Haddad., 
1996) and that hGH might have a role in this local IGF-1 production (Adams and 
McCue, 1998). Zanconato et al. (1994) found 4 wk of treadmill exercise training in 
female rats to result in an increase in hepatic and skeletal muscle IGF-1 mRNA. 
However, additional GH suppression, with GHRH antisera, inhibited IGF-1 mRNA to 
a greater extent in the liver than in skeletal muscle suggesting a less important role of 
hGH in the regulation of muscle IGF-1 production than hepatic IGF-1 production. It 
is, therefore, possible that exercise results in an acute increase in local production of 
IGF-1 in exercising muscle by an, as yet, unidentified mechanism. Furthermore, acute 
exercise-induced increases in circulating IGF-1 levels, rather than being of hepatic 
origin, might reflect an efflux of locally produced IGF-1 from exercising muscles. 
Since serum IGF-1 concentrations in the present study were not elevated following 60 
min of recovery from a single sprint but, in fact, returned to pre-exercise levels within 
10 min of recovery, it seems that circulating IGF-1 does not play a role in the 
attenuation of the hGH in repeated bouts of sprint exercise separated by 1 h of 
recovery. These results do not, however, preclude the possibility that IGF-1 produced 
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locally in the pituitary gland is involved in the regulation of the hGH response to 
repeated exercise. 
The increased serum hGH concentrations following a single sprint were found to have 
returned to pre-exercise levels within 2 h of recovery and remained at this resting 
concentration until 4 h of recovery (when the second sprint was completed in Trial B). 
The second sprint in Trial B was observed to elicit a hGH response although there 
was a trend for a decreased hGH AUC (P=0.09) and a lower mean highest measured 
hGH (P=0.09). These results suggest that there is still a degree of inhibition of hGH 
release, but that it is not as great as that seen in Trial A with 60 min of passive 
recovery. However, the fact that serum hGH concentrations are at resting levels 
immediately prior to the second sprint in Trial B suggests that hGH does not play a 
direct role in the inhibition of its own secretion in this trial. 
In contrast to both sprints in Trial A, the first sprint in Trial B did not result in an 
acute increase in circulating IGF-I concentrations. The explanation for this is unclear, 
but it does suggest that more research is required to further the understanding 
exercise-induced IGF-I synthesis and release. However, it was expected that there 
would be an increase in circulating IGF-I levels in response to the increase in serum 
hGH concentrations following the first sprint in Trial B, since Marcus et al. (1990) 
demonstrated an acute increase in IGF-I several hours after rhGH administration. In 
addition, Bengtsson et al. (1993) identified a dose-dependent increase in circulating 
IGF-I concentrations following rhGH treatment of hGH deficient adults. In the 
present study there does appear to be a small elevation in IGF-I concentrations 180 
min after the first sprint in 3 subjects, however, by 240 min of recovery (when the 
second sprint was performed in Trial B), serum IGF-I concentrations were not 
significantly different from levels prior to sprint 1. In fact, in 6 out of the 7 subjects 
for which IGF-I was measured 240 min after sprint 1, serum IGF-I concentrations 
were lower than they were before sprint 1. These findings, in addition to the 
observation that IGF-I immunoreactivity only started to increase 2 days after, and 
were not significantly elevated until 4 days after, a single bout of 192 eccentric 
contractions in rats (Yan et al., 1993), suggest that hGH-induced increases in 
circulating IGF-I following exercise take longer than 4 h to become apparent. It is 
unlikely, therefore, that IGF-I played a significant role in the attenuation of the hGH 
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response to the second sprint, and, therefore, that another mechanism is responsible 
for the tendency for an attenuated hGH response in this trial. 
The results of the present study demonstrate that serum FFA concentrations are 
elevated 4 h after a single 30 s sprint. Administration of rhGH has been shown to 
induce a significant increase in lipid intermediates, with concentrations of NEF A, 3-
hydroxybutyrate and glycerol remaining elevated for at least 300 min (Vahl et al., 
1997), which is 60 min longer than the recovery period in the present study. In 
addition, Casanueva et al. (1987) demonstrated that FFA can block hGH secretion 
directly at the pituitary gland. In the present study it is, therefore, possible that hGH 
secretion induced by the first sprint elicited an increase in lipolysis and, consequently, 
increased circulating FFA levels. In turn these FFA might participate in the 
attenuation of the hGH response to a second sprint performed after 4 h of recovery 
from the first sprint. 
Another possibility is that the smaller hGH response to sprint 2 compared with sprint 
1 in Trial B is a reflection of the smaller metabolic response, measured by lower 
blood lactate and plasma ammonia concentrations and higher pH levels, to sprint 2. A 
number have studies have suggested that afferent signals from metabolic receptors in 
the muscles might have a role in the regulation of the hGH response to exercise 
(Kozlowski et al., 1983; Nevill et al., 1996b; Viru et al, 1998). However, Kjaer et al. 
(1996a) used electrically induced cycling exercise with afferent sensory blockade by 
epidural anaesthesia and found no decrease in the hGH response compared with 
voluntary cycling at the same V02 as in electrically induced exercise. Exercising 
under hypoxic conditions, which enhances the metabolic response in exercising 
muscle, would be expected to increase both afferent feedback from muscle metabolic 
receptors and blood-mediated afferent signalling. Kjaer et al. (1999) demonstrated 
that in subjects cycling under hypoxic conditions, epidural anaesthesia did not blunt 
the hGH response. These results infer that afferent feedback from muscle metabolic 
receptors is not as important as a blood-borne feedback mechanism in the regulation 
of the hGH response to exercise. 
However, previous studies in this thesis have provided evidence that blood lactate 
concentrations and blood pH do not play an important role in the regulation of hGH 
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secretion, since there was a divergence between both blood lactate and blood pH 
responses and the hGH response to exercise at different pedal speeds (Chapter 5). In 
addition, following 6 weeks of sprint training there is an attenuation of the hGH 
response to sprint exercise, with no significant differences in the blood pH response to 
sprinting, and increased highest measured post-exercise blood lactate concentrations 
(Chapter 6). However, the relationship between plasma ammonia and serum hGH 
concentrations is less clear, and in Trial B there is a tendency for both to be lower 
following sprint 2. It is, therefore, possible that plasma ammonia might play a role in 
the regulation of the hGH response to exercise, and that lower plasma ammonia 
concentrations following sprint 2, rather than any feedback effects, are responsible for 
the smaller hGH response to the second bout of sprinting. 
It is possible that when the second sprint was completed in Trial B, exercise-induced 
hGH release was still attenuated, but that this was overcome by the subjects' fasted 
states since they had not eaten for -18 h at the onset of the second sprint. However, it 
is unlikely that fasting alone increased serum hGH concentrations in the present study 
since Galbo et al. (1981) did not identify any change in resting hGH concentrations 
following a 59 h fast. Conversely, Galbo et al. (1981) measured higher plasma hGH 
concentrations during exercise in healthy men following a 59 h fast compared with an 
overnight fast. It is, therefore, possible that there was an interaction between fasting 
and exercise, a possibility that was discussed by Kanaley et al. (1997) as an 
explanation for an augmented hGH response to repeated submaximal exercise. It is 
also possible that the time of day that each sprint was completed affected the hGH 
response since, in Trial B, the first sprint was completed between 0930 and 1000, and 
the second sprint between 1330 and 1400 by all subjects. However, Galliven et al. 
(1997) and Scheen et al. (1998) did not observe any changes in the magnitude of the 
hGH response to exercise at different times of day. Therefore, the tendency for a 
reduced hGH response to the second sprint in Trial B is probably a result of feedback 
inhibition rather than the effect of time of day. 
Resting serum IGF-1 concentrations in Trial C were lower than resting concentrations 
in Trial B, the previous day. This might reflect a change in the pattern of nocturnal 
hGH secretion as a result of exercise on the previous day. Kern et al. (1995) found 
that moderate intensity exercise altered the temporal pattern of nocturnal hGH 
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secretion without affecting total hGH secretion. Specifically, peak hGH was 
diminished during early sleep. Since IGF-I concentration correlates better with 
pulsatile than basal GH secretion (Maiter et al., 1988) this might reduce the 
circulating concentration of IGF-I the following morning. 
In contrast to the first sprint in Trial B, the 30 s cycle ergometer sprint in Trial C did 
induce an acute IGF-I response, although there was no significant difference between 
the trials because of the lower resting serum IGF-I concentrations in Trial C. These 
lower resting IGF-I levels in Trial C might be expected to result in an augmented 
hGH response to sprinting due to reduced inhibition by IGF-I, whilst, conversely, 
higher pre-exercicse serum FFA concentrations day 2 than on day 1 might be 
expected to attenuate the hGH response to exercise. However, there was no 
difference in the hGH response to the sprint in Trial C, compared with the first sprint 
in Trial B. In contrast, there was a lower plasma ammonia response to the sprint 
performed on day 2 compared with the sprint performed on day 1. This dissociation 
between the hGH response to exercise and the plasma ammonia response to exercise 
suggests that increased plasma ammonia concentrations following sprint exercise 
might not play a major role in the regulation of the exercise-induced hGH response. 
The PPO attained during the sprint performed on day 2 was also lower than that in the 
sprint on day 1. This did not significantly alter the hGH response to the exercise bout 
and suggests that PPO is not an important factor in the regulation of the hGH response 
to sprint exercise. It appears, therefore, that sprint exercise on the previous day does 
not affect the hGH response to sprint exercise via an IGF-I mediated, or any other, 
mechanism. 
In conclusion, this study has provided further evidence for direct hGH autoinhibition 
when exercise bouts are separated by 1 h of passive recovery. However, a longer 
recovery period does not fully restore the hGH response to sprint exercise despite a 
return of serum hGH concentrations to resting levels. This divergence between the 
hGH response and pre-exercise hGH levels suggests the presence of another 
mechanism for the inhibition of hGH in response to repeated exercise. Since IGF-I 
concentrations were not elevated immediately prior to a second sprint performed 4 h 
after the first, it is possible that this mechanism is a hGH-induced increase in 
circulating FFA. There is a tendency for resting IGF-I levels to be lower following 
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exercise on the previous day, possibly as a result of a change in the temporal pattern 
of nocturnal hGH secretion. However, the hGH response to cycle ergometer sprinting 
is not altered by these changes and the hGH response to sprint exercise on consecutive 
days is similar. 
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CHAPTERS 
GENERAL DISCUSSION 
The aim of this chapter is to draw together the findings of the experimental studies in 
this thesis, to provide an explanation for these findings and to consider how the results 
of the four studies have provided information regarding the mechanisms regulating 
the release of hGH as a result of exercise. 
8.1. Main findings 
• Chapter 4 describes the time course of the hGH response to a single cycle 
ergometer sprint of either 6 s or 30 s duration. A single 30 s sprint resulted in a 
marked (530 %) increase in serum hGH concentrations with highest measured 
mean serum hGH concentrations more than four and a half times greater than 
those seen when a single 6 s sprint was performed. A 30 s sprint also resulted in 
the exercise-induced elevation in hGH concentrations persisting for between 90 
and 120 min, compared with less than 60 min following the 6 s sprint. In 
addition, this study highlights the inter-individual variation in the hGH response to 
sprint exercise, identifying differences in both the magnitude of, and time taken to 
reach highest measured hGH concentrations across the 8 subjects taking part in 
the study. 
• Chapter 5 investigates the effect of repeated sprinting on the hGH response to 
exercise, and also considers the influence that manipulating pedalling rate, and 
therefore the number of muscle actions, during a sprint has on hGH secretion 
following sprinting. As in Chapter 4, a single 30 s sprint was found to be a potent 
stimulus for hGH release, and hGH concentrations remained elevated for at least 
60 min. However, when a second sprint was completed 60 min after the first, 
hGH concentrations were not elevated any further, that is there was no hGH 
response to the second sprint. In addition, cycle ergometer sprinting at a faster 
pedalling rate (more muscle actions) resulted in a hGH response twice as great as 
that following a sprint performed at a slower pedalling rate, despite a similar 
metabolic response. 
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• Chapter 6 considers the effect of a short-term sprint-training programme on the 
hGH response to repeated sprint exercise. Six weeks of combined speed and 
speed-endurance training resulted in a blunting of the hGH response to a maximal 
cycle ergometer sprint compared with pre-training values, despite improvements 
in sprint performance. In addition, in both pre- and post-training repeated sprint 
tests, the first sprint resulted in a marked hGH response whilst the hGH response 
to the second sprint, completed 60 min later, was attenuated (as in Chapter 5). 
• Chapter 7 examines the effect of the length of the recovery period between sprints 
on the attenuation of the hGH response to the second sprint, with particular 
reference to the possible role of IGF-L Consistent with the results in Chapters 5 
and 6, there was a marked increase in serum hGH concentrations following a 
single 30 s sprint, but when a second sprint was completed 60 min later there was 
no further hGH response. Extending the recovery period to 4 h did not result in 
complete restoration of the hGH response to the second sprint, however, 24 h of 
recovery was sufficient to allow full recovery of the hGH response to a further 30 
s sprint. 
8.2. The time course of the hGH response to a single sprint 
Relatively few studies have considered the time course of the hGH response to 
exercise, and none have previously described the entire time course of the hGH 
response to sprint exercise. The study that is described in Chapter 4 required subjects 
to complete a single 6 s sprint in one trial, and a single 30 s sprint in another. A single 
6 s sprint resulted in an increase serum hGH concentrations of more than 200 % over 
resting levels, and levels remained elevated for 60-90 min after exercise. 
In all four experimental chapters a single 30 s sprint resulted in a marked hGH 
response with highest measured mean serum hGH concentrations ranging from 11.9 
to 37.7 mU.r1 observed between 20 and 40 min after exercise. The results of the 
study in Chapter 4 demonstrate highest measured mean hGH concentrations to be 
more than four and a half times greater following a 30 s sprint than following a 6 s 
sprint. Furthermore, in all four experimental chapters hGH concentrations remained 
elevated for at least 60 min of recovery. In Chapters 5 and 6, and in one trial in 
Chapter 7, subjects completed a second 30 s sprint at this time and therefore it was not 
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possible to study the entire time course of the hGH response to sprint exercise. 
However, in Chapters 4 and 7 serum hGH concentrations following exercise were 
studied for 3 h and 4 h, respectively. Serum hGH concentrations were found to 
elevated for between 90 and 120 min in both studies, although, the results in Chapter 
4 show that whilst hGH concentrations had returned to pre-exercise values within 120 
min of recovery in most individuals, they remained elevated for a longer period in 
some subjects. Kraemer et al. (1990) found that various resistance exercise protocols 
resulted in different hGH responses, however, in each case hGH concentrations had 
returned to pre-exercise values within 2 h. Raynaud et al. (1983) studied the time 
course of the hGH response to different types of work, but only measured hGH 
concentrations for 60-90 min post-exercise, at which point hGH levels were still 
elevated in some, but not all, subjects. 
The results of the study reported in Chapter 4 show inter-subject variability in both 
the magnitude of the hGH response to sprint exercise, and the time taken to reach 
highest measured concentrations (Figure 4.5). These findings are consistent with 
those of Raynaud et al. (1983), and this inter-subject variability provides some 
explanation for the difficulty encountered in the identification of relationships 
between hGH concentrations and other variables when attempting to determine the 
mechanisms responsible for exercise-induced hGH secretion. Furthermore, the 
variation between subjects in the results of these studies highlights the difficulty of 
reporting data of this nature, and supports the suggestion of Raynaud et al. (1983) that 
care must be taken when drawing conclusions from averaged hGH results when there 
is inherent variability between the responses of different individuals. It has been 
suggested that it is possible to determine distinct groups of individuals with similar 
patterns of hGH response to exercise (Raastad et al., 2000), however, such 
distinctions could not be made in the study in Chapter 4. This finding suggests that 
there is a continuum covering the inter-subject variation in the magnitude of the hGH 
response to sprint exercise which cannot be clearly divided into sub-groups according 
to subjects' 'responsiveness'. 
In summary, the results in this thesis show that sprint exercise results in a marked 
increase in serum hGH concentrations. In addition, both the magnitude and duration 
of the hGH response to sprint exercise is determined, directly or indirectly, by the 
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length of the sprint. Furthermore, the results of this thesis have highlighted the inter-
individual variation in the hGH response to exercise, identifying that care must be 
taken when drawing conclusions from data with such inherent variability. 
8.3. The effect of repeated exercise on the hGH response to sprinting 
In the studies reported in Chapters 5, 6 and 7 the same protocol was used in at least 
one of the trials, whereby subjects completed a single sprint followed by 60 min of 
recovery, at which time a second 30 s sprint was performed. The results of all three 
studies identified a marked increase in serum hGH concentrations after the first, but 
not the second, sprint. Similarly, all three studies found that 60 min after the first 
sprint, that is immediately before the performance of a second sprint, hGH 
concentrations were still above pre-exercise concentrations. This finding is consistent 
with the observation in Chapter 4 that serum hGH concentrations remain elevated for 
between 90 and 120 min in most subjects, and even longer in some. 
Other studies have identified an attenuation of spontaneous and GHRH-stimulated 
GH secretion after exogenous GH administration in rats (Lanzi and Tannenbaum 
1992a; 1992b ), whilst repeated GHRH administration in humans has been shown to 
result in a progressively decreasing hGH response (Ghigo et al., 1991). However, the 
evidence regarding the effect of repeated bouts of exercise on the hGH response is 
less equivocal. Kanaley et al. (1997) demonstrated an augmented hGH response to 
repeated bouts of 30 min exercise at 70 % V02max, whilst Cappon et al. (1994) found 
that the hGH response to 10 min of constant power cycling, at an intensity 
corresponding to 50 % of the difference between lactate threshold and V02max, was 
attenuated by prior exercise. The results of the studies in this thesis support the 
results of Cappon et al. (1994), suggesting that repeated high intensity exercise will 
result in an attenuation of the hGH response. 
The mechanism by which the hGH response is attenuated is not entirely clear. Jaffe et 
al. (1993) suggested that pituitary stores of hGH far exceed the amount released as a 
result of a single GHRH stimulus, yet they identified a suppression of the hGH 
response to repeated GHRH administration. Roles for circulating hGH, IGF-1 and 
FF A have all been suggested in the attenuation of the hGH response to repeated 
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stimuli. In Chapters 5, 6 and 7 it was evident that hGH was elevated as a result of the 
first sprint, and was still high after 60 min of recovery, when the second sprint was 
performed. Growth hormone has the ability to inhibit its own release, possibly at the 
level of the pituitary gland (Pontiroli et al., 1991), or at the hypothalamus. 
Immunoneutralisation of somatostatin has been shown to reverse rhGH-induced 
attenuation of spontaneous and GHRH-induced GH release in rats (Lanzi and 
Tannenbaum, 1992a; 1992b). These results and the finding of Burton et al. (1991), 
who demonstrated a colocalisation of GH receptor mRNA in somatostatin neurons in 
the rat, provide strong evidence of a role for somatostatin in hGH-induced negative 
feedback, however, a possible role for GHRH secretion cannot be excluded (Lanzi 
and Tannenbaum, 1992a). 
The results of the study described in Chapter 7 show that 4 hr of recovery from a 
single 30 s cycle ergometer sprint allows time for exercise-induced elevations in hGH 
to return to pre-exercise levels. This finding is consistent with the results in Chapter 
4, which demonstrate that hGH concentrations return to pre-exercise levels within 120 
min of recovery in most subjects. However, when a second sprint was performed 
after 4 h of recovery from the first sprint there was a tendency for the hGH response 
to be attenuated. Therefore hGH secretion was still inhibited, but it is unlikely that 
this is a result of hGH inhibition of its own release. 
It might be expected that there would be an increase in circulating IGF-I 
concentrations within 4 h as a result of the hGH response to the first sprint, since 
Marcus et al. (1990) demonstrated an acute increase in IGF-I several hours after rhGH 
administration. In addition, an increase in circulating IGF-I might inhibit hGH 
secretion, since a purified IGF-I preparation has been shown to inhibit GH release 
from rat pituitary cells in culture, and to stimulate a dose-dependent release of 
somatostatin release from hypothalarnic explants (Berelowitz et al., 1982). The 
infusion of rhiGF-I has also been shown to suppress pulsatile and GHRH-stimulated 
hGH secretion in male subjects (Jaffe et al., 1998). However, in the study in Chapter 
7, serum IGF-1 concentrations increased immediately after exercise, probably as a 
result of increased local production of, and increased efflux from exercising muscles 
of, IGF-I, but returned to pre-exercise levels within 10 min. Whilst there appeared to 
be an increase in circulating IGF-I concentrations 3 h after the first sprint, IGF-I had 
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returned to pre-exercise levels by 4 h, when the second sprint was performed. 
Therefore inhibition of hGH secretion cannot be explained by increased circulating 
IGF-I concentrations in this trial. In contrast, the results of the study reported in 
Chapter 7 demonstrate elevated FF A concentrations after 4 h of recovery after a 
single 30 s sprint. It is possible, therefore, that a hGH-induced increase in FFA might 
explain the inhibition of hGH release after 4 h of recovery, since Casanueva et al. 
(1987) demonstrated that FFA can block hGH secretion directly at the pituitary gland. 
In summary, in the studies in this thesis it is likely that, where hGH levels are elevated 
as a result of prior exercise, further hGH release is inhibited either directly at the 
pituitary or at the level of the hypothalamus, through an increase in somatostatin 
release and/or a decrease in GHRH secretion. With a longer period of recovery, 
which allows exercise-induced elevations in hGH to return to pre-exercise values, the 
attenuation of the hGH response to a second bout is still apparent, possibly as a 
consequence of elevated FF A concentrations. It is likely that increased circulating 
IGF-I concentrations might also have a role in the inhibition of hGH secretion, but the 
failure to raise serum IGF-I levels in the study in Chapter 7, means that it is not 
possible to comment on this mechanism from the results of this thesis. 
8.4. The effect of training on the hGH response to sprinting 
A number of studies have considered the effect that exercise training has on the hGH 
response to exercise, but there is little agreement between the results of these studies. 
Concentrations of hGH following exercise have been found to increase (Bunt et al., 
1986; Bonifazi et al., 1998; McCall et al., 1999), decrease (Bloom et al., 1976; 
Weltman et al., 1997), and not to change (Kraemer et al., 1990) as a result of training. 
The results of the study presented in Chapter 6 show that 6 wk of sprint training 
resulted in an attenuation in the hGH response to sprint exercise. This finding is not 
consistent with the only other short-term, longitudinal training study that includes a 
control group (McCall et al., 1999), which found that resistance training resulted in an 
augmentation of the hGH response to exercise. The reason for the conflicting 
findings of these two studies is unclear, but it might reflect the different exercise 
performed during both training and testing. 
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It is possible that the attenuation of the exercise-induced hGH response in the study in 
Chapter 6 is a result of a sudden increase in training volume for the subjects. 
Overtrained endurance cyclists have been found to have impaired pituitary function 
(Urhausen et al., 1998), although Fry et al. (1998) did not identify a decrease in 
circulating hGH concentrations after exercise following high intensity resistance 
overtraining. It is, therefore, not clear whether overtraining might have occurred in 
the study reported in this thesis. However, when the results of this study and those of 
Bloom et al. (1976) and Weltman et al. (1997), who also observed a decrease in 
exercise-induced hGH secretion, are taken together, it is unlikely that in all of these 
cases an attenuation of the hGH response was a manifestation of overtraining. 
The results of the study described in Chapter 6 also demonstrate that 6 wk of sprint 
training does not alter resting hGH concentrations, and this finding is in agreement 
with training studies employing short-term endurance (Bonifazi et al., 1998) and 
resistance exercise (Kraemer et al., 1998; McCall et al., 1999). However, Weltman et 
al. (1992) found that a longer period (1 yr) of endurance training resulted in an 
increase in resting hGH concentrations in women. In addition, it has been shown that 
resting IGF-I concentrations, which have been used as measure of integrated hGH 
secretion since it is hGH dependent, increase after two weeks of endurance training 
(Roelen et al., 1997). From the results of the study in Chapter 6 it appears that short-
term sprint training does not alter resting hGH concentrations, but it might be that this 
is due to the fact that resting hGH levels are so low that detection is difficult. In order 
to satisfactorily determine the effect of training on hGH concentrations at rest, more 
than one resting sample would have to be taken. In fact, it would be interesting to 
determine the effect of exercise training on integrated 24 h hGH secretion, which 
would provide a much clearer picture regarding the effect of training on hGH 
regulation. 
8.5. Possible mechanisms regulating hGH secretion following snrint exercise 
The roles of lactate and pH 
The study described in Chapter 5 demonstrates that manipulating pedalling rate, and 
therefore the number of muscle actions, during sprint exercise has no effect on the 
blood lactate or blood pH response to that exercise. This finding is in agreement with 
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studies manipulating pedalling rate during maximal isokinetic cycling (Jones et al., 
1985) and sprinting on a friction loaded cycle ergometer (Cherry et al., 1998). 
However, the results in Chapter 5 show that there is a greater hGH response to 
sprinting against an applied resistance of 7.5 %, compared with 10 %, of the subjects' 
body mass, that is there was a greater hGH response when pedalling at faster pedal 
speeds. The divergence in the blood pH and blood lactate and the serum hGH 
responses suggests that blood lactate and blood pH do not regulate the secretion of 
hGH during exercise. 
The findings of the study reported in Chapter 6 demonstrate that 6 wk of sprint 
training results in an attenuation of the hGH response to exercise, despite an increase 
in highest measured mean blood lactate concentrations, and no change in blood pH 
responses. These findings are consistent with those of Weltman et al. (1997) who 
described a different time course for the alteration of hGH and blood lactate 
concentrations as a result of exercise, following 6 wk of endurance training. The 
results of these studies suggest that blood lactate and pH do not regulate exercise-
induced hGH secretion. 
Whilst significant correlations have been found between blood lactate and muscle 
lactate (Cheetham et al., 1986), and between blood pH and muscle pH (Allsop et al., 
1990), poor predictability of muscle pH from a given value of blood pH has also been 
reported (Allsop et al., 1990). If the blood lactate concentrations and blood pH levels 
found in Chapters 5 and 6 in this thesis reflect muscle lactate concentrations and 
muscle pH levels, it would appear that there is neither a role for blood-borne 
regulation of hGH secretion by lactate and pH, nor a role for metabolic receptors in 
skeletal muscle. Kjaer et al. (1999) blocked afferent nerve activity using epidural 
anaesthesia, and found that this did not blunt the hGH response to leg cycling 
exercise, suggesting that exercise is not modulated by afferent feedback from muscle 
metabolic receptors. This finding supports the conclusions of the studies in this 
thesis. 
Proprioceptive feedback 
It has been suggested that activity in motor centres might directly stimulate pituitary 
hormone secretion during exercise (Kozlowski et al., 1983; Kjaer et al., 1987; Kjaer et 
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al., 1989b; Kjaer et al., 1996b). In the study in Chapter 5 it is possible that sprinting 
at faster pedalling rates was associated with greater motor centre activity, resulting in 
a larger hGH response. However, the sprints performed in these trials were, by 
definition, maximal, making a higher level of motor centre activity at faster pedalling 
rates unlikely. Another possibility is that proprioceptive feedback from exercising 
muscles provides a stimulus for hGH release. Kjaer et al. (1996b) suggested that 
humoral feedback mechanisms and autonomic nervous reflexes might exert redundant 
control of pituitary hormonal responses, whilst Gosselink et al. (1998) found evidence 
of a proprioceptive mechanism for the regulation of bioassayable, but not 
immunoassayable, GH in rats. Significant correlations between both PPR and MPR 
and serum hGH concentrations in the study in Chapter 5 suggest that a proprioceptive 
mechanism might also play a role in the regulation of immunoassayable hGH during 
sprint exercise. 
A possible role for plasma ammonia 
In Chapter 5 it was found that the plasma ammonia response to sprint exercise at 
faster pedalling rates was greater than the response to sprinting at slower pedalling 
rates. Although no significant correlations were found, the plasma ammonia response 
to sprinting at different pedalling rates followed the same trend as the serum hGH 
responses. In addition, Chapter 6 identified a decrease in both the plasma ammonia 
response to sprint exercise and the serum hGH response to exercise following 6 wk of 
sprint training. In Chapter 7, when a second sprint was completed 240 min after the 
first, there was a tendency for both the plasma ammonia and the serum hGH 
responses to be lower than they were following the first sprint, although a 24 h 
recovery period resulted in a dissociation between the hGH response and plasma 
ammonia response to the sprint on the second day. However, the results of all of 
these studies, taken together, indicate that there might be an association between 
circulating ammonia concentrations and hGH secretion. 
It has been proposed that blood ammonia produced during exercise might have direct 
access to the brain, and, since it is neurotoxic, it has been implicated as having a role 
in the development of central fatigue (Mutch and Banister, 1983; Banister and 
Cameron, 1990). Increases in brain ammonia stimulates glutamine synthesis, which is 
the most important alternate pathway for ammonia disposal in the brain (Lockwood et 
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al., 1979). The increased synthesis of glutamine from glutamate and ammonia is 
catalysed by an increase in the activity of glutamine synthase, which is found mainly 
in the glial cells. Furthermore, glutamine synthesis results in decreased brain 
glutamate content, and, as glutamate is a precursor for GABA synthesis, enhanced 
glutamine synthesis as a result of increased brain ammonia levels might also decrease 
GABA levels (Cooper and Plum, 1987). Intravenous injection of ammonium acetate 
in rats has been found to result in a decrease in the brain content of glutamate and 
GABA between 15 and 30 min after administration (Kanamatsu and Tsukada, 1999). 
In addition, exercise to exhaustion was found to result in increased brain glutamine in 
both trained and untrained rats, whilst brain glutamate were slightly decreased only in 
trained rats, which ran more than four times longer than control rats and had -50% 
higher brain ammonia after exercise (Guezzenec et al., 1998). 
The use of 13C labelling in rats has demonstrated that the anaplerotic pathway 
contributes to y-aminobutyric acid (GABA) and glutamate synthesis through 
trafficking of glutamine from glia to neuron (Kanamatsu and Tsukada, 1999). In the 
same study, intravenous injection of ammonium acetate was found to increase the rate 
of contribution of the anaplerotic pathway to brain amino acid synthesis, probably due 
to an increase in pyruvate carboxylase (PC) activity (Kanamatsu and Tsukada, 1999). 
Lapidot and Gopher (1994) reported that the anaplerotic pathway could account for 16 
% of GABA synthesis, whilst Kanamatsu and Tsukada (1999) estimated a 13 % 
contribution after glucose administration, and a 23 % contribution when glucose 
administration was combined with that of ammonium acetate. It seems, therefore, 
that blood ammonia produced as a result of exercise might cross the blood-brain 
barrier, resulting in increased activity of glutamine synthase and a consequent 
decrease in brain glutamate and GABA content. However, it is likely that an 
additional increase in PC activity maintains TCA pool intermediates allowing 
continued synthesis of glutamate via a-keto glutarate. 
Both glutamate and GABA are known to act as neurotransmitters. Glutamate is an 
exitatory amino acid (EAA), whilst GABA is an inhibitory amino acid, and it has 
been suggested that there might be a role for both in the control of anterior pituitary 
hormone secretion. In this thesis, smaller increases in plasma ammonia 
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concentrations and serum hGH concentrations were observed following sprinting at 
slower pedalling rates compared with faster pedalling rates (Chapter 5), and following 
a 6 wk training period (Chapter 6). It is possible that the smaller plasma ammonia 
responses to sprint exercise at slower pedal speeds and following training might result 
in a smaller reduction of brain content of glutamate and GABA. Since glutamate is 
thought to stimulate hGH release, a smaller reduction in brain glutamate content as a 
result of reduced ammonia production might be expected to result in a greater hGH 
response. However, this is not consistent with the findings of the studies in this thesis 
which identify smaller increases in plasma ammonia concentrations to be 
accompanied by smaller hGH responses to exercise. Therefore, it is possible that 
reduced GABAergic inhibitory tone is more important in regulating the magnitude of 
the hGH response to exercise, and the smaller increases in plasma ammonia 
concentrations observed following sprinting at slower pedalling rates, and following a 
6 wk training period, might result in a smaller reduction of brain content of GABA. 
The resulting higher brain content of GABA might, in turn, inhibit exercise-induced 
hGH secretion, resulting in lower serum hGH concentrations. 
It is possible, therefore, that increased plasma ammonia during exercise has a role to 
play in the regulation of the hGH response to exercise, since increases in plasma 
ammonia might cross the blood-brain barrier and alter brain content of the 
neurotransmitters glutamate and GABA via a change in the rate of glutamine 
synthesis. However, uncertainty over the effect of increases in circulating ammonia 
concentrations on brain glutamate and GABA content, in addition to the need for 
greater understanding of the role of both glutamate and GABA in the regulation of 
hGH secretion means that further work must be done to establish the importance of 
this potential mechanism for exercise-induced hGH secretion. 
Summary of mechanisms of hGH release during sprint exercise 
From the results of the studies in this thesis it is possible to comment on various 
potential mechanisms involved in the regulation of exercise-induced hGH secretion. 
Previous studies have considered the roles of blood lactate and blood pH, but the 
results of the studies described in Chapters 5 and 6, indicate that neither blood lactate 
nor blood pH are the prime regulators of the hGH response to exercise. Similarly, if it 
is assumed that blood lactate concentrations and blood pH levels reflect the situation 
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in exercising muscles, these results also infer that the proposed afferent signalling 
from muscle metabolic receptors do not regulate the magnitude of the hGH response 
to exercise. 
Although it has not been possible to study the level of motor activity during exercise 
as part of the studies in this thesis, it is likely that motor centre activity plays an 
important role in hGH release. In addition, it is possible that proprioceptive feedback 
signals might provide a mechanism for the modulation of hGH secretion. In addition, 
blood-borne afferent signalling might be important, since Chapters 5 and 6 identified 
similar changes in the plasma ammonia responses and the serum hGH responses to 
the sprint exercise at different pedalling rates, and following a short-term training 
programme, respectively. It is possible that increased circulating ammonia 
concentrations alter amino acid synthesis in the brain, resulting in a change in the 
brain content of GABA, which, in turn, has a role in the regulation of hGH secretion. 
8.6. Possibilities for future research 
From the results of the studies in this thesis it appears that blood pH and blood lactate 
concentrations do not have a principal role in the regulation of the hGH response to 
exercise. It is inferred from these findings that accumulation of metabolites in 
muscle, sensed by metabolic receptors in the muscle, does not determine the 
magnitude of the hGH response, however, direct measurement of muscle metabolites 
using the muscle biopsy technique would provide further evidence that this is the 
case. In addition, the results of the studies in this thesis have suggested that there is a 
possible link between ammonia production during sprint exercise and the resulting 
hGH response. Manipulation of circulating ammonia concentrations both at rest and 
during exercise would provide further information about this potential axis for hGH 
regulation. Alternatively, phosphorylase deficient individuals, who have been 
observed to have abnormally elevated ammonia production during exercise, or AMP 
deaminase deficient individuals, who have an inability to deplete adenine nucleotides 
to IMP and ammonia during cellular conditions of energy imbalance, could be studied 
to compare the hGH response to exercise in these conditions to that of healthy 
individuals. 
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There is still some doubt as to the relative importance of somatostatin and GHRH in 
regulating the hGH response to exercise, and it has been proposed that other GHRPs 
occur in the body. Therefore, further study is required to better understand the 
mechanisms by which the hGH response to exercise is regulated. The effect of the 
administration of octreocide (a somatostatin analogue), GHRH or other GHRPs prior 
to exercise on hGH secretion has been considered in some studies. However, further 
studies increasing somatostatinergic tone using octreocide, or _ decreasing 
somatostatinergic tone using pyridostigmine might elucidate the importance of this 
hypothalamic factor, whilst administration of GHRH and/or GHRPs, or a GHRH-
antagonist would provide further information about the importance of these peptides 
in regulating pituitary hGH secretion. 
It has been identified that there is a feedback loop inhibiting the hGH response to 
repeated stimuli. It is possible that this is mediated by elevated circulating levels of 
hGH itself, but the fact that the hGH response to exercise did not fully recover after 4 
h of recovery, when serum hGH had returned to pre-exercise levels suggests that 
another mechanism is important. It would be interesting to discover the length of 
time that is required for the recovery of the hGH response to exercise, as well as to 
determine the mechanisms involved. A role for increased circulating FF A 
concentrations in inhibiting hGH secretion has been postulated in this thesis, and the 
importance of FF A in the attenuation of hGH secretion with repeated exercise 
warrants further study. One method by which the role of FF A might be investigated 
is by blocking lipolysis with acipimox. A full understanding of the refractory period 
of the hGH response to exercise could provide important information in the 
maximisation of the anabolic effect of exercise. 
Chapter 6 of this thesis considered the effect of a short-term sprint training 
programme on the hGH response to exercise. The influence that different types of 
training (endurance, resistance, sprint), over both the short-term and the longer-term, 
have on the hGH response to exercise warrants further study, since there is little 
agreement between the results of studies that are currently available. In addition, the 
effect of training on integrated 24 h hGH and IGF-1 concentrations would provide an 
interesting focus for further study, particularly in children, adolescents, frail elders or 
those in chronic disease states, since the anabolic role of both hGH and IGF-1 
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secretion following exercise might have important clinical implications. Furthermore, 
the effect of a combination of short-term training and hGH administration in both 
normal and GH deficient subjects would provide information regarding the efficacy of 
this combined approach to the treatment of GHD, in addition to providing evidence of 
the effects of GH abuse on exercise performance. At present there is very little 
scientific evidence that administration of GH to healthy individuals improves 
performance, and it might be that training alone is the best stimulus for improved 
performance in healthy individuals, without any benefit of hGH abuse. 
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APPENDIX A 
SUBJECT DOCUMENTS: 
HEAL m IDSTORY QUESTIONNAIRE 
RETURN FORM 
ETHICAL ADVISORY COMMITTEE DOCUMENTS: 
EXAMPLE RESEARCH PROPOSAL 
CLEARANCE NOTES 
HEALTH SCREE~ FOR STUDY VOLUNTEERS Name or Number 
It is important that volunteers participating in rese:m:h studies are currently in good health and have had 
no significant medical problems in the past. This is to ensure (i) their own continuing well-being and 
(ii) to avoid the possibility of individual health issues confounding study outcomes. 
Please complete this brief questionnaire to confirm fitness to participate: 
1. At present, do you have any health problem for which you are: 
(a) on medication, prescribed or otherwise ................. Yes I I 
(b) attending your general practitioner ....................... Yes U 
(c) on a hospital waiting list .................................. Yes 0 
2. In the past two years, have you had any illness which require you to: 
(a) consult your GP .......................................... Yes! I 
(b) attend a hospital outpatient department .................. Yes il 
(c) be admitted to hospital ................................... Yes: J 
3. Have you ever had any of the following: 
(a) Convulsions/epilepsy ...................................... Yes ·_1 
(b) 1\sthma ...................................................... Yes .-1 
(c) Ecze=na ...................................................... Yes i 
(d) Diabetes ..................................................... Y cs . ; 
(e) A blood disorder ........................................... Yes 
(f) 
(g) 
H d . . I t!a lnJtlr' ................................................. Yes : 
. -
Di!r~srive oroblems ........................................ Yes i 
- . -
(h) He:m ;Jrobiems ............................................. Yes ! 
(i) 
(j) 
Probiems with bones or jointS ......................... Yes ·_1 
Dismroance of bal:mce/coordination ..................... Yes 
(k) Nurnbnt!ss in banes or fee: ............................... Yes ·_1 
(1) Disturbance of vision ...................................... Yes _! 
(m) Ear I hearing problems .................................... Yes· I 
(n) Thyroid problems .......................................... Yes '_! 
(o) Kidney or liver problems ................................. Yes·_! 
NoD 
NoD 
NoD 
r-; No; I 
·-.--
Noi i 
,..... 
Noi l 
'-
....-
Noi i 
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.. r 1-1 
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If YES to any question, please describe briefly if you wish (e~ to confirm problem 
wasiis short-lived. insignificant or well controlled. l .......................................... . 
Additional questions for female participants 
( . . ' 1/ ' ·1 V -, a) are your pen a as norma regUlar ........................... t!S _1 
(b) "th ''1'''7 ' ' are you on e p11 ....................................... Yes ,_: 
(c) could you be pregnant'? .................................. Yes _I 
(d) are you t:L.l(ing hormone replaceme:u the:-Jpy (ERT)'? Y~s: 
wu~hborou:,;h :.:mv~~~;:·; 
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,--
No: ! 
No!_ 
.--
No[_J 
Non 
RETURN SLIP: 
I am interested in participating in the "recovery from sprint exercise" project: 
NAME:~------------------------------ AGE: ____ __ ADDRESS: ______________________________________ ___ 
TELEPHONE:( daytime) ________ (evening)-------
• Do you think you are better in: 
- activities requiring endurance [ ] 
- activities requiring power/speed [ ] 
Please tick (...f) the appropriate box. 
• If you are an. active sportsman, please indicate the sport and level of performance 
(e.g. recreational, varsity, national etc.) 
SPORT: LEVELO~F~P~E=RF~o=RMAN~-=c=E~:---------------------------------------------
• How often do you train at present? (please tick (...f) the appropriate box): 
not at all 1-3 times/week 4-6 times/week more 
[ ] [ ] [ ] [ ] 
STATEMENT OF INFORMED CONSENT: 
I have read the above outline of procedures which are involved in this investigation, and I 
understand what will be required of me. I have had the opportunity to ask for further 
information and for clarification of the demands of each of the procedures. I am aware that I 
have the ri2ht to withdraw from the study at any time, with no ohli2ation to 2ive 
reasons for mv decision. 
I agree to take part in the "sprint cycling study". 
SIGNED: DATE: 
------------------------------ -------------
vnTNESSEDBY: _________________________ __ 
PLEASE RETURN AS SOON AS POSSIBLE TO 
KEITH STOKES, Ph.D. student 
OR 
DR. MARY NEVILL 
DEPT. OF PHYSICAL EDUCATION AND SPORTS SCIENCE 
LOUGHBOROUGH UNIVERSITY 
ETHICAL ADVISORY COMMITTEE 
RESEARCH PROPOSAL FOR HUMAN BIOLOGICAL INVESTIGATIONS 
This application should be completed after reading the Code of Practice paying 
particular attention to the advice given in Section 6.3. 
(i) Applicants: 
Dr. Mary E. Nevill and Mr. Keith A. Stokes 
(iii) Aims and Outline of the Pro.iect: 
During a single bout of exercise a number of metabolic and hormonal changes take place 
concurrently. It is difficult to discriminate which of these changes are important in regulating 
the human Growth Hormone (hGH) response to sprint exercise. However, these changes 
recover at different rates following exercise. Therefore if a second sprint is completed during 
the recovery period it may be easier to discover the factors which are important in regulating 
the hGH response to sprint exercise. 
Serum hGH concentrations remain elevated one hour after a single 30-s sprint (Nevill et al., 
1996, Stokes et al., 1999). Furthermore recent work in this department has demonstrated that 
iftwo 30-s sprints are completed separated by one hour of recovery, hGH release is attenuated 
following the second sprint (Stokes et al., 1999). It may be, therefore, that hGH has a direct 
negative feedback effect on its own release. However, the effect of repeated bouts of sprint 
exercise on the hGH response when hGH levels have returned to baseline before the second 
sprint has not been considered. 
It has also been postulated that Insulin like Growth Factors (IGF) have a negative feedback 
effect on hGH release. IGF are released a few hours after an exercise bout, stimulated by 
elevated hGH levels in the blood. The IGF response to a single 30-s maximal sprint is not 
known and, therefore, neither is the effect that this may have on the hGH response to repeated 
bouts of maximal sprinting. 
This proposed study therefore seeks to build on the findings of current work and it is hoped 
that the information gained will further the understanding of the mechanisms regulating hGH 
release. 
(iv)_ Names and status of investigators: 
Dr. Mary E. Nevill- Senior Lecturer, Dept. ofP.E., S.S. & R.M., Loughborough University 
Dr. Henryk K.A. Lakomy- Lecturer, Dept. ofP.E., S.S. & R.M., Loughborough University 
Mr. Keith A. Stokes -Research Student 
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(v) Subjects (see Section 6.3e): 
The subjects will be largely student volunteers (aged 18-35 years) from the Department ofPE, 
SS&RM. Ten physically active male subjects will be recruited. All subjects will have the 
study explained to them in verbal and written form (requirements, possible risks and 
discomforts), and will sign a voluntary consent form which clearly states that they may 
withdraw from the study at any time without giving any reason. 
Subjects will also be required to complete a medical questionnaire in the presence of an 
experimenter (to provide clarification and assistance) prior to any test. Any subject with a 
known history of cardiovascular or coagulation/bleeding disorders or metabolic disease will 
be excluded. 
All subjects will be thoroughly familiarised with the equipment and procedures of the study 
during 3-4 familiarisation visits. 
Although information will be kept on a computer, each subject will be entered as a number 
rather than a name, and will not be identifiable. This is in accordance with the data protection 
act. 
(vi) Location (any special facilities to be used): 
The work will be carried out in the Sports Science laboratories of the Department of Physical 
Education, Sports Science and Recreation Management at Loughborough University. 
(vii) Duration (including demand on subject's time): 
Prior to any experimental testing the subjects will be asked to complete at least three practice 
sessions (30 min each) in order to become familiarised with all-out sprinting on the cycle 
ergometer. 
The main tests will involve four visits to the laboratory. One trial will consist of a single visit 
lasting approximately three hours. One trial will consist of a single visit lasting approximately 
seven hours. One trial will consist of two visits, on consecutive days, each visit lasting 
approximately three hours. 
(viii) Reasons for undertaking the study (e.g. contract, student research): 
This is a staff and Ph. D. research project examining the human Growth Hormone response to 
sprint exercise. 
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(ix) Methodology (a brief outline of research design): 
Ten male subjects will attend at least three practice sessions before completing three main 
trials in a randomised order. On the day of each trial subjects will report to the laboratory in 
the morning in a rested and post-absorptive state. Trial A will be completed in a single visit to 
the laboratory and will consist of two 30-s sprints separated by one hour of passive recovery. 
Blood samples will be drawn via a venous cannula during the hour between the sprints and for 
two hours following the second sprint. Trial B will be completed in a single visit consisting of 
two 30-s sprints separated by four hours of passive recovery. Blood samples will be drawn via 
a venous cannula during the four hours between the two sprints and for two hours following 
the second sprint. Trial C will be completed in two visits to the laboratory on consecutive 
days. On each day subjects will complete a single 30-s sprint. Blood samples will be drawn 
via a venous cannula for two hours following each of the sprints. 
(iv) Procedures and measurements (for experimental and control subJects) 
Sprinting will be performed on a modified cycle ergometer, described by Lakomy (1986). 
Power output will be measured during each sprint. 
Practice sessions - During the 3-4 practice sessions subjects will be thoroughly familiarised 
with the equipment to be used and will have the opportunity to practice sprinting on a cycle 
ergometer. 
Main tests-
(A) Subjects will complete a standardised submaximal warm-up followed by a maximal 30-s 
sprint. They will then rest on a couch for one hour before repeating the warm-up and 
sprint. Venous blood samples will be drawn via a cannula at rest, after each warm-up and 
5, 10, 20, 30, 40 and 60 minutes after each sprint and 90 and 120 minutes after the second 
sprint. 
(B) Subjects will complete a standardised submaximal warm-up followed by a maximal 30-s 
sprint. They will then rest on a couch for four hours before repeating the warm-up and 
sprint. Venous blood samples will be drawn via a cannula at rest, post warm-up and 5, 10, 
20, 30, 40, 60, 90, 120, 180 and 240 minutes after the first sprint and post warm-up and 5, 
10, 20, 30, 40, 60, 90 and 120 minutes after the second sprint. 
(C) On day one subjects will complete a standardised submaximal warm-up followed by a 
maximal 30-s sprint. They will then rest on a couch for three hours. Venous blood 
samples will be drawn at rest, post warm-up and 5, 10, 20, 30, 40, 60, 90, 120 and 180 
minutes after the sprint. On day two exactly the same protocol will be followed. 
The total blood volume drawn during trial A will be approximately 150ml, during trial B 
approximately 200ml and during trial C approximately 150ml per visit (i.e. 300ml over two 
days). The total blood volume drawn for each subject over the whole study will therefore be 
approximately 650ml. Blood samples will be analysed for lactate, ammonia, pH, Het, Hb, 
hGH, insulin, cortisol, IGF and catecholamines. All blood sampling, handling and analysis 
will be done according to the University" Code of Practice for handling biological fluids. 
PRMJ KDil'ResHuBiolnv'NOVEMBER 94 Research protocol, page 3 
x1 Possible risks, discomforts and/or distress see Section 6.3k : 
The experiment involves maximal sprint exercise and is therefore demanding. However there 
will be an opportunity to practice sprinting on the cycle ergometer in order to become 
accustomed with this form of exercise. 
The cannula will be placed under local anaesthetic (lignocaine), and therefore discomfort will 
be minimised. Blood sampling via a cannula may cause minor bruising and carries an 
extremely small risk of plastic or air embolism. However, good practice minimises this risk~ 
Dr. M.E. Nevill, who will perform the cannulations, has the approval of the Committee for 
carrying out these procedures. Blood samples will only be drawn by individuals approved by 
the ethical committee. All procedures will be carried out in accordance with the Code of 
Practice for Workers having Contact with Body Fluids. 
(xii) 
Throughout the preliminary and main trials study participants will be supervised by at least 
two investigators. 
(xii) Names of investigators and personal experience of proposed procedures 
and/or methodolo ies: 
Dr. Mary E. Nevill- 16 years experience of similar investigations in this laboratory. Trained 
in venous cannulation by the Leicestershire Ambulance Service. Dr. Nevill has the approval 
of the Ethical Committee to perform cannulations. 
Dr. Henryk K.A. Lakomy - 16 years experience in sports science research. Dr. Lakomy has 
interfaced the cycle ergometer with a microcomputer and has written the necessary computer 
programmes. 
Mr. Keith A Stokes - Has been trained in, and is responsible for, withdrawing blood via the 
cannula by the Leicestershire Ambulance Service. 
None. 
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(xv) Do any investigators stand to gain from a particular conclusion of the 
research project: 
No. 
(xvi) Whether the University's Insurers have indicated that they are content for 
the University's Public Liability Policy to apply to the proposed Investigation 
(Committee use only): 
(xvii) Whether the insurance cover additional to (xv) has been arranged by the 
Investigator (see Section 6.3o): 
No. 
(xviii) In the case of studies involving new drugs or radioisotopes, written approval 
for the study must be obtained from the appropriate national body and 
submitted with the protocol. State if applicable: 
Not applicable. 
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(xix) Declaration 
I have read the University's Code of Practice on Investigations on Human 
Subjects and completed this application. 
Signature of applicant: 
Signature of Head of Department: 
·············································•············ 
Date: .......................................................... 
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Human growth hormone response to repeated bouts of 
maximal sprint cycling. 
Investigator: Keith Stokes* 
Supervisors: Dr. M.E. Nevill, Dr. H.K.A. Lakomy 
Department of P.E., Sports Science and Recreation Management, Loughborough 
University, Loughborough, Leics., LEJJ 3TU. 
*Research (Ph.D.) Student 
Dates: September to December 1999 
INTRODUCTION 
In the light of increasing Growth Hormone abuse by sports performers it is 
important to understand the pattern of natural growth hormone release after 
exercise. A number of studies have considered the growth hormone response to 
prolonged submaximal exercise but very few have looked at the growth hormone 
response to sprint exercise. 
Previous work in this laboratory has shown that a single 30-s sprint results in 
elevated growth hormone concentrations for at least 60-min after exercise. Further 
work has shown that if two 30-s sprints are completed with 60-min of recovery in 
between, there is no apparent growth hormone response to the second sprint. It is 
possible that the growth hormone circulating as a result of the first sprint prevents 
the release of further growth hormone after the second sprint. No one has yet 
considered the growth hormone response to repeated sprint exercise when growth 
hormone levels have reached resting levels before the second sprint. 
METHODS 
Sprinting will be performed on a cycle connected to a microcomputer which 
calculates instantaneous power output by counting flywheel revolutions. 
Ten male subjects will be recruited for this study. You will complete 3-4 practice 
sessions during which time height and weight measurements will be taken, the 
resistance to be applied to the ergometer will be calculated (7 .5% of your body 
weight) and you will have an opportunity to practice cycle ergometer sprinting. 
You will then complete 2 main trials in a random order. Trial A will be completed 
in a single visit to the laboratory and will consist of two 30-s sprints separated by 
one hour of passive recovery. Trial B will be completed over a two-day period. On 
the first day you will complete two 30-s sprints separated by four hours of passive 
recovery. The following day you will complete a single 30-s sprint. During each 
main trial venous blood samples will be taken via a cannula at rest and after each 
sprint in each trial. 
TIME COMMITMENT AND REQUIREMENTS 
You will be asked to report to the laboratory on the day of each main trial in a 
rested state following an overnight fast. 
Practice sessions will require 3-4 separate visits to the laboratory. Each session will 
last approximately 40 minutes. Trial A will consist of a single visit to the 
laboratory lasting approximately 3 hours. Trial B will consist of two visits to the 
laboratory on consecutive days, the visit on the first day lasting approximately 7 
hours and the visit on the second day lasting approximately 3 hours. 
LOCATION 
The work will be carried out in the Sports Science laboratories of the Department of 
Physical Education, Sports Science and Recreation Management at Loughborough 
University (Old Sports Hall building (RR) where the swimming pool is). 
POSSIBLE RISKS AND DISCOMFORTS 
The experiment involves maximal sprint exercise and is therefore demanding. 
However there will be an opportunity to practice sprinting on the cycle ergometer in 
order to become accustomed with this form of exercise. 
The cannula will be placed under local anaesthetic (lignocaine), and therefore 
discomfort will be minimised. Blood sampling via a cannula may cause minor 
bruising and carries an extremely small risk of plastic or air embolism. However, 
good practice and the experience of Dr. M.E. Nevill, who will perform the 
cannulations, minimise these risks. 
The investigators are at all times vigilant in their observations of subjects 
performing under the prescribed exercise conditions, and are ready to terminate any 
test should you report, or appear, to be unduly stressed. 
If at any time you feel that you wish to withdraw from the study then you will be 
free to do so without any obligation to give any reason for your decision. 
CONFIDENTIALITY 
Although information will be stored on a computer, each subject will be entered as a 
number rather than a name and will not be identifiable. This is in accordance with 
the Data Protection Act. 
You will be provided, on request, with a full record of your performance data. 
FURTHER INFORMATION 
Any questions about this study or future studies in this area are welcome. If you 
have any doubts or questions, please ask for further explanation by contacting Keith 
Stokes in the Sports Hall Balcony office, RR105 (at the end of the corridor and up 
the stairs, telephone- 228183) or bye-mail: k.a.stokes@lboro.ac.uk 
Student Office, Academic Registry 
Telephone: 2498 Fax: 223905 
E-mail: W.J.Ciarke@lboro.ac.uk 
Memorandum 
To: 
cc. 
From: 
Dr ME Nevill, PE, SS, RM 
Mr K A Stokes, PE, SS, RM 
Dr RH Hooper, Chair, EAC 
Mr D Massey, University Insurance Officer 
Wendy Clarke 
Secretary to the Ethical Advisory Committee 
Subject- Ethical Clearance for Research Proposal 
1• Lot;Ighb.orough 
• University 
Date: 1 October 1999 
Research Protocol: Human growth hormone response to repeated bouts of maximal sprint 
cycling 
Reference No. R99/Pll 
I write to confirm that the above research proposal has been cleared by the University's Ethical 
Advisory Committee and may now proceed under your direction. 
For your information I enclose the Committee's cover sheet which gives the conditions on which 
clearance is granted. This document and the proposal you submitted to the Committee is the 
approved protocol which will be lodged in the Committee's files. Thank you for assisting the 
Committee with its work. 
Title: 
Applicants: 
Departments: 
LOUGHBOROUGH UNIVERSITY 
ETHICAL ADVISORY COMMITTEE 
RefNo: R 99/Pll 
HUMAN BIOLOGICAL INVESTIGATION 
RESEARCH PROPOSAL 
Human growth hormone response to repeated bouts of maximal 
sprint cycling 
Dr M E Nevill, PE, SS, RM 
Mr K A Stokes, PE, SS, RM 
PE, Sports Science and Recreation Management 
Date of clearance: 1 October 1999 
Comments of the Committee: The Committee was content to issue clearance after 
receiving a satisfactory response to their comments. 
Investigators: Mr K A Stokes, PE, SS, RM 
APPENDIXB 
BLOOD ASSAYS: 
HAEMOGLOBIN 
HAEMATOCRIT 
BLOOD LACTATE 
PLASMA AMMONIA 
SERUM HUMAN GH 
SERUM INSULIN 
SERUM CORTISOL 
SERUMIGF-I 
B.l. Haemoglobin (Cyanmethaemoglobin Method) 
Principle 
Haemoglobin+ Cyanide+ Ferricyanide ---7 Cyanmethaemoglobin 
(Van Kampen and Zijlstra, 1961) 
Reaction mixture 
The reaction mixture ('Drabkins') was made from a kit (Boehringer Mannheim) by 
diluting with distilled water (1000ml) and contained phosphate buffer, potassium 
cyanide, potassium ferricyanide and detergent. It was then stored in a brown bottle at 
between + 15°C and + 20°C. 
Procedure 
1. In duplicate, 20~1 of whole blood was added to 5.0 ml ofthe reaction mixture in a 
plastic tube and mixed. 
2. The tubes were left to stand for at least 5 min, but not longer than 24 hr. The 
exact time varied between runs but in most cases samples were analysed at the end 
of a trial and the time samples were left to stand did not exceed6 hr. 
3. The absorbance of the sample was measured using a spectrophotometer (Cecil 
Instruments) at a wavelength of 546 nm in a cuvette with a l.Ocm light path. The 
reaction mixture on its own was used as a blank in order to zero the 
spectrophotometer. Relative absorbance (A) (absorbance of sample- absorbance 
of blank) was therefore taken as the reading on the spectrophotometer. 
4. The haemoglobin concentration of the sample was then calculated from the 
following equation: 
Haemoglobin concentration (g.IOO mr1) = (37.2 x A)+ 0.06 
(Wintrobe, 1956) 
B.2. Heamatocrit (%Cell Volume) 
Procedure 
1. In triplicate, haematocrit tubes (Scientific Instruments) were approximately three-
quarters filled with whole blood. The blood was then run up and down the tube to 
mix it. 
2. The tubes were sealed at one end with plasticine by placing them in a 'miniseal' 
tray. They were then left for analysis at the end of the trial. Samples were not -
left for more than 7 hr before they were analysed. 
3. Tubes were placed in a microcentrifuge (Hawksley Ltd.) with the sealed end 
towards the outside and centrifuged for 14 min. 
4. Percentage cell volume was calculated by placing each tube in a reader 
(Hawksley Ltd.) where the base (bottom) line of the reader was aligned with the 
base of the red cells and the top line intersected the top of the plasma. The middle 
line was then adjusted so that it intersected the top of the red cells and the 
percentage cell volume read from the scale. 
Plasma Volume 
Once haemoglobin and haematocrit values were known, plasma volume could be 
calculated using the method of Dill and Costill (1974). 
B.3. Blood Lactate 
Principle 
The fluorimetric assay for lactate is based on that described by Maughan (1982). 
NAD~NADH 
Lactate-----------~ Pyruvate 
lactate dehydrogenase 
The lactate concentrations reported in Chapters ? and ? were obtained by dispensing 
the samples and reagents by hand and analysing using a fluorimeter (Locarte) (non-
automated analyser protocol) whilst those in Chapters ? and ? were obtained using an 
automated analyser (Cobas Bio, Roche Diagnostics) protocol. In essence, these two 
methods are the same but both procedures will be explained in full. 
Non-automated analyser protocol 
Reaction mixture 
2.0mgNAD 
10.0 ~I LDH 
per 1.0 ml ofhydrazine buffer (pH -9.4) 
Standards 
In addition to a blank of2.5% perchloric acid, working standards of 1, 2.5, 5, 10, 15 
and 20 mM were prepared from 1.0 mM Sodium L-Lactate stock solution. 
Protocol (each sample was analysed in duplicate) 
1. After being allowed to thaw at room temperature, samples were mixed 
(Whirlimix) and centrifuged for 3 min at 13000 rev.min-1 (Eppendorf Centrifuge 
5415C). 
2. 20 ~I of either standard or supematant was pipetted into a glass fluorimeter tube 
and 200 ~tl of reaction mixture was added. 
3. The tubes were mixed thoroughly (Whirlimix), covered, and left to incubate at 
room temperature for 30 min. 
4. 1.0 ml of lactate diluent (0.07M HCL) was added to each tube and they were 
mixed thoroughly (Whirlimix) in order to stop the reaction. 
5. The fluorescence of the blanks, standards and samples were measured (Locarte). 
6. A linear regression plot of the standards was made and the lactate concentration of 
the samples was calculated. 
Automated analyser protocol 
Reaction mixture 
1.7 mgNAD 
7.0 J.ll LDH 
per 1.0 ml ofhydrazine buffer (pH -9.4) 
Standards 
The Cobas Bio automated analyser automatically blanks itself. The reagent tray can 
only accommodate three standards and so standards with concentrations over the 
appropriate range were used. For the studies described in this thesis standards of 5, 
10 and 15 mM were chosen. In addition a commercially available quality control -
(Sigma) at a concentration of 2.1 mM was run with each batch of samples. Both 
standards and quality control were diluted in 2.5% perchloric acid in the same ratio as 
the samples. 
Procedure 
1. The automated analyser (Cobas Bio, Roche Diagnostics) was switched on and the 
self-check was completed. 
2. The test code for the lactate assay was selected on the keyboard. 
3. The standards, quality control and samples were mixed thoroughly (Whirlimix) 
and centrifuged for 3 min at 13000 rev.min-1 (Eppendorf Centrifuge 5415C). 
4. The reagent tray was filled with the three standards and the reaction mixture. 
Pressing the 'START' button initiated the programme on the analyser. When the 
assay was complete, the concentrations of the standards were printed both in units 
and as a percentage of their expected values (i.e. 5, 10 and 15 mM). This step 
was repeated until all standards were 99-101% of their expected concentrations. 
5. Approximately 100 J.ll of sample or quality control was placed into each of the 25 
cups comprising the sample disc. During each run two of the cups (the first and 
last) contained the quality control. The sample cups were pressed firmly into 
position on the disc and it was placed on the turntable. 
6. The reagent tray was re-filled with reaction mixture, if necessary, and the assay 
was run. The concentration of each sample and quality control was printed in 
mM. 
B.4. Plasma Ammonia 
Blood Collection 
When the blood was drawn -1 ml whole blood was dispensed into a calcium 
heparinised eppendorf tube (prepared using the method described below). Samples 
were centrifuged inmmediately for 3 min at 13000 rev.min"1 (Eppendorf Centrifuge 
5415C). The plasma was then removed and pipetted into a plain eppendorf tube and 
immediately snap frozen until the end of the trial and then stored at -70°C until it was -
analysed, not more than 48 hr later. The time from blood being drawn to freezing was 
kept to a minimum in order to prevent contamination from external nitrogen sources 
and was always less than 15 min. 
Preparation of Ca/Hep tubes 
1. The required amount of Ca/Hep was calculated: 
1 mg (or ml) of Ca/Hep contains 183 units; 15 units are needed per ml 
of whole blood and each eppendorf tube would contain -1.5 ml of 
whole blood. Therefore, each eppendorf tube required -30 units of 
Ca/Hep (rounded up to allow for wastage). 
E.g. for a batch of 300 eppendorf tubes, 9000 units (300 x 30) would 
be required. This is equivalent to -50 mg (9000 + 183) of Ca!Hep 
which would be added to 1.2 ml ( 4 x 300) of distilled water. 
2. 4)..1.1 of this solution was then be pipetted into each eppendorftube. 
Principle 
The spectrophotometric assay is based on the methods described by Neeley and 
Phillipson (1968) and van Anken and Schiphorst (1974): 
GLDH 
2-0xoglutarate + NH3 + NADPH ---~ Glutamate + NADP 
The decrease in absorbance at 340 nm, due to the oxidation of NADPH, 1s 
proportional to the plasma ammonia concentration. 
Reaction mixture 
The reagents are found in bottles found in a commercially available kit (Sigma 
Diagnostics). 
Reagent solution 
The reagent solution was reconstituted with the volume of distilled water indicated on 
each vial label. Each reagent then contained: 
2-0xoglutarate 3.4 mmol.L-1 
NADPH 0.23 mmol.L"1 
In addition the reagent mixture contained buffer, stabilisers and nonreactive fillers. 
Enzyme solution 
L-Glutamate dehydrogenase 1200 U/ml 
Glycerol 50 % (v/v) 
Phosphate buffer pH 7.4 
Standards 
Each kit included an ammonia control solution at a concentration of 294 !J.mol.L "1• In 
addition control solutions at ammonia concentrations of 29.5 and 118 !J.mol.L-1 were 
used (Sigma Diagnostics). 
Procedure 
1. A series of 1.5 ml disposable plastic cuvettes with a lightpath of 1 cm were set up 
for BLANK, STANDARD 1 (29.5 !J.mol.L-1, in duplicate), STANDARD 2 (118 
!J.mol.L"1, in duplicate), STANDARD 3 (294 !J.mol.L"1, in duplicate) and 
SAMPLES. 
2. 0.5 ml of the reagent solution was added to each cuvette. 
3. 150 !J.l of distilled water was added to the BLANK cuvette, 100 !J.l of distilled 
water and 50 !J.l of ammonia control solution to each of the STANDARD cuvettes 
and 150 !J.l of plasma to each of the SAMPLE cuvettes. 
4. Cuvettes were covered with sealing film (Nescofilm, Bando Chemical Ind. Ltd., 
Kobe, Japan) and mixed by gentle inversion. 
5. Cuvettes were allowed to equilibrate for approximately 3 min at room 
temperature. 
6. INITIAL absorbance of each cuvette was read (Cecil Instruments) and recorded at 
340 nm. 
7. 5 !J.l of enzyme solution was added to each cuvette, cuvettes were mixed by gentle 
inversion and left to stand for approximately 5 min at room temperature for the 
reaction to complete. 
8. FINAL absorbance of each cuvette was read and recorded at 340 nm. 
9. The ammonia concentration was calculated using the following equations: 
~A= INITIAL A- FINAL A 
STANDARD Ammonia (pmol.r1) = ((~ASTANDARD- ~ABLANK) x 35.8) x 58.8 
SAMPLE Ammonia (~tmol.r 1 ) = ((~ASAMPLE- ~ABLANK) x 11.93) x 58.8 
Where the factor 58.8 converts !J.g.mr1 to pmol.r1• 
Serum human growth hormone, cortisol and insulin. 
Principle 
Commercially available kits were used for the determination of serum human growth 
hormone (hGH), insulin (both Medgenix, Biosource) and cortisol (Milenia, DPC) 
concentrations by routine ELISA. Microtitration plates pre-coated with specific 
monoclonal antibodies are supplied into which serum samples and standards are 
pipetted. Standards and samples containing hGH, cortisol or insulin (according to the -
assay) react with capture antibodies coated on the wells of the microtitation plates 
(Mabs 1) and with monoclonal antibodies (Mabs 2) labelled with horse radish 
peroxydase (HRP). During incubation a sandwich forms (coated Mabs 1- hormone-
Mabs 2 - HRP). The microtitation plate is washed to remove any unbound enzyme 
labelled antibodies. A revelation solution is added and incubated before a stopping 
agent is added and the microtitration plate is read at the appropriate wavelength. The 
amount of substrate turnover is determined colorimetrically by measuring the 
absorbance which is proportional to the hormone concentration. The procedures for 
each of the assays are similar but they will be described in full. 
B.5. Serum Human Growth Hormone (hGH) 
Medgenix-hGH-EASIA, Biosource. 
Reagents 
- Microtitration plate 
- Standard 0 mU.r1 in sheep serum, sodium merthiolate 
- Standards 1, 5, 15, 100 mU.r1 in sheep serum, sodium merthiolate 
- Controls 1 and 2 in human serum, sodium merthiolate 
- Anti-hGH-HRP conjugate in Tris-HCl buffer with bovine serum albumin and 
preservatives 
- Tween 20, 20% (washing solution) 
- Chromogen TMB (Tetramethylbenzidine) 
- Substrate buffer, H202 in acetate/citrate buffer 
- H2S04 1.8 N (stopping reagent) 
Procedure 
1. Reagents were prepared according to the instructions in each kit. 
2. 50ttl of each standard, control or sample was pipetted into the appropriate wells. 
3. 50ttl of Anti-hGH-HRP conjugate was pipetted into each well. 
4. The standards, controls and samples were incubated for 1 hr at room temperature 
on a horizontal shaker (Automix III, Heidolph) set at 700 ± 100 rpm. 
5. The plate was washed using an automated washer (Denley Wellwash 4 mk 2) by 
aspirating the liquid from each well, dispensing 0.4 ml of washing solution into 
each well, aspirating the content of each well, dispensing 0.4 ml of washing 
solution into each well for a second time and aspirating the content of each well. 
6. · 200)ll of freshly prepared revelation solution (chromogen TMB and substrate 
buffer) was pipetted into each well within 15 min following washing. 
7. The standards, controls and samples were incubated for 15 min at room 
temperature on a horizontal shaker (Automix Ill, Heidolph) set at 700 ± 100 rpm, 
avoiding direct sunlight. 
8. 50)ll of stopping reagent was pi petted into each well. 
9. Absorbance was measured within 1 hr using an ELISA plate reader (Anthos htll 
microplate reader, Anthos Labtec Instruments) and the results printed. 
B.6. Serum Insulin 
Medgenix-INS-EASIA, Biosource. 
Reagents 
- Microtitration plate 
- Standard 0 mU.r1 in human serum, sodium merthiolate 
Standards 5, 15, 50, 150, 500 mU.r1 in human serum, sodium merthiolate 
- Controls 1 and 2 in human serum, sodium merthiolate 
- Anti-insulin-HRP conjugate in Tris-HCl buffer with bovine serum albumin and 
preservatives 
- Tween 20, 20% (washing solution) 
- Chromogen TMB (Tetramethylbenzidine) 
- Substrate buffer, H202 in acetate/citrate buffer 
- H2S04 1.8 N (stopping reagent) 
Procedure 
1. Reagents were prepared according to the instructions in each kit. 
2. 50J.!l of each standard, control or sample was pipetted into the appropriate wells. 
3. 50J.!l of Anti-insulin-HRP conjugate was pipetted into each well. 
4. The standards, controls and samples were incubated for 30 min at room 
temperature on a horizontal shaker (Automix Ill, Heidolph) set at 700 ± 100 rpm. 
5. The plate was washed using an automated washer (Denley WellwashA rnk 2) by 
aspirating the liquid from each well, dispensing 0.4 ml of washing solution into 
each well, aspirating the content of each well, dispensing 0.4 ml of washing 
solution into each well for a second time and aspirating the content of each well. 
6. 200J.!l of freshly prepared revelation solution (chromogen TMB and substrate 
buffer) was pipetted into each well within 15 min following washing. 
7. The standards, controls and samples were incubated for 15 min at room 
temperature on a horizontal shaker (Automix Ill, Heidolph) set at 700 ± 100 rpm, 
avoiding direct sunlight. 
8. 50!J.l of stopping reagent was pi petted into each well. 
10. Absorbance was measured within 1 hr using an ELISA plate reader (Anthos htii 
microplate reader, Anthos Labtec Instruments) and the results printed. 
B. 7. Serum Cortisol 
Milenia-Cortisol, DPC 
Reagents 
- Ligand-labelled cortisol 
- Cortisol antiserum (containing rabbit anti-cortisol antibodies) 
Cortisol enzyme-labelled anti-ligand (containing horseradish peroxidase-labelled -
anti -ligand) 
- Cortisol calibrators (0, 1, 5, 10, 20, 50 mU.r1 in processed human serum) 
- Second antibody-coated microplate 
- TMB/substrate solution 
- Buffered wash solution concentrate 
- Stop solution 
Procedure 
1. Reagents were prepared according to the instructions in each kit. 
2. 25 ).!1 of each calibrator, control or sample was pi petted into the appropriate wells. 
3. 100 IJ.l of ligand labelled cortisol was pi petted into each well. 
4. 100 ).!1 of cortisol antiserum was pi petted into each well. 
5. The standards, controls and samples were incubated for 1 h at room temperature 
on a horizontal shaker (Automix Ill, Heidolph) set at 1300 ± 100 rpm. 
6. 25 ).!1 of cortisol enzyme-labelled anti-ligand was pipetted into each well. 
7. The standards, controls and samples were incubated for 30 min at room 
temperature on a horizontal shaker (Automix Ill, Heidolph) set at 1300 ± 100 rpm. 
8. Each well was aspirated and washed a total of four times using an autowasher 
(Denley Wellwash 4 mk 2) by dispensing 300 ).!1 of Wash Buffer into each well 
and aspirating the contents completely. After the last wash any remaining buffer 
was removed by aspirating or decanting and then inverting the plate and blotting it 
against clean paper towelling. 
9. 200 IJ.l ofTMB/substrate solution was pipetted into each well. 
10. The plate was incubated at room temperature in the dark without shaking for 30 
·mm. 
11. 50J..Ll of stop solution was pipetted into each well. 
12. Absorbance was measured at 450 nm within 15 min using an ELISA plate reader 
(Anthos htii microplate reader, Anthos Labtec instruments) and the results 
printed. 
B.8. Serum Insulin-like Growth Factor I (IGF -I) 
Quantikine® IGF-1 Immunoassay, R&D Systems Europe. 
Principle 
A commercially available kit was used for the determination of serum insulin-like 
growth factor-! (R&D Systems Europe). The assay employs the quantitative 
sandwich enzyme immunoassay technique. A micro titration plate pre-coated with -
monoclonal antibodies specific for IGF-1 is supplied. Standards and pre-treated 
samples are pipetted into the appropriate wells and any IGF-1 present is bound by the 
immobilised antibody. After washing away any unbound substances, an enzyme-
linked polyclonal antibody specific for IGF-1 is added to the wells. A further wash 
removes any unbound antibody-enzyme reagent and then a substrate solution is added 
to the wells and colour develops in proportion to the amount of IGF-1 bound in the 
initial step. The colour development is stopped and the intensity of the colour 
measured. 
Reagents 
- IGF-1 microplate coated with a murine monoclonal antibody against IGF-1 
- IGF-1 conjugate - polyclonal antibody against IGF-1 conjugated to horse radish 
peroxidase, with preservative. 
- IGF-1 standard- recombinant human IGF-1 in a buffer with preservative. 
- Assay diluent RD1-53- a buffer with preservative. 
- Calibrator diluent RDS-22- a buffer with blue dye and preservatives. 
- Pretreatment A - an acidic dissociation solution. 
- Pretreatment B - buffered protein with a blue dye and preservatives. 
- Wash Buffer Concentrate- a 25-fold concentrated solution of buffered surfactant 
with concentrated solution. 
- Colour reagent A- stabilised hydrogen peroxide. 
- Colour reactant B- stabilised chromogen (tetramethylbenzidine). 
- Stop solution- 2 N sulphuric acid. 
Procedure 
1. All reagents, working standards and samples were prepared as directed in the kit 
instructions. 
2. 150 !ll of Assay Diluent RD 1-53 was pi petted into each well. 
3. 50 !ll of standard or pre-treated sample was pipetted into the appropriate wells. 
The plate was covered with the adhesive strips provided in the kit and incubated 
at 2-8 °C for 2 hr. 
4. Each well was aspirated and washed a total of four times using an autowasher 
(Denley Wellwash 4 mk 2) by dispensing 400 !ll of Wash Buffer into each well 
and aspirating the contents completely. After the last wash any remaining buffer 
was removed by aspirating or decanting and then inverting the plate and blotting 
it against clean paper towelling. 
5. 200 J.Ll of cold IGF-I conjugate (stored at 2-8 °C until use) was pipetted into each 
well. The plate was covered with a new adhesive strip and incubated at 2-8 °C for 
1 hr. 
6. The aspiration/wash cycle (step 4) was repeated. 
7. 200 J.Ll of Substrate Solution (Colour Reagents A and B) was pipetted into each 
well and the plate was incubated at room temperature, whilst being protected from 
light, for 30 min. 
8. 50 J.Ll of Stop Solution was pi petted into each well and the plate was tapped gently 
to ensure thorough mixing. 
9. Optical density was determined within 30 min using a microplate reader (Anthos 
htii microplate reader, Anthos Labtec Instruments) set at 450 nm. With 
wavelength correction set at 540 nm. 

